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Nucleophosmin (NPM) is a ubiquitous protein that has numerous cellular functions. A 
frame-shift mutation at its C-terminus allows for the creation of additional nuclear export 
signal (NES) motif which caused an aberrant localization of NPM to the cytoplasm that 
alters the interaction dynamics of NPM and its interactors with respect to spatial and 
temporal kinetics. In previous study, cytoplasmic residing nucleophosmin (NPMc) is 
shown to abrogate apoptosis through its interaction with cleaved caspase 8 and caspase 6 
in acute myeloid leukaemia cells (AML) cells (1). However, several scientific studies 
reported that a compromised state of apoptosis render cells the utilization of an 
alternative (possibly rudimentary) cell death pathway upon tumour-necrosis-factor-
related-apoptosis-inducing ligand (TRAIL) treatment (2). Of late, the study of alternative 
cell death pathway is gaining traction as a possible therapeutic route for apoptosis 
insensitive cells (3).  
The emergence of an inducible and regulated form of necrosis termed necroptosis with 
receptor interacting protein 1 (RIP1) as a precursor (4) allows for the ease of necrosis 
investigation on cell model. So far, no study or any occurrences of alternative cell death 
have been reported in cytoplasmic NPM bearing cells.  We demonstrated that NPM 
interacts with receptor interacting protein 1 (RIP1) at the cytoplasm and promotes its 
cleavage blunting necroptosis. In a system where apoptosis is already compromised, 
inhibition of this alternative form of cell death pathway further potentiates cell survival. 
Incidentally, the level of necrotic cells in NPMc bearing cells remained high causing a 
pro-inflammatory cellular environment even when necroptosis is inhibited. We proposed 
that this phenomenon is caused by RIP3 mediated necrosis, independent of RIP1 kinase 
functions. This potentiates a chronic inflammatory environment which may then facilitate 
proliferation and/or carcinogenesis thus contributing to the acute nature of this disease.  
x 
Taken together, this study aimed to elucidate the functions of RIP proteins and its 
etiology in NPMc bearing cells with respect to cell death. It is hoped that this study laid 
the groundwork for possible manipulation of NPM and RIP1 cytoplasmic interaction as a 















LIST OF FIGURES 
1.1 Schematic representation of NPM1 functional domains  ...........................................2 
1.2 Schematic representation necroptosis cell death.....................................................28 
1.3 Schematic representation of molecular pathway of necroptosis. ..............................31 
1.4 Schematic diagram showing the sequence of PARP-1 major fragments obtained by 
cathepsins B and G proteolysis. .................................................................................34 
1.5 Schematic diagram showing the domain organization of RIP kinase family proteins.
................................................................................................................................39 
1.6 Schematic diagram showing the domains and post translational modifications of 
RIP1. .......................................................................................................................43 
1.7 Schematic diagram showing the domains of RIP3. ................................................48 
3.1 Expression of NPM is unperturbed upon exposure to cytotoxic drugs in myeloblast 
cells.  ........................................................................................................................68 
3.2 Wild type NPM translocates to the cytoplasm upon cytotoxic treatment. .................70 
3.3 Apoptosis is inhibited in OCI-AML3 cells and necrotic cells number is high. ..........74 
3.4 Further induction of primary necrosis is inhibited in OCI-AML3 cells. ...................79 
3.5 Release of pro-inflammatory proteins into the culture media. .................................83 
3.6 Knockdown of NPM affects RIP1 cleavage and potentiates PARP-1 cleavage in OCI-
AML3 cells. .............................................................................................................85 
3.7 NPMc enhances caspase 8 mediated RIP1 cleavage. ..............................................89 
4.1 Overexpression of NPMc rescue OCI-AML2 cells from apoptosis and necroptosis ..93 
4.2 Cells bearing NPMc favours non apoptotic cell death ............................................95 
4.3 Autophagy is potentiated in OCI-AML3 cells upon cytotoxic treatment ..................98 
4.4 RIP3 is overexpressed in OCI-AML3 cells and its functional kinase activity rescue 
cells from apoptotic death ....................................................................................... 100 
xii 
4.5 Abrogation of RIP1 kinase did not affect NPM stability and induced RIP3-mediated 
necrosis in OCI-AML3 cells .................................................................................... 105 
4.6 Knockdown of RIP1 promotes PARP degradation in OCI-AML3 upon cytotoxic 
stress ..................................................................................................................... 106 
4.7 Mode of cell death in NPMc expressing cells. ..................................................... 110 
5.1 RIP1 kinase is cleaved in NPMc expressing cells and NPM degradation corresponds 
to decreased RIP1 cleavage ..................................................................................... 113 
5.2 RIP1 kinase co-localizes with NPM at the cytoplasm........................................... 116 
5.3 RIP1 kinase interacts with NPM and its mutants in vivo and in vitro ..................... 118 
5.4 Direct interaction of RIP1 kinase with NPM is unperturbed by TRAIL treatment .. 120 
5.5 Nucleophosmin interacts with RIP1 and caspase 8 but is not a member of pre-death 
inducing signaling complex (DISC) ......................................................................... 124 
5.6 NPM degradation rescue cells from caspase 8 mediated RIP1 cleavage................. 127 
6.1 Inhibition of NPM translocation to the cytoplasm potentiates cell death ................ 132 
6.2 Inhibition of RIP1 kinase activity did not increased TRAIL induced apoptosis in OCI-
AML3 cells ............................................................................................................ 136 
6.3 TRAIL potentiated cell death upon RIP1 kinase knockdown in OCI-AML3 cells .. 137 
6.4 RIP1 and RIP3 kinases knockdown in OCI-AML3 cells did not potentiate myeloid 
differentiation......................................................................................................... 139 
6.5 RIP1 and RIP3 kinases knockdown showed no significant difference in NF-ĸB p52 
and p65 activation of OCI-AML3 cells .................................................................... 143 
6.6 TRAIL decreased ERK activation upon RIP3 but not RIP1 kinase knockdown in 
OCI-AML3 cells .................................................................................................... 145 
6.7 Disruption of RIP proteins in NPMc expressing cells promotes cell death ............. 150 
7.1 Working model summing up the interaction of RIP1 and NPM in the regulation of 
cell death ............................................................................................................... 155 
xiii 
7.2 Key observations elucidated in this study............................................................ 156 
7.3 Protein binding predictions using Zdock ............................................................. 161 











LIST OF TABLES 
Table 1. A table showing post translational modifications in NPM .................................4 
Table 2 A table showing 10 most common balanced aberrations in acute myeloid 
leukemia (AML). ......................................................................................................10 
Table 3 A table showing the distinctive features of AML with cytoplasmic mutant NPM 
(NPMc+)..................................................................................................................13 
Table 4 A table showing that both AML cell lines are not isogenic and each carry 















1.1.1 Nucleophosmin is a multifunctional protein 
Nucleophosmin (NPM) (also known as B23) phosphoprotein exists in three alternatively 
spliced isoforms (5) with a conserved N-terminal region which contains a hydrophobic 
region (5–8). The predominant NPM isoform 1 encodes 294 amino acid bases at 37kDa 
(9). Not much is known currently about the other two NPM isoforms. Located on 
chromosome 5q35, the NPM1 gene contains 12 exons. In this study we focus on isoform 
1 of the NPM protein. 
Nucleophosmin protein is capable of self-oligomerization (10,11) and widely functional 
as a chaperone protein (8) in a CRM-1 dependent (12) manner. The regulated shuttle 
between nucleus and cytoplasm allow for its interaction with other proteins (13–22), 
nucleic acids (9,23,24) and histones (6,25–29).  
Nucleophosmin predominantly exists as an oligomer (30–33) in the granular regions of 
the nucleolus where it participates in ribosome biogenesis (34–39), cell cycle progression 
(40), genomic stability (41–44) and control of centrosome duplication (45–51). The 
oligomerization of nucleophosmin is necessary (10,11) for proper protein localization and 
function (52–54). 
1.1.2 NPM domain 
The N terminal of NPM is non-polar and a site for protein oligomerization, crucial for its 
molecular chaperone activities. Efficient nucleolar accumulation of NPM is dependent on 
this domain. The acidic region at the centre of NPM protein domain is a site for histone 
binding (8,32,55) which is partitioned by a region exhibiting ribonuclease activity. The 
2 
basic region at the C-terminal domain of NPM is involved in nucleic acid binding (56). 
The downstream aromatic region attributed by tryptophans at amino acid 288 and 290 
(5,57) is important for NPM binding to nucleolus.  
Leucine-rich nuclear export signal (NES) motifs reside at the oligomerization region 
while a bipartite nuclear localization signals (NLS) reside at the C-terminal (58). These 
motifs control the localization and compartmentalization of NPM proteins (59) (alongside 
several phosphorylation sites) as it influenced its association with centrosomes and other 
functional activities (6). 
 
1.1 Schematic representation of NPM1 functional domains 
Adapted from Falini et al. (PROTEIN SCIENCE 2013 VOL 22:545—
556) (58). The N-terminal consists of two leucine-rich nuclear export 
signals (NES) that are utilized by Crm-1transport system. The central 
domain house the bipartite nuclear localization signal (NLS) and a 
nucleolar localization signal (NoLS) is located at the C-terminus. The 
ribonuclease activity domain is marked in red horizontal arrow. 
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1.1.3 Post translational modifications 
Nucleophosmin undergoes several post translational modifications prior to being 
functional. Phosphorylation of nucleophosmin are demonstrated in cell cycle regulation 
(60–63), DNA damage response (64,65), chaperone activity (12), RNA binding 
(55,66,67) and centrosome duplication (47,68). Sumoylation occurring in NPM proteins 
are largely responsible in maintaining protein stability (69,70), localization (71) and 
interaction (72). It is also involved in apoptosis (71). On the other hand, acetylation of 
NPM is implicated in the enhancement of chromatin transcription (26). 
A well-documented nucleophosmin phosphorylation by cyclin-dependent kinase 2 
(CDK2) – cyclin E at threonine 199 (Thr 199) is essential during centrosome duplication 
(48). 
These post translational modifications of NPM proteins and several others contribute to 











Table 1. A table showing post translational modifications in NPM 
Adapted from Colombo et al. (Oncogene 30, 2595-2609, 09 June 2011) 
(73). Regulation of NPM activities through post translational 
modifications. A table showing amino acid modifications 
(phosphorylated and sumoylated) on NPM, its modifier and the functions 
they are involved in.  
 
Modified amino acids Modified by Involved in 
Serine 4 (S4) Phosphorylated by polo-like 
kinase 1 (Plk1) 
mitosis 
Serine 4 (S4) Phosphorylated by polo-like 
kinase 2 (Plk2) 
S-phase 
Serine 10 (S10) Phosphorylated by unknown 
CDK 
G2-M transition 
Serine 70 (S70) Phosphorylated by unknown 
CDK 
G2-M transition 
Serine 125 (S125) Phosphorylated by casein 
kinase II and ATR 
DNA damage response, 
chaperone activity and 
NPM1 mobility 
Serine 254 (S254) Phosphorylated by unknown 
kinase in  mitosis 
N.A. 
Threonine 199 (T199) Phosphorylated by CDK2 in 
G1-phase; CDK1 in mitosis 
Centrosome duplication 
and DNA damage 
response 





Phosphorylated by CDK1 in 
mitosis 
RNA binding 
Arginine 230 (R230) Sumoylated Stability, localization, 
proteins interaction and 
apoptosis 
Arginine 263 (R263) Sumoylated Stability, localization, 
proteins interaction and 
apoptosis 
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1.1.4 Localization and expression of NPM proteins 
NPM reside abundantly in the nucleoli where it performs its main functions (8,32). 
Therefore, proper compartmentalization of NPM and its expression level in these 
organelles are crucial for proper functioning. NPM translocates from nucleolus to 
nucleoplasm upon treatment with certain anti-tumour drugs (10,74).  
The export of NPM protein to the cytoplasm utilizes the classical Ran-Crm-1 export 
system (50). The nuclear export sequence (NES) motif on protein binds to an exportin, 
(Crm1) and RanGTP forming a heterotrimeric complex in the nucleus (75). When GTP is 
hydrolysed upon complex transport to the cytoplasm, NPM is released. This Crm-1-
RanGDPs complex then diffuses back to the nucleus where GTP is exchanged in place of 
GDP by RanGEFs (76). This export system can be inhibited using the drug Leptomycin 
B (77–79).  
An import mechanism similar to the export mechanism of NPM proteins requires a 
nuclear localization signal (NLS) (80,81) and nucleolar localization signal (NuLS) (82). 
These motifs present on NPM are responsible for its nucleolar-nuclear-cytoplasmic 
shuttling mechanism. It is also demonstrated that a block in NPM protein shuttling ability 
or loss of NPM expression will subsequently affect protein translation and create cell 
cycle arrest (12).  
Nucleophosmin upregulation normally occurs in actively dividing cells as compared to 
normal resting cells. NPM expression is also upregulated upon genotoxic stress (83) and 
in many carcinomas such as bladder, prostate, colon and gastric (84–87).  
NPM overexpression has been shown to promote survival and uncontrolled cell growth 
(88)  as the ribosome biogenesis is enhanced (89). The overexpression of NPM in NIH 
3T3 and HeLa/S3 cells confer resistance to cell death and UV-induced growth arrest 
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(65,90). NPM may therefore have a role in the regulation of cell death likely playing a 
protective function.  
NPM expression is usually downregulated in cells undergoing different iation (91) or 
apoptosis (92), thus allowing for p53 phosphorylation (93). NPM is shown to be essential 
in embryonic development as well as involved in the upkeep of genomic stability as NPM 
(-/-) embryos could not survive. It was reported that NPM highly mutated in 
haematological malignancies. NPM is also haploinsufficient as NPM (+/-) heterozygosity 
potentiates oncogenesis (44) and unable to suppress blood tumorigenesis (94).  
1.1.5 Roles of NPM proteins 
As discussed previously, NPM chaperone protein shuttles between the cytoplasm (95) 
and nuclear region through binding of the nuclear localization peptides (96). These 
molecular chaperoning activities include the prevention of protein aggregation, enzyme 
protection upon thermal denaturation and assistance in renaturation of chemically 
denatured proteins (97). The C-terminus of NPM can bind nucleic acids (24,98) and 
preribosomal ribonucleoprotein particles (99). NPM association with preribosomal 
particles, implicates its role in ribosome biogenesis (100–102). NPM possesses an 
intrinsic ribonuclease activity which (103,104) when lowered, favour tumour growth 
(105).  
NPM localizes at the centrosomes and upon CDK2/ cyclin E phosphorylation at threonine 
199 (Thr 199) (48) dissociates with it and this initiates centriole duplication (49). Re-
localization of NPM back to centrosomes after mitosis and the segregation of one NPM 
bound centrosome to each daughter cells, ensure proper DNA duplication (45,47). 
NPM forms complex with nucleolar prote ins p120 (106) and nucleolin (107) as well as 
several viral proteins like Rex (human T-cell leukemia virus) (108), Rev (109) and Tat 
7 
(human immunodeficiency virus) (110) and HDV (Hepatitis delta virus) antigens (111), 
influencing the subcellular localization of these proteins. 
NPM is a direct target for a transcriptional factor Myc oncogene (112). NPM is involved 
in cellular proliferation and transformation (18). Malignant transformation was also 
reported in NIH3T3 cells with overexpression of exogenous NPM (113). 
Interaction of NPM with retinoblastoma (pRb) have been shown to stimulate DNA 
polymerase alpha activity in vitro (114,115) further implicating NPM in controlling the 
cell cycle progression.  
Other roles of NPM includes its ability to suppress both p53 dependent and independent 
apoptosis (116), inhibit differentiation (117) and promotes cell proliferation (88) which 
will be discussed in the next section.  
1.2 NPM mutation and cancer 
1.2.1 Acute Myeloid Leukemia 
Acute myeloid leukemia is an aggressive disease of myeloid neoplasm (118). Maturation 
arrest at its myeloblastic stage caused an aberrant accumulation of immature blasts 
leading to leukemogenesis (119). 
The basis of haematopoiesis lies in the balance of its stem cells to initiate self-renewal 
system and lineage-specific differentiation to generate committed stem cells (120). These 
cells further yield functional myeloid cells such as granulocytes, monocytes, red blood 
cells and platelets (121). In leukemogenesis, this balance is perturbed due to an 
oncogenic event(s) that caused the evasion of differentiation, apoptosis and senescence 
(122). Acute myeloid leukemia is a heterogenous disease which makes treatment 
challenging even up till now (123).  
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AML can arise from patients predisposed to myelodyplastic or myeloproliferative 
syndromes or other haematological disorders such as aplastic anaemia. This type of AML 
is termed secondary AML. 
Myelodysplastic syndromes (MDS) are categorized by various hematopoietic 
dysfunctional diseases (124). Apoptosis acceleration of myeloid cells and their precursors 
accompany early MDS occurrence (125). Subsequent genetic aberration may contribute 
to AML progression characterized by an arrest in differentiation and the accumulation of 
blast cells (120). 
De novo or primary AML usually develop from the transformation of single 
haematopoietic stem cells or at any point in haematopoiesis from the stem cell to lineage-
committed progenitor cell blocking terminal differentiation (120,126).  
WHO classification states that myeloblasts must make up 20% of nucleated cells in bone 
marrow or blood prior to AML diagnosis (118) while the French-American-British 
(FAB) classification cap it at 30%.. 
Although AML cells seem homogenous, only a subset of mutated myeloid progenitor 
blast cells has the potential to form colonies of leukemic cells [AML-Colony Forming 
Units (CFU)] usually upon exposure to growth factors (122,127). Studies suggest that this 
subset of cells acts as a stem cells in maintaining leukemogenesis. These blast cells have 
been utilized as model system to understand the cellular and molecular biology of 
haematopoiesis and its deregulation (128).  
Myeloid lineage is identified by the expression of surface markers such as CD13, CD33 
or CD117 usually detected by flow cytometry. The identification of Auer rods and 
presence of myeloperoxidase (MPO) cytochemical staining is another method commonly 
used (118). Differentiation of blast cells along monocytic lineage expresses one or more 
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monocytic surface markers CD14, CD64, CD11b or CD11c (118). CD34 markers 
expressed in undifferentiated hematopoietic stem cells are used as prognostic for overall 
survival (129).  
Thus, the therapeutic strategies in leukemia are geared towards identification and 
abrogation of aberrant stem cells, promotion of terminal differentiation, induction of cell 
death and control of cell growth.  
1.2.1.1 Translocations 
The first discovery of translocation in human neoplasia was the breakpoint cluster region 
protein (BCR) and Abelson murine leukemia viral oncogene homolog 1 (ABL1) 
translocation at t(9;22)(q34;q11) in a condition later known as Philadelphia chromosome 
(130). Since then many more gene translocations were discovered in myriad of diseases 
catapulting the advancement of molecular cytogenetics (131).  
Gene translocations of Runt-related transcription factor 1 (RUNX1) also known as acute 
myeloid leukemia 1 protein (AML1) and core-binding factor, beta subunit (CBFB) that 
encode for hematopoietic transcription factor are common in AML (132). About half of 
this translocation is attributed to inversion at inv(16)/t(16;16) or t(16;16)(p13.1;q22) 
(133) disrupting the CBFB and Myosin, Heavy Chain 11, smooth muscle (MYH11) gene 
(134). The fusion protein CBFB-MYH11 arrest myeloid differentiation leading to 
leukaemogenesis (135).  
Another translocation involving RUNX1 gene includes chromosomal rearrangements at 
t(8;21)(q22;q22) of RUNX-RUNX1T1(ETO) gene which is common in childhood AML. 
Cytogenetics abnormalities at t(15;17)(q22;q21) occurs in acute promyelocytic 
leukaemia. A chromosome translocation involving promyelocytic leukemia (PML) gene 
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and the retinoic acid receptor α (RARα) gene generates a fusion protein that caused a 
block in terminal differentiation and increased survival (136). 
The mixed lineage leukemia (MLL) chimeras constitute 15% of all AML cases (131). The 
MLL gene rearrangements are associated with aggressive acute leukemia originating 
from both lymphoblastic and myeloblastic lineage (137). 
The Table 2 below shows 10 most recurrent gene fusions in AML. 
Aberration Gene Fusion Frequency (%) 
t(8;21)(q22;q22) RUNX1-RUNX1T1 4.3 
t(15;17)(q22;q21) PML-RARA 4.1 
der(11q23) MLL fusions 2.4 
Inv(16)(p13q22) CBFB–MYH11  2.3 
t(9;22)(q34;q11) BCR–ABL1 0.7 
inv(3)(q21q26) RPN1–EVI1 0.6 
t(6;9)(p22;q34) DEK–NUP214 0.3 
t(1;22)(p13;q13) RBM15–MKL1 0.2 
t(8;16)(p11;p13) MYST3–CREBBP 0.1 
t(7;11)(p15;p15) NUP98–HOXA9 <0.1 
Table 2 A table showing 10 most common balanced aberrations in 
acute myeloid leukemia (AML). 
Adapted from Mitelman et al. (Nature Reviews Cancer 7, 233-245, Apr 
2007) (131).  
The impact of translocations and gene fusions on cancer causation.  
 
 
A rare translocation of nucleophosmin (NPM) and myelodysplasia/myeloid leukemia 
factor 1 (MLF1) at t(3;5)(q25.1;q34) generated a 54kDa NPM-MLF1 fusion protein that 
caused the aberrant translocation of MLF1 (a cytoplasmic residing protein) to the 
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nucleus/nucleolar region (138). Furthermore, it is also reported that this translocation 
caused cytoplasmic NPM translocation without NPM1 gene mutation (139). 
1.2.1.2 Mutations 
Genes abnormalities of the signaling transduction pathway are common in AML (140). 
Fms-related tyrosine kinase 3 (FLT3), a receptor tyrosine kinase receptor is frequently 
mutated in a third of AML patients (141). Most FLT3 mutations involve an internal 
tandem duplication (ITD) that caused a constitutive activation of signaling pathway 
leading to heightened cell growth (142–145). A significant proportion of AML patients 
carry both FLT3/ITD and NPM1 mutation and it was reported this group have the worst 
prognosis outcome (5,146).  
CCAAT/Enhancer Binding Protein (C/EBP), alpha transcription factor mutation in AML 
caused a maturation arrest by abrogating the activation of granulocytic differentiation 
genes (147). This gene mutation frequently occurs in patients with normal karyotype 
constituting about 10% of AML patients (148).  
At least one form of the three rat sarcoma viral oncogene homolog (RAS) genes, H 
(Harvey), N (Neuroblastoma), K (Kristen) are mutated in one third of AML patients. 
Overexpression of wildtype ras gene has been reported to transform rodent fibroblasts 
(149). Studies showed that activating mutation of ras genes does not initiate 
leukemogenesis events rather are generated during the disease progression (150) 
Point mutation of the v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
(KIT) gene caused a constitutive activation of this protein which enhanced signaling for 
cell proliferation and survival (140). Kit is frequently mutated in adult patient with 
simultaneous core-binding factor (CBF) gene rearrangements and mutations (151). 
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The mutation of isocitrate dehydrogenase 1 and 2 (IDH1/2) in acute myeloid leukemia 
cases was reported to impair histone demethylation and subsequent differentiation block 
(152,153). 
The mutation of the DNA methyltransferase 3A (DNMT3A), an enzyme that catalyzes de 
novo DNA methylation was reported in 20% of adult de novo AML with normal 
karyotype (154). DNMT3A mutations were shown to give an unfavourable prognosis 
(154).  
Nucleophosmin (NPM1) gene mutation is common and occurs in 50% of AML with 
normal karyotype (118) and will be discussed further in the next section. 
1.2.1.3 Cytoplasmic mutant NPM 
Nucleophosmin (NPM1) gene is mutated in 50-60% of adult acute myeloid leukemia 
(AML) with normal karyotype (5,155–160).  Mutations at tryptophan residues 288 and 
290 (129,155,161) located at the aromatic region of the C-terminal of NPM caused a 
frameshift that renders a creation of an additional nuclear export signal (NES) motif 
(59,82). These modifications caused an aberrant localization of NPM in the cytoplasm 
and its subsequent accumulation, is termed as NPM-cytoplasmic positive (NPMc+) 
(5,82,162). NPMc positive cases occurs in 25-35%  of AML patients with both de novo 
and secondary origin (82,163).  
NPMc positive AML and FLT3-ITD (fms-related tyrosine kinase 3-internal tandem 
duplications) mutations frequently occurs in adults and females (164). NPMc positive 
expression was seldom seen in patients with MLL-PTD, CEBPA, KIT, and NRAS 
mutations (5,165) but about 40% of patients have simultaneous FLT3-ITD positive 
occurrence (166,167). Below is Table 3 showing the distinctive features of AML with 
cytoplasmic mutated NPM (NPMc+) in AML (129). 
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Table 3 A table showing the distinctive features of AML with 
cytoplasmic mutant NPM (NPMc+) 
Adapted from Falini et al. (Blood 117 (4), 1109-1120, Jan 2011) (129). 
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a 




Deregulation of haematopoietic stem cells‘ division versus terminal differentiat ion 
disrupts the balance of constant cell number in tissue. Traditionally, treatments for AML 
have been towards induction therapy to promote cellular differentiation (168). Most 
leukemic cells are immature blast cells and high growth kinetics implied that they are 
constantly in the cell cycle. It is demonstrated that treatment with chemicals that inhibits 
DNA synthesis caused > 90% of blast cells to die. This underlies the nature of the blast 
cells which are likely aberrant progenitors (transit amplifying cells) rather than true stem 
cells.  
To date, hematopoietic stem cell transplant (SCT) such as allogenic (allo) SCT still 
remains the most effective leukemia therapy to achieve complete remission (169). 
Standard treatment with cytosine arabinoside (AraC) (170) although effective, did not 
affect tumour progenitor cells allowing recurrence (171). Numerous studies had been 
made to find a more effective dosage of AraC to counter this problem (172). A 
consolidation therapy was later established by exposing patients to a higher dosage of 
(usually) the same chemotherapy drugs after complete remission to prevent relapse (169). 
In recent years, treatments have progressed towards targeted therapies. One of the firstly 
used targeted therapies was the all-trans-retinoic acid (ATRA) in acute promyelocytic 
leukemia (173). In AML, targeted therapy targets kinase-activating gene mutations (i.e. 
FLT3 and KIT) in the form of tyrosine kinase inhibitors (TKIs) such as sunitinib and 
imatinib (173). Many new drugs are being tested in clinical trials which includes 
nucleoside analogues, hypomethylating agents, alkylating agents, tyrosine kinase 
inhibitors, immunotoxins as well as monoclonal antibody (169). However, due to  the 
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genetically heterogeneous nature of AML, advancement in therapy seems to point 
towards an individualized treatment (174) which favours combination therapy (169).  
These treatments include combining toxic peptide with a targeted protein like ligand for a 
specific receptor to abrogate tumour cells while leaving normal cells intact (175).  The 
toxic peptides are then able to activate multiple cell death pathways in tumour cells to 
override resistance to the main death pathway like apoptosis. Monoclonal antibody 
therapies can also be used in tandem with chemotherapy for leukemia treatments (176).  
1.2.2 Oncogene 
As an oncogene, NPM mutations can be loosely classified as ―Class I and class II 
oncogenes‖. Class I oncogenes have proliferative advantage to leukemic cells (i.e. FLT3, 
KIT, NRAS/KRAS, and PTPN11) while Class II oncogenes contribute to myeloid 
maturation arrest (i.e. CEBPA, NPM1, and certain recurrent chromosomal 
translocations/inversions) (118,173). Class II oncogenes have also been proposed as 
founder mutations due to their exclusivity (such that two ―class II‖ mutations do not 
occur together in AML) and the stability of these mutations in which it is still detectable 
in relapse cases (173). 
The downregulation of NPM transcript during retinoic acid induced cellular 
differentiation (91) and sodium butyrate-induced apoptosis (92) is well documented. 
Overexpressed NPM cells are resistant to UV-induced growth inhibition and cell death 
(90,177). The heightened NPM expression confers a protective role in differentiation and 
apoptosis potentiating cellular transformation of cells. It is reported that NPM prevents 
p53 accumulation in the mitochondria and subsequent apoptosis by anchoring p53 at the 
nucleus. The involvement of NPM in apoptosis and cellular differentiation is clearly 
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illustrated in these observations. As an oncogene, it binds to tumour suppressor genes 
such as pRb, p53 and p14Arf.  
1.2.3 Tumour Suppressor 
NPM‘s role in oncogenesis remains controversial (9,73,178,179) because NPM1 
oncogenic (18,42,93,180) and tumour suppression functions (17,181) have been reported, 
and this antagonistic characteristic depends on several factors such as the level of gene 
expressions, interacting partner proteins, and its subcellular compartmentalization.  
NPM binds to tumour suppressor ARF protein and prevents its proteasomal degradation. 
NPM interaction with protein kinase PKR suppressed the latter pro-apoptotic functions. 
With respect to p53 studies, several groups reported that NPM may stabilize p53 and 
promote senescence. Binding of NPM to murine double minute 2 (Mdm2 also known as 
Hdm2) a p53 E2 ubiquitin ligase prevents p53 degradation.  
1.3 NPM as an interacting partner 
As a multifunctional chaperone protein, NPM binds to many key players involved in 
maintaining cells‘ homeostasis. There are several known protein-interactions intensively 
studied and reported in literature.  
1.3.1 Nucleolin 
Nucleophosmin (B23) interacts with nucleolin (C23) (107) and ribonucleoproteins 
participating in ribosome biogenesis (107) and cell cycle control (13,182). NPM and 
nucleolin plays a role in genotoxic stress response in the cell (183). Recently, 
nucleophosmin and nucleolin have been implicated in the K-Ras stabilization at the 




It is reported that NPM regulates p53 level and activity (22,41,185). Several studies 
(41,186) highlight p53 stability ties in with NPM compartmentalization in the nucleolus. 
The relocation of NPM away from nucleolus triggers p53 activation as the binding and 
inhibition of Mdm2 (a p53 E3-ubiquitin ligase) by NPM (187–189) is lifted. 
Nucleophosmin also binds p53 directly at the N-terminal and inhibits p53 
phosphorylation (ser15) in response to cytotoxic stress and affect its transcriptional 
activities (186,190,191).  
1.3.3 ARF 
Nucleophosmin is known to co-localize with tumour suppressor ARF in the nucleolus 
(190,192–194) and other nucleolar proteins. Nucleophosmin and ARF interactions cross 
stabilized each other (43,195,196). ARF affects NPM polyubiquitination (197) while 
NPM protects ARF from degradation (189). The precise mechanisms of these interactions 
are still debatable (178,198). However, studies shows that NPM and ARF activities are 
highly correlated in the regulation of cell proliferation (37,72,192,199) and cell death 
(178,196)  
1.4 Human leukemic cell lines 
A number of human leukemic cell lines derived from patients with leukemia have been 
established over the years. These cell lines provide a good platform to investigate gene 
expression, differentiation, cell proliferation and cell death.  For the purpose of this study 
we examined the cell lines used in myeloid leukemia. Lozzio et al. established K-562 
early myeloblastic cell lines from pleural effusion of chronic myeloid leukemia patient 
(200). The establishment of HL-60 cell lines from peripheral blood from a woman with 
acute promyelocytic leukemia were done by Collins et al. (201). The KG-1 cell line, 
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derived from bone marrow of a man with erythroleukemia was established by Koeffler et 
al. (202). A similar cell line KG-1a derived from the parental KG-1 cells consist of very 
young myeloblasts (203). Tsuchiya et al. established THP-1 cell line isolated from 
peripheral blood of male acute monocytic leukemia patient (204). Unlike other myeloid 
cell lines, THP-1 does not have prominent chromosomal abnormalities (203).  
These cells can be induced to differentiate to macrophage-like or mature red blood cells 
in the case of K-562 cells. Therefore, human derived leukemic cell lines also provide the 
opportunity to study characteristic of a homogenous population during myeloid 
maturation (203). Jurkat T lymphocyte cell line was derived by Schneider et al. from a 
male patient with T cell leukemia (205).  
The OCI-AML2 cell line was established from the peripheral blood of a male with acute 
myeloid leukemia (AML FAB M4) by McCulloch et al. (206,207). OCI-AML3 cell lines 
established by the same group (207) was derived from a male with acute myeloid 
leukemia (AML FAB M4) and carries the NPM1 gene mutation (type A) (208). Both 
OCI-AML2 and OCI-AML3 cell lines are non-isogenic but carry a DNA (Cytosine-5)-
Methyltransferase 3 Alpha (DNMT3A) mutation (154). This enzyme is involved in CpG 
DNA methylation which is important for embryonic development (209). 
In this study, OCI-AML2 and OCI-AML3 cells were used as model to investigate AML 
etiology with respect to wild type and cytoplasmic mutant NPM status. A comparison 




Table 4 A table showing that both AML cell lines are not isogenic 
and each carry different cytogenetic profile. 
OCI-AML2 OCI-AML3
Cell type Acute myeloid leukemia (human) Acute myeloid leukemia (human)
Origin established from the peripheral blood 
of a 65-year-old man with acute 
myeloid leukemia (AML FAB M4) in 
1986 at diagnosis
established from the peripheral blood of 
a 57-year-old man with acute myeloid 








Morphology single, round to oval cells in 
suspension
single, mostly round cells growing in 
suspension
Medium 80% alpha-MEM + 20% h.i. FBS 80% alpha-MEM + 20% h.i. FBS
Subculture maintain at 0.5-1.5 x 10
6
 cells/ml; 
seed out at ca. 0.5 x 10
6
 cells/ml; 
possibly no cell growth during first 3-4 
days; 
upon thawing viability drops to about 
50%
maintain at ca. 0.5-2.0 x 10
6 
cells/ml; 
seed out at ca. 0.5 x 10
6
 cells/ml; 
split saturated culture 1:3 to 1:4 every 2-
3 days; 
at first cultivate in 12- or 24-well-plates
after thawing cells grow slowly


















cytoplasmic CD68 (+) 
HLA-DR (-)
Cytogenetics human hyperdiploid karyotype with 










der(17)t(2;17)(p23;q24.1) - sideline 
with +der(5) - carries apparent variant 
translocations involving several ANLL 
breakpoints: 1p36, 3q21, 3q26 
(megakaryocytic abnormalities), 
12p13, 17q24 (FAB-M4)
human hyperdiploid karyotype - 48(45-




dup(17)(q21q25) - sideline with r(Y)x1-2 
- hemizygous for RB1
Viruses PCR: EBV (-)
        HBV (-)
        HCV (-) 
        HIV (-)
        HTLV-I/II (-)
        SMRV (-)
ELISA: reverse transcriptase negative
PCR: EBV (-)
        HBV (-)
        HCV (-)
        HIV (-)
        HTLV-I/II (-)
        SMRV (-)
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Adapted from DSMZ Catalogue.http://www.dsmz.de/de/kataloge.html. 
A comparison of AML cells carrying wild type NPM and mutant 
cytoplasmic NPM.  
 
1.4.1 Other cell lines used 
Primary AML cells are derived from human peripheral blood mononuclear cells 
(PBMCs) of AML patients and were isolated using density gradient centrifugation. The 
selection of undifferentiated hematopoietic stem cells (HSCs) was carried out using 
CD34 positive cell surface markers.  
HEK 293 cells are a human embryonic kidney cell line derived from renal epithelium 
(210). These cells are widely cultivated mammalian cells that can be easily maintained 
and transfected with an exogenous gene (211). It is also large used for virus production 
for gene transduction (212). The T variants of HEK 293 cells contained the SV40 Large 
T-antigen (213,214).  
The HT-29 cell line is derived from human colon adenocarcinoma and has been shown to 
be a robust cell model for necroptosis (215). It is a useful model system to study 
differentiation in vitro (216). 
1.5 Cell death 
In tumour cells, the cell death evasion is the primary mechanism for survival. There are 
many ways in which cells die. The common and classical cell death pathway is termed 
apoptosis. Tumour cells often develop resistance to apoptosis however cell death can still 
occur via other form of cell mechanism although not efficiently (217). Recent 
advancements in cancer therapy revolve around the development of drugs that could 
exploit the induction of cell death through these alternative cell death pathways (3,218). 
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Three main cell death mechanisms have been classified namely apoptosis (caspase 
dependent), necrosis (caspase independent) and autophagy (lysosomes dependent). 
1.5.1 Apoptosis 
Apoptosis is a programmed cell death, identified by morphological changes such as cell 
shrinkage, nuclear fragmentation, chromatin condensation, plasma membrane blebbing 
and formation of apoptotic bodies (4). It is a caspase (219) and ATP dependent process 
where the dying cell assembled into ordered morphology during self-degradation (220). 
Apoptosis is highly regulated and is also involved in many biological processes such as 
brain and embryonic development as well as the proper functioning of the immune 
system (221,222). Apoptotic pathway comprised of two types: intrinsic pathway and 
extrinsic pathway which then triggers a caspase cascade comprising initiator caspases (-2, 
-8, -9, -10)(223), executioner caspases (-3, -6, -7) (224) and inflammatory caspases (-1, -
4, -5) (225–227).  
The intrinsic or loosely known as the mitochondrial cell death pathway can occur through 
the initiation of DNA damage, activation of Bcl-2 like protein 4 (Bax) and Bcl-2 
homologous antagonist (Bak). Upon induction, initiator caspases 8 and 9 are activated 
and this trigger a caspase cascade leading to cell death. Bid cleavage by caspase 8, 
generates a truncated Bid (tBid) which translocates to the mitochondria (228) and caused 
the cytochrome C re lease (229). This caused the formation of apoptosome (230) and 
activation of caspase 9, together with apoptotic protease activating factor 1 (Apaf 1) 
(231) activate the effector caspase 3 and subsequent apoptosis (232). 
The extrinsic pathway is initiated upon ligands binding to specific death receptors at the 
surface of the cell. This then trigger the formation of DISC complex downstream the 
22 
death receptor activating the initiator procaspase 8. Cleavage of caspase 8 into its active 
form initiates a caspase cascade leading to apoptosis.  
Over the past decades, many studies showed that the hallmark of cancerous cells involved 
a defective apoptotic cell death pathway. In that time, other cell death pathways that are 
non-apoptotic have also been discovered adding to the plethora of mechanisms that could 
be exploited for cancer therapy (233–235).  
Initial detection of apoptotic cells was done using electron microscopy (236) to view the 
morphological changes in cells. The budding and formation of apoptotic bodies was later 
viewed using a standard phase contrast light microscopy (237). Staining cells with DNA 
dyes like propidium iodide (PI) and Hoechst 33342 allow for examination of chromatin 
and nuclear fragmentation via fluorescence or confocal laser scanning microscopy. Flow 
cytometry can also be utilized to quantify the stained cells.   
Analysis of DNA degradation of apoptotic cells can be done using agarose gel 
electrophoresis. DNA fragmentation of the nuclear extract can be seen as DNA laddering 
on the gel. Another would be ―comet assay‖ in which DNA is allowed to migrate in an 
electric field after which it was stained with DNA dyes and views using fluorescence 
microscopy.  
Measurement of DNA content is another method to determine the apoptosis occurrence. 
Intercalating DNA dyes such as PI can be used to measure DNA content via flow 
cytometry with cell cycle program that detect a dist inct region prior to the G0/G1 peak.  
The quantification of dead cells using PI does not discriminate necrotic or apoptotic cell 
death. The Annexin V assay developed by Vermes et al. (238) showed that detection of 
phosphatidylserine (PS) expression via flow cytometry coupled with PI staining is an 
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effective way to detect early apoptotic events. By tabulating the results in a dot plot of 
Annexin V versus PI staining, early and late apoptotic cells can be discriminated 
TUNEL (terminal deoxynucleotidyl transferase mediated dUTP nick end labelling) assay 
utilizes the activated endonucleases which can be labelled in situ at the DNA strand 
breaks of apoptotic cells (239).  
In apoptotic cells, the activation of caspases can be detected via the generation of active 
caspase fragments from the cleavage of their inactive zymogens. Caspase activity can be 
quantified using assays that measure the release of chromophore/fluorophore of 
colorimetric/fluorimetric labelled substrates which correlate with its activities. 
Alternatively, immunoblotting of the cleaved active downstream effector caspases like 
caspase 3 have been used widely in studies as an apoptosis indicator. 
The measurement of mitochondrial transmembrane potential (Δψm) can be used as an 
indicator for mitochondrial health. As cell dies, the collapse of transmembrane potential 
align with the opening of mitochondrial permeability transition pore that releases 
cytochrome C to the cytosol triggering downstream apoptotic cascade.   
1.5.2 Necrosis 
Necrosis is a cell death occurrence that can be defined morphologically via electron 
microscopy. Necrotic cells usually exhibit translucent cytoplasm, swelling of cellular 
organelles, and loss of plasma membrane integrity (240). The loss of membrane potential 
may be due to cellular energy depletion, membrane lipids damage or loss of homeostatic 
ion mechanism (241). 
Necrosis is an unregulated form of cell death which is inflammatory in nature (241) 
compared to apoptosis (242). These cells release ‗danger cues‘ that may induce 
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proinflammatory effects which further activate an immune response and in some cases 
promote cancer growth (243). The activation of proinflammatory modules termed 
inflammasomes can induce cytokine production and dendritic cell maturation (243). 
Many studies have suggested that necrosis is the primordial cell death pathway in cells 
and only becomes apparent once apoptosis mechanism is blocked (4,240). The release of 
inflammatory proteins to the extracellular environment upon necrosis induction triggers a 
swift recruitment of a defensive or a reparative response to multicellular regions that have 
sustained damage or invasion. This potentiates an early warning system able to react to 
events that may otherwise compromise the integrity of the whole organism (244). 
Necrotic death can be induced by hypoxic condition, glucose depletion, acidosis, and 
increased reactive oxygen species (ROS) production in cell (241,245,246). ROS have a 
role in a number of cellular processes. High expression of ROS can lead to cell or DNA 
damage and oxidative stress (247).   
Cells have developed a method to maintain ROS equilibrium. Using an antioxidant 
system, superoxide dismutases (SOD) converts the extremely toxic superoxide anions 
into hydrogen peroxide and oxygen. Hydrogen peroxide is subsquently broken down by 
catalase into water and oxygen (248). Overexpression of SOD and catalase have been 
used in studies illustrating therapeutic benefit to neurodegeneration (249) and ROS 
related death (250,251). Notably, these evidences showed that necrotic cell death can be 
inhibited by removing ROS using antioxidants or maintaining its intracellular balance.  
1.5.2.1 PARP-1 induced necrosis 
ROS-induced DNA damage caused PARP-1 overactivation (252). The activation of 
uncleaved PARP-1 is triggered by DNA strand breaks causing the destabilization of 
chromatin to facilitate DNA repair enzymes in accessing the nicked DNA (253). As a 
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chromatin associated enzyme, PARP-1 transfers long, branched poly(ADP-ribose) 
polymers in NAD+ dependent manner upon binding to DNA strand breaks (254). The 
depleting cellular nicotine adenine dinucleotide (NAD+) pool unable cell to maintain its 
glucose metabolism (255) and ATP production resulting in necrosis induction (256). 
Excessive PARP-1 activation by alkylating DNA damage caused programmed necrosis 
(255). 
Poly(ADP-ribose)polymerase-1 (PARP-1) is a nuclear enzyme involved in DNA repair, 
DNA stability and transcriptional regulation. Los et al. demonstrated that TNF-induced 
necrosis is potentiated upon treatment with caspase inhibitors when  PARP-1 cleavage is 
prevented (257). The proteolytic cleavage of PARP-1 have been used extensively as an 
indicator of apoptosis execution (258).  Caspases 3 and 7 cleave 116kDa PARP-1 at the 
amino acid sequence DEVD (Asp-Glu-Val-Asp) site generating 89 and 24kDa fragments 
(259,260).  This cleavage prevents necrotic induction and inhibits PARP-1 dependent 
release of proinflammatory mediators (255).  
The biochemical mechanism of PARP-1 is still unknown. However, PARP-1 cleavage 
has been deemed as an important event as it dictates the switches between apoptosis and 
necrosis through death receptor signaling pathway. Other studies (261–263) showed a 
consistent link between PARP-1  and necrosis but not apoptosis (256).  
While studies in PARP-1 (-/-) cells showed that PARP-1 is dispensable in apoptotic 
response to various stimuli (264), PARP-1 deficient mice was shown to be protected from 
inflammation, diabetes, myocardial and cerebral ischemic injury (257,265,266). 
Inhibition of PARP-1 activity promotes genomic instability leading to tumour formation 
(267). NAD+ replenishment have been shown to rescue cells from PARP-1 mediated cell 
death (268).PARP-1 also participates in other cell death model (256,267,269–271). 
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1.5.3 Programmed necrosis 
Recently, a programmable form of necrosis known as necroptosis has generated a buzz in 
the field of cell death studies. Modulated by serine/threonine kinase activity of RIP1, 
necroptosis challenged the notion that necrotic cell death is unregulated.  
Programmed necrosis is triggered by the cytokines such as TNF family ligands upon 
apoptotic mechanism inhibition such as treatment with pan caspase inhibitor (zVAD-
fmk) (272). RIP1 kinase-dependent activation of necroptosis is initiated by the 
recruitment of RIP3 to a complex involving RIP1, FADD and caspase 8, known as 
necrosome (273). The complex subsequently forms a functional heterooligomeric 
amyloid (fibrous protein aggregates) structure possibly a platform for programmed 
necrosis signaling. 
Upon necrosome formation and RIP3 kinase activation via RIP1 phosphorylation, several 
interactors of RIP3 such as mixed lineage kinase domain-like (MLKL) and 
phosphoglycerate mutase family member 5 (PGAM5) were recruited to the necrosomal 
complex. MLKL phosphorylation by RIP3 kinase is critical for necroptosis execution 
(274). A series of events ensued downstream MLKL that caused mitochondrial fission 
resulting in an increased in permeability transition and ROS production which may 
initiate downstream cell damage (275).  
Caspase 8 is implicated in the suppression of programmed necrosis mediated by RIP 
proteins. O‘Donnell et al. showed cleavage of cylindromatosis (CYLD) protein by 
caspase 8 generates a survival signal that inhibits programmed necrosis (276). Activation 
of NF-κB pathway is also known to increase expression of pro survival proteins with 
antioxidant activities that may block programmed necrosis (275).  
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Necroptosis can be blocked by necrostatin-1, an inhibitor of kinase activity of RIP1 (277) 
as it abrogates the assembly of the RIP1/RIP3 complex further implicating these kinases 
in necrotic cell death (278). 
Compared to apoptosis, metabolic ATP consumption remains high in necrosis and this 
depletes the intracellular ATP demonstrated through the overactivation of the poly(ADP-
ribose) polymerase (PARP1) (257). Subsequent irreversible bioenergetic compromise 
results in cell death (241). 
Furthermore, inhibition of RIP1, cyclophilin D, PARP-1 and AIF have all been shown to 
affect necroptosis execution (4). 
The participation of necroptosis in biological processes is indeed diverse. This includes 
cell death induced by a variety of stimulus, T-cell population expansion, homeostasis and 
embryogenesis as well as its contribution to the mechanism of inflammation related 
diseases( 273). Necroptosis  also partakes in the pathogenesis of ischemic injury (277). 
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1.2 Schematic representation necroptosis cell death. 
Upon activation of death receptors by cytokines such as TNF family 
ligands, RIP1 K63-ubiquitination facilitates pro survival NF-κB pathway. 
Deubiquitination of RIP1 protein caused its interaction with proapoptotic 
proteins activating caspase 8 and downstream apoptotic cascade. This 
inhibits necrotic cell death. In an event of caspase inhibition, RIP1 and 
RIP3 interact, forms necrosome and activated via phosphorylation. RIP3 
then recruit downstream players such as MLKL and PGAM5 before 
subsequently activating signaling events that result in necrotic cell death. 
Drp1 dephosphorylation by PGAM5 induces mitochondrial fission which 
may contribute to increased permeability transition and ROS production 





1.5.3.1 Induction of necroptosis 
Upon induction of necroptosis and necrosome complex formation, RIP3 actively recruit 
glycogen phosphorylase (PYGL), glutamate-ammonia ligase (GLUL), glutamate 
dehydrogenase 1 (GLUD1) and fructose-1.6-biphosphatase 2 (FBP2) causing an elevated 
breakdown of glycogen and glycolysis. These events caused mitochondrial dysfunction 
leading to an excessive production of ROS, PARP-1 overactivation (causing depletion of 
NAD+) and reduced ability to generate ATP. Mitochondrial ROS generated as a result of 
oxidative respiration is an excellent inducer of lysosomal membrane permeability (LMP) 
and subsequently leads to the release of proteases activating death signaling pathways in 
the cytosol (280). This active form of necrosis initiates an inflammatory response.  
Programmed cell necrosis can be induced extracellularly or initiated intracellularly and 
play an important role in many processes such as those in vascular-occlusive disease, 
neurodegenerative diseases, infection, inflammatory diseases, cancer and upon exposure 
to toxins (244,281,282). 
Extracellular induction of programmed necrosis by TNF family ligands is potentiated 
upon apoptosis inhibition using pan caspase inhibitors (zVAD-fmk) (283). TRAIL (part 
of TNF family) cytokines, are known to induce apoptosis in many human cancer cell 
lines while preserving normal cells integrity (284). Intracellular induction of programmed 
necrosis by staurosporine (STS) is also reported in U937 cell line with defective caspase 
machinery (285).  
Other members of the PARP family, PARP-2 and BH3-only protein Bcl-2 modifying 
factor (BMF) was shown to be involved in necroptosis although its mechanism is 
unknown (286). 
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Recently, it was demonstrated that necroptosis can be induced by mTOR inhibition when 
antioxidant defense via nuclear factor (erythroid derived 2)-like 2 (Nrf2) nuclear 
translocation and mitophagy blockade (287). 
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1.3 Schematic representation of molecular pathway of necroptosis.  
Adapted from Galluzzi et al. (International review of cell and molecular 
biology 2011 VOL 289: 1-35) (288). Programmed necrosis from 
molecules to health and disease). Upon death receptor stimulation, 
formation of complex I ensues at the cytoplasmic region recruiting 
TRADD, RIP1, cIAPs, TRAF2 and TRAF5. At complex I, K-63 linked 
polyubiquitination of RIP1 triggers the canonical NFkB pathway. 
TNFR1 internalization followed by RIP1 deubiquitination by CYLD (in 
a condition where cIAPs are inhibited), initiates complex II formation. 
Complex II (DISC) includes RIP1,RIP3, TRADD, FADD, caspase 8. 
Activation of caspase 8 with concomitant inactivation of RIP1 and RIP3 
in this complex initiates apoptosis. When caspase 8 activation is blunted, 






1.5.3.2 Analyzing necroptosis 
It is hard to distinguish necrotic and necroptotic cell death due to the unavailability of 
clear cell death markers like caspase activation in apoptosis. While the release of high 
mobility group B1 protein (HGMB1) to the extracellular matrix can be used as a marker 
for necrotic cells in general (289), it is suggested that the presence of RIP1 or RIP3 in 
mitochondrial fractions denotes necroptotic cells (290–292).  
There are several other methods that have been suggested to measure necroptosis. 
Although a single definitive determinant of necroptosis occurrence is absent, a 
combination of measurement methods may be employed (293).  
Most direct way of detecting necroptotic cells is via observation of morphological 
features of necrosis such as early membrane and organelle swelling. The gold standard 
for morphological observations is to utilize electron microscopy although bright light 
microscopy might suffice in identification of cell swelling. The measurement of plasma 
membrane integrity using propidium iodide (PI) uptake is routinely used in flow 
cytometry but do not discriminate primary or secondary necrotic cell death. 
Counterstaining PI stained cells with Annexin V followed by flow cytometry analysis 
allow for an estimation of the percentage of apoptotic (Annexin V (+)/PI (-)), necrotic 
(Annexin V (-)/PI (+)) or secondary necrotic (Annexin V (+)/PI (+)) cells in the 
population. Other cell survival assays such as MTT assay only gives information on loss 
of cell viability but not the mode of death.  
In vitro kinase analysis can be employed to determine the kinase activity of RIP1, the 
mediator of necroptosis. Degterev et al. identified a small-molecule inhibitor Necrostatin 
1 (Nec-1) that inhibit the kinase activity of RIP1 simultaneously inhibiting necroptosis 
(294). Cells undergoing necroptosis will be rescued via necrostatin-1 treatment. 
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Necroptotic cell death is induced via pan-caspase inhibitor(z-vad-fmk) and caspase 8 
inhibitor (IETD-fmk) therefore detection of caspase 3 cleavage is unlikely.  
Necroptotic cells have high mitochondrial transmembrane potential probably due to 
inhibition of adenine nucleotide translocase (ANT) by RIP1 dependent signals which 
prevent the transport of ADP into mitochondria thus resulting in reduced ATP (291). 
Mitochondrial transmembrane potential can be measured using mitotracker red dyes that 
stains live mitochondria and loses its potential to retain dyes once mitochondria is 
damaged and membrane potential compromised.  
Apoptotic cells exhibit a PARP-1 cleavage of 89 kDa fragment while necrotic cells is 
characterized by cleaved major fragments (89/85, 50 kDa) and minor fragments (40, 35 
kDa). PARP-1 cleavage in necrotic death precedes extensive degradation of DNA thus 
could be used as an indicator of necrosis (295). Gobeil et al. reported that PARP-1 is 
cleaved by lysosomal proteases (cathepsins B and G)  in necrotic cells (296). 
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1.4 Schematic diagram showing the sequence of PARP-1 major 
fragments obtained by cathepsins B and G proteolysis. 
Adapted from Gobeil et al. (Cell death and differentiation 2001 VOL 8:  
588- 594) (296). Characterization of the necrotic cleavage of poly (ADP-
ribose) polymerase (PARP-1): implication of lysosomal proteases).  
 
 
1.5.3.3 RIP3 mediated necrosis 
Recently, studies showed that necrotic cell death can proceed without the activation of 
RIP1 kinase and formation of necrosome. Upton et al. demonstrated that murine 
cytomegalovirus infection triggers a form of necroptosis that requires RIP3 but not RIP1 
(297,298). Zhang et al. also demonstrates that overexpression of RIP3 was shown to 
induce necroptosis even in the absence of RIP1 (299,300). 
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In TLR signaling, caspase 8 is shown to suppress RIP3 dependent programmed necrosis 
initiated via TRIF-RIP3-MLKL pathway, cytokine activation or RIP1-RIP3 necroptosis 
pathway. In binding TRIF, RIP3 have been shown to outcompete RIP1 highlighting the 
critical role of RIP3 in necrotic death (301).  
Vercammen et al. first demonstrated how inhibition of caspases promotes TNF-mediated 
cell death in L929 cells instead of rescuing it (283). This cell death was later identified as 
being necrotic in nature and RIP3 dependent.  
Several RIP3 complexes exist upstream necrosis initiation and these converged to a main 
kinase protein before necrosis execution.  
1.5.3.4 AIF- mediated necrosis 
Recently it was reported that necroptosis can be mediated by mitochondrial apoptosis-
inducing factor (AIF) (302,303). AIF mitochondrial release is stimulated by PARP-1 
activation which further activates it and promotes DNA degradation (304). AIF resides at 
the inner mitochondrial membrane and only release from mitochondria following 
caspase-independent (calpains and cathepsins) proteolytic cleavage to yield a soluble 
proapoptotic protein (truncated AIF) (303). Calpains cleaves AIF in calcium-dependent 
manner while cathepsins mediated cleavage does not involve calcium. AIF cleavage also 
requires Bcl-2 family proteins such as Bax or Bid (305). 
AIF-mediated necroptosis can be induced by alkylating DNA damage (303) that is RIP1 
dependent in studies such as retinal detachment induced photoreceptor necrosis or 
glutamate-induced oxytosis in hippocampal HT-22 cells (306,307). 
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1.5.4 Autophagy 
Macroautophagy (referred to as autophagy) is an evolutionary intracellular degradation of 
cells‘ organelles in the cytoplasm with the help of lysosome to maintain cell survival in a 
bioenergetics crisis. Cellular damage may promote autophagy to prevent accumulation of 
damaged proteins and organelles (308). Many aggressive cancers have upregulated 
autophagy as it is dependent on it for survival (309). Evidences also showed that Ras 
driven cancers usually requires autophagy for survival (310,311). Autophagy provides a 
backup energy reservoir crucial for cell‘s survival like in the case of yeast undergoing 
starvation (312). 
Autophagy plays a number of physiological and pathophysiological roles such as T-cell 
survival and proliferation (313). Nakai et al. demonstrated the protective response of 
autophagy on cardiomyocytes during hemodynamic stress (314). It also regulates the 
control of infectious pathogens. Recently, it is also implicated in cell death. It was 
reported autophagy also plays a role in neurodegenerative diseases (315,316).  
Autophagic cell death can occurs upon cytokines and chemicals treatment like arsenic 
trioxide (317) and histone deacetylase inhibitors (318). It can be triggered by caspase 
inhibition involving ROS accumulation, membrane lipid oxidation and loss of plasma 
membrane integrity (319). Caspase 8 inhibition activates autophagy via the involvement 
of RIP1 and JNK (320). 
The process of autophagy requires several steps from sequestration, merging to 
lysosomes, degradation and utilization of degraded products (321). Autophagy is induced 
by nutrient starvation and possibly hypoxia (322–324). HIF-1, a regulator of hypoxia 
might be involved in autophagy mediation (325). Autophagy occurrence is indicated by 
processing of microtubule-associated protein 1A/1B-light chain 3 LC3-1 to the 
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autophagasome localized LC3-II form. The puncta formation of LC3 can be observed in 
cells undergoing autophagy.   
Autophagy can be inhibited using compounds or expression knockdowns that target key 
autophagic proteins such as ATG7, ATG8 or RIP1 which will block ROS accumulation 
and subsequent cell death (319). Yu et. al demonstrated that autophagy degrades catalase, 
a key component of ROS scavengers disrupting the intracellular ROS balance resulting in 
its accumulation (319).  
The PI3-kinase/AKT pathway is implicated in cell growth through activating mTOR in a 
situation where autophagy is inhibited (326). Cells with a constitutive activation of PI3-
kinase/AKT/mTOR signaling may be susceptible to necrosis as upon nutrient deprivation 
as apoptosis and autophagy is downregulated (327). Apoptosis is the preferred means of 
cell death but when inhibited, autophagy may act to sustain cell‘s viability but a 
prolonged state may lead to cell death. Necrotic cell death occurs in instances where 
apoptosis and autophagy is inhibited. However this form of cell death is inflammatory 
and in some cases actually promotes tumour progression.  
Autophagy has roles in both tumour generation and survival depending on the cell 
conditions rendering its role in cancer rather complicated. The mechanism of autophagic 
cell death or survival and in which condition this switches; is still not elucidated. 
However, studies showing degradation of several proteins like catalase (319), peroxisome 
(328), α-synuclein (329) and Ald6p (330)  during autophagy may gives some insights to 
the mechanism of this process.  
1.5.5 Mitochondria: Final frontier in cell death 
Mitochondria are the powerhouse of cells. Upon cytotoxic assault such as increased 
intracellular Ca
2+
, alkaline pH, ROS and inorganic phosphate the permeability transition 
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(PT) pores at the mitochondrial inner membrane opens. Transient opening of pores allow 
for the release of apoptogenic factors facilitating apoptosis. However, prolonged pores 
opening may result in necrotic cell death (331–333).   
Excess mitochondrial ROS production can cause DNA cleavage, DNA protein 
crosslinking and oxidation of purines (334). This leads to p53 and PARP-1 activation. 
The p53 activation may cause apoptosis and cell arrest but an overactivation of PARP-1 
initiates necrosis. PARP-1 activation also shut down glycolysis needed for ATP 
production. Highly proliferating lymphocytes or tumour cells which utilizes glycolysis 
more than oxidative phosphorylation are more sensitive to cell death (335). 
Incidentally, ROS causes lipid oxidation that lead to the loss of membranes integrity of 
major organelles causing an influx of proteases and Ca
2+
 in the cytosol resulting in 
necrosis. ROS damage the disulphide bonds or break up the sulfhydral links of proteins 
altering its function (336).  
Cyclopholin D (CYPD) is a component of the mitochondrial permeability transition pore 
that regulates the opening of the pore at the inner membrane and is inhibited by 
cyclosporine (241). Agostinis et al. demonstrated that an overexpression of CYPD 
sensitizes neuronal cell line to mitochondrial permeability transition (MPT) and necrosis 
but caspase activation and apoptosis are inhibited. Notably, MPT may have an 
antagonistic role in the apoptosis and necrosis (337). 
CYPD deficiency caused cells to be resistant to necrosis stimulated by H2O2 and Ca
2+
 
overload while apoptosis is not affected (338). This study cemented CYPD-mediated 
MPT as a key effector of cellular necrosis although the mechanism is still unclear. 
Notably as pointed out by Kroemer et al. inhibiting caspases usually delay rather than 
prevent cell death in cells that utilize the mitochondrial death pathway (339). 
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1.6 RIP1 kinase is a Janus like protein 
The RIP serine/ threonine kinases are a family of seven membered proteins which share a 
homologous kinase domain with varying functional domains (340). The variable C-
terminal domains of RIP family members allow RIP proteins to each have diverse 
functions (340). All RIP proteins are involved in modulating NF-kB or cell death 
pathways. RIP1 is the most well studied of the RIP proteins and play a crucial role in 
death receptor pathway (341). RIP2 is involved mainly in immune responses (342) and 
RIP3 play a major role in necrotic cell death(299). Both RIP 6 and RIP7 are implicated in 
Parkinson‘s disease (343).  
 
1.5 Schematic diagram showing the domain organization of RIP 
kinase family proteins. 
Adapted from Zhang et al. (Cellular and Molecular Immunology 2010 
VOL 7:  243- 249) (340). Receptor-interacting protein (RIP) kinase 
family. They share homologous kinase domain (KD). RIP1 and RIP2 
contain C-terminal death domains (DD) and caspase activation and 
recruitment domain (CARD) respectively. RIP3 possess a unique C 
terminus. The RIP homotypic interaction motif (RHIM) is found in both 
RIP1 and RIP3. RIP4, RIP5 and RIP6 possess the ankyrin repeats (ANK) 
domains while both RIP6 and RIP7 contains a Leucine-rich repeat (LRR) 
motifs and Ros of complex proteins/ C-terminal of Roc (Roc/COR) 




RIP1 kinase is an adaptor protein that is both pro survival and pro death depending on the 
cellular context and the type of cytotoxic trigger present (341). RIP1 is known to 
participate in many cellular stress responses. The most studied extrinsic death pathway is 
the TNF receptor (TNFR) super family. Upon TNF ligand binding, death inducing 
complex (DISC) is formed, leading to apoptosis. When caspase activation is 
compromised, cell death switches to be necrotic like. RIP1 mediates this death receptor-
induced programmed necrosis termed necroptosis. The importance of RIP1 is 
exemplified by a study using RIP1-deficient T cells which are resistant to death induced 
by TNF ligands in the presence of caspase inhibitors (344).  
It is established that the kinase activity of RIP1 is required for necroptosis induction. The 
discovery of necrostatin-1, a small molecule that inhibits necroptosis acts to blunt the 
RIP1 kinase activity (277).  
RIP1 is involved in many complexes downstream the death receptor. A cytosolic death 
inducing complex, ripoptosome, containing RIP1, FADD, caspase 8 assembled 
simultaneously upon cIAP depletion (345). Tenev et al.  2011 showed that etoposide-
mediated activation of necroptosis occurs in the absence of cIAPs and is not NF-κB 
pathway mediated (346). Thus, formation of ripoptosome are able to convert 
proinflammatory cytokines into pro-death signals (346).  
Two different forms of RIP1 ubiquitination occur downstream the death receptor 
activation. Interaction of NEMO and Lys(K)-63-ubiquitinated RIP1 subsequently lead to 
the activation of NF-kB pathway which transcribed genes inhibiting apoptosis (347). NF-
kB pathway confers a delayed response to apoptosis inhibition as it is dependent on the 
synthesis of new proteins such as cFLIP (348). On the other hand, Lys (K)-48 
ubiquitination of RIP1 primed it for proteasomal degradation (349).  
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The post translational modification of RIP1 reconciles the pro survival and pro apoptotic 
activities of RIP1 and gives an insight on why different cytokines and proinflammatory 
ligands elicit different cell fate. 
1.6.1 Structure 
The RIP1 kinase protein contains three main domains. The amino terminus kinase 
domain harbour many post translational modifications like phosphorylation and 
ubiquitination with phosphorylation at Ser 161 being the most vital for necroptosis 
initiation (350). Necrostain-1, a small molecule inhibiting necroptosis also binds RIP1 at 
this site (351) this prevents RIP1 recruitment to FADD and subsequent RIP3 recruitment 
to complex (294). The kinase activity of RIP1 is dispensable for NF-kB activation (352). 
Cho et al. demonstrated that the kinase activity is also required for the stable interaction 
between RIP1 and RIP3 (352).  
The RIP homotypic interaction motif (RHIM) located at the intermediate domain is 
responsible for the RIP1 and RIP3 interaction. The phosphorylation of both RIP1 and 
RIP3 is considered to be the driving force for assembly of the RIP1 – RIP3 pro-necrotic 
complex (352). Cho et al. demonstrated that tetra-alanine substitutions in the RHIM of 
both RIP proteins abolished their interaction (242). However, mutagenesis studies 
showed that inhibition of these phosphorylation sites have little influence on TNF-
induced necroptosis (350). 
The intermediate domain of RIP1 is where the ubiquitination of Lys 377 occurs and is 
required for the activation of IκB kinase (IKK) and NF-κB activation (353). The 
interaction with NF-κB essential modulator (NEMO/IKK-γ) with RIP1 polyubiquitin 
chains facilitates IKK activation and subsequent downstream NF-κB pathway (353) 
Binding of major key proteins involved in changing the post translational states of RIP1 
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takes place in the intermediate domain. For example by deubiquitylating RIP1, the 
enzyme cylindromatosis (CYLD) prevents RHIM-dependent oligomerization of RIP1 and 
RIP3 into a necrosome (354). The ubiquitin-modifying enzyme A20 (TNFAIP3) switches 
K-63 polyubiquitin chains to K-48 polyubiquitin chains in RIP1 priming it for 
proteasomal degradation (355).  
The C-terminal of RIP1 is characterized by the death domain which is conserved in FAS, 
TNFR1, FADD and TRADD (356). Upon the induction of death signaling via the death 
receptor, RIP1 binds to the death complex downstream the receptor to initiate the 
formation of various intracellular complexes mediating cellular fate.  
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1.6 Schematic diagram showing the domains and post translational 
modifications of RIP1. 
Adapted from Ofengeim et al. (Nature Reviews Molecular Cell Biology 
Nov 2013 VOL 14: 727- 736 (357). Regulation of RIP1 kinase signalling 
at the crossroads of inflammation and cell death). The amino-terminal 
kinase domain has several post translational modifications most 
prominently the phosphorylation of Ser161 where necrostatin 1 binds 
and important for necroptosis. The intermediate domain contain the 
ubiquitinated Lys377 where large number of proteins particularly those 
involved in NF-kB activation interacts. It also housed the receptor-
interacting protein homotypic interaction motif (RHIM) which is 
conserved in RIP family proteins and facilitates RIP3 interaction. The 
death domain of RIP1 is crucial for initiation of death receptor signaling 
and apoptosis. Cleavage of RIP1 by caspase 8 is at position D324 at the 
intermediate domain.  
 
 
1.6.2 Cellular context and substrates 
Both pro-survival and pro-death signals originate from RIP1 recruitment to the same 
signaling complex. It is hypothesized that the differentiating signal outcome lies in the 
post translational modification of RIP1 (358). O‘Donnell et al. suggested that 
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ubiquitination of RIP1 diverts the otherwise death inducing function of the protein to a 
cytoprotective one (359).    
RIP1 modification via the attachment of the nondegradative polyubiquitin chains by 
cIAPs takes place rapidly upon its recruitment to the TNF receptor. This attachment of 
nondegradative polyubiquitin chains at lysine 377 provides a scaffold for the recruitment 
and activation of pro survival kinases subsequently leading to the NF-κB signaling. It is 
reported that mutation at this site inhibits RIP1 ability to activate NF-κB pathway (360). 
This polyubiquitination chains also provide steric hindrance to FADD and caspase 8 
binding of RIP1.  
During normal conditions, ubiquitinated RIP1 promotes cell survival (361). However, 
with the absence of cellular inhibitor of apoptosis (cIAPs), RIP1 associates with the death 
inducing complex comprises of FADD, caspase 8 amongst others (348). This shifted its 
pro-survival roles to pro-death.  
Gyrd-Hansen and Meier also states that cIAPs are positive regulators of canonical NF-κB 
pathway (p65/p50 or p105/p50) and are required to suppress the constitutive activation of 
noncanonical NF-κB signaling (NIK/p100/p52) (362). 
Two ubiquitin enzymes are responsible for changing the state of RIP1. A20 acts as a dual 
ubiquitin-editing enzyme removing nondegradative ubiquitin chains (Lys-63) to 
attachment of degradative ubiquitin chains (Lys-48) to RIP1 effectively switching NF-κB 
activation upon TNF treatment to promotion of proteasomal degradation of RIP1 (359). 
The enzyme cylindromatosis (CYLD) deubiquitylates RIP1 (279) and downregulates NF-
κB activation allowing for RIP1 kinase to initiate the death signaling complex where 
FADD and caspase 8 are recruited.  It is shown that NEMO (essential for IKK complex 
phosphorylation) is a negative regulator of CYLD (363) which binds specifically to the 
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K63-linked polyubiquitin chains of RIP1 prior to NF-κB activation (364). On the other 
hand, both caspase 8 and RIP3 do not possess ubiquitin binding domains (359).  
Cleavage of RIP1 by caspase 8 at D324 blunts its ability to activate necroptosis (365). 
Cleaved RIP1 (RIPc) showed an enhanced interaction with TRADD and FADD 
potentiating apoptosis (366,367). It generates an NF-κB inhibitory fragment that inhibits 
downstream proinflammatory NF-κB activation (368).  
1.6.3 RIP1 expression 
Overexpression of RIP1 results in JNK, p38, ERK and NF-κB activation (369). However, 
the role in JNK activation is still debatable as Kelliher et al. showed contradictory 
findings (370). It is also noted that only the kinase domain of RIP1is required for ERK 
activation, while not for the rest (371). 
Several studies showed an induction of apoptosis and necrosis/necrosis-like cell death is 
potentiated in RIP1 overexpression depending on cell types (372,373). The cell‘s fate 
upon receptor stimulation is also dependent on the sensitivity of the cell as well as the 
different expression and post translational states of RIP1 and RIP3. Zhang et. al 
demonstrates that an overexpression of RIP1 in wild type MEFs cells leads to necroptosis 
while overexpression of RIP1 in RIP3-deficient MEFs converts it to apoptosis (299). 
Feoktistova et. al showed that the expression of IAPs to be a crucial point in this cell fate 
as it caused a spontaneous ripoptosome formation in HaCat cells (272). 
RIP1 is stabilized by heat shock protein 90 (Hsp90). This association is exemplified by 
Hsp90 inhibitor geldanamycin treatment which upon Hsp90 inactivation simultaneously 
inactivate, destabilize and degrade RIP1 (374,375). The RIP3 protein expression is also 
suppressed by geldanamycin possibly through the same mechanism (288). The caveat is 
geldanamycin acts on all Hsp90 targets for example, Raf-1 of the MAPK pathway. 
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Therefore, RIP1 ablation via this chemical treatment must be verified with knockdown 
studies.   
Many studies showed that genetic ablation of RIP1 results in neonatal lethality surviving 
less than a week of age (370,376–378). Cell death was inhibited by necrostatin-1 but not 
z-VAD-fmk in L929 cells with the knockdown of RIP1 expression. This clearly illustrate 
that necrotic cell death occurs in RIP1 deficient cells and apoptosis inhibition does not 
rescue cells from death. The conversion of necrotic death to apoptotic death is also not 
likely (242). It was reviewed by Han et al. that deletions of either RIP1, RIP3 abrogates 
TNF- or Fas-induced necroptosis (279). This illustrates the essential role of these kinases 
in death receptor-mediated necroptosis. 
1.7 RIP3 is a pronecrotic player 
RIP3, a member of the RIP family member is involved in the TNFR1 signaling complex 
and was shown to mediate apoptosis induction and NF-κB activation (379). RIP3 possess 
a unique C terminus which differs from RIP1 and RIP2 (380). An activating kinase, it 
regulates RIP1-dependent and independent programmed necrosis (300). 
Unlike RIP1 which is recruited to FADD upon death receptor induction, RIP3 associates 
with FADD constitutively (352). Welz et al. further showed that FADD protects against 
RIP3-dependent necrosis and prevent inflammation (381). Phosphorylation of RIP3 by 
RIP1 allows for a stable formation of RIP1-RIP3 pronecrotic complex (361) a prelude to 
necrotic death.   
RIP3 regulates necroptosis in a caspase-independent process through reactive oxygen 
species (ROS) production and inhibition of adenine nucleotide translocase (ANT) causing 
heightened glycogenolysis, glycolysis and glutaminolysis (273).  
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1.7.1 Structure 
RIP3 consists of N-terminal kinase domain that is identical to RIP1. It has a unique C-
terminal where the RIP homotypic interaction motif (RHIM) resides and this facilitates 
its interaction with RIP1 (273) and other RHIM containing proteins like TIR-domain-
containing adaptor-inducing interferon-β (TRIF) of the toll-like receptors (TLRS) 
pathway (301).  
The interaction of RIP1 and RIP3 at the RHIM stabilizes the complex and forms 
necrosome prior to phosphorylation and necrotic death. Both RIP3 and mixed lineage 
kinase domain-like (MLKL) interact at their kinase domains where RIP3 phosphorylates 
MLKL (274). 
Caspase 8 which cleaved RIP1 at D324 position is also implicated in RIP3 cleavage at 
D328 (382), terminating necrosis. However, this truncated RIP3 (329-518 a.a.) (only 
possessing C-terminus domain) can still form punctate that initiates caspase-dependent 
apoptosis and caused a heightened NF-κB activation (382). Feng et al. also demonstrated 




1.7 Schematic diagram showing the domains of RIP3. 
Adapted from Moriwaki et al. (Genes and development 2013 VOL 27: 
1640 - 1649) (383). RIP3: a molecular switch for necrosis and 
inflammation. The phosphorylated site denotes as S199 and S227 and 
crucial lysine residues for kinase activity K50.  
 
 
RIP3 was shown to contain the nuclear localization signal (NLS) at the 442 to 472 amino 
acid position confers it as a nucleocytoplasmic shuttling protein. This NLS triggers the 
commonly cytoplasmic protein to apoptosis in the nucleus (384) and was shown to be 
required for both RIP3-induced apoptosis, RIP3-mediated NF-κB activation, RIP1/RIP3 
interaction and RIP3 self-dimerization (384). RIP3 also possess two leucine-rich nuclear 
export signals (NES) that are highly conserved and are found in p53, p73, MDM2, HIV-1 
Rev, STAT1, cyclin B1, MAPKK and IκBα (384). Treatment with Leptomycin B results 
in nuclear translocation of RIP3 suggesting a CRM-1 dependent mechanism. Yang et. al 
discovered a third NES at the N terminus of RIP3 and its nuclear export activity is 
insensitive to Leptomycin B rendering it CRM-1 independent (384). 
As with RIP1 and RIP2, the kinase domain of RIP3 was not required for either NF-κB 
activation or apoptosis induction. However, RIP3 is an autophosphorylating protein 
kinase (380). A kinase-dead form of RIP3 (K50A) was unable to bind MLKL due to 
blunted kinase activity. The absence of MLKL binding RIP3, arrest the necrosome at its 
precursor form manifesting as small but uniformly distributed cytoplasmic punctae. 
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Phosphorylation of RIP1 at S161 and RIP3 at S199 within the necrosome complex is 
required for necrosome assembly (361). MLKL and RIP3 interact at the basal level but 
this interaction is heightened during TNF-α mediated necrosome initiation (274). 
Autophosphorylation of RIP3 at S227 allows for a stable complex formation with MLKL 
which connects necrosome to the downstream effectors located at mitochondria or 
lysosomes(274). MLKL does not possess intrinsic kinase activity and MLKL function 
can be blocked by necrosulfonamide (NSA) (274).  
Downstream of RIP3 kinase, MLKL binding and phosphorylation at T357 and S358 
triggers phosphorylation of mitochondrial enzyme phosphoglycerate mutase family 
member 5 short form (PGAM5S) (385) facilitating necrosis.  
1.7.2 Cellular context and substrates 
Caspase 8 cleaves RIP3 blunting its signaling pathway and in severe circumstances 
caused embryonic lethality (386,387).  Several studies suggested that RIP3 modify 
caspase 8 and facilitate a negative feedback loop through cleavage of  RIP1, RIP3 and 
CYLD (276,367,382). The mechanism of this modification is not known. Suppression of 
caspase 8 activities promotes TNF-α induced necroptosis in RIP3 expressing cells (299). 
Necroptosis have a role in host defence during infection with pathogens that encode 
caspase 8 inhibitors (354). RIP3 mediated cell death could occur independent of RIP1. 
Upton et. al showed the activation of a viral-induced RIP3 signaling upon IAP depletion 
(298). RIP3 dependent necrosis can be induced by murine cytomegalovirus (MCMV) 
infection in cells expressing DNA-dependent activator of interferon regulatory factors 
(DAI). This RIP3 mediated death can be inhibited by MCMV-encoded viral inhibitor of 
RIP activation (vIRA) (388). 
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Necrotic complexes downstream the death receptors ligation or genotoxic stress exposure 
contains different protein members; but all contain RIP3. This clearly highlights the 
importance of RIP3 as a pronecrotic kinase in cell death regulation.  
RIP3 mediated cell death usually implicates mitochondrial fragmentations. Necrosome 
associates with MLKL/PGAM5L complex before recruiting PGAM5S to activate 
dynamin-1-like protein (Drp1) crucial for mitochondrial fission. The mitochondria attack 
complex (MAC) consists only of PGAM5 and Drp-1 facilitates necrosis induced via 
signals such as calcium flux and oxidative stress. This provides a converging platform in 
the programmed necrotic pathway via different stimulus.  
1.7.3 RIP3 expression 
RIP3 is a critical mediator of necroptosis as genetic ablation of RIP3 can rescue cells 
from inflammatory responses during development once the apoptotic pathway is blocked 
(348). 
RIP3 expression varies considerably in different cell types. High expression is detected in 
macrophages and lymphocytes, but hardly expressed in retina and cardiac myocytes 
(279). This varied expression might have to do with what type of cell death is required 
for the regulation of those cells. It was reported too that RIP1 elevated expression is 
detected in the disease model of acute pancreatitis, retinal detachment and wound healing 
(307,389,390). It is noted that wound healing shares similar traits to inflammation 
process.  
Caspase 8 acts to inhibit RIP3 functions through cleavage. To overcome this inhibitory 
effect, caspase inhibitors could be employed or by elevating the expression of RIP3 as in 
a case of tissue damage (307,389). RIP3 expression is associated with increased 
production of ROS and also influences the metabolic activity of mitochondria (299).  
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Overexpression of RIP3 attenuates both RIP1 and TNF receptor induced NF-κB 
activation and is also a potent inducer of apoptosis as it can selectively bind initiator 
caspases and causes its activation (379,380,391). RIP3 overexpression triggers RIP3 
mediated necrosis (272) and caused embryonic lethality of mice lacking caspase 8 and 
FADD (386).  
Ectopic RIP3 induction to cells with low or no RIP3 expression could easily switch the 
death mechanism from apoptotic to necrotic (299). This is exemplified in the occurrence 
of atherosclerotic plaques in vivo (392). RIP1 and RIP3 dependent necroptosis eliminates 
T cells in caspase 8 or FADD deficient background and can be rescued upon necrosome 
disruption (354).  
Unlike RIP1, RIP3 deficient mice (Rip3-/-) are viable with no visible defect suggesting 
that necrotic death is not critical in normal conditions when caspase-8 dependent 
apoptosis machinery is functional (279). Several studies showed how the loss of RIP3, 
severely impaired RIP1 recruitment to complex II in MEFs (352), reduce the caspase 3 
activities of MDA-MB-231 cell line  in response to etoposide treatment (346) and protect 
liver from TNF induced focal necrosis (393). RIP3 ablation rescues microglia from 
necroptosis underscoring an absolute requirement for the initiating of necrotic death 
(394). Kaiser and Oberst et. al suggested that developmental defects (cardiac, vascular 
and haematopoietic) observed in caspase 8 knockout mice are caused by RIP3-mediated 
necrosis (386,387). RIP3 deficiency was shown to increase viral replication of both 
vaccinia virus and murine cytomegalovirus in mice (298,352). 
An overexpression of dominant-negative RIP3 mutant only blunts caspase activation but 
not NF-κB signaling induced by TNF-α suggesting an intermediary function in apoptosis 
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(379). Understanding RIP3 mediated necrosis and the development of inhibitors of this 
pathway could potentially pave a new way in treating diseases potentiated by RIP3.  
1.8 Necrosis as cell survival mechanism 
Necrotic cell death has garnered a new-found interest in the field of cell death soon after 
the discovery of programmed necrosis. New mechanisms and regulations are still 
unearthing to augment or manipulate necrosis as a therapeutic tool (395).  
The promotion of necrotic death in tumour cells which circumvent apoptosis through 
increased expression of anti-apoptotic proteins such as XIAP, cIAPs, Bcl-2 and Bcl-xL or 
mutation in the pro-apoptotic proteins such as p53 and Bax served to eradicate these cells 
(396).  
Programmed necrosis can induce cell death as well as promote cancer growth and 
metastasis due to its proinflammatory nature (397). Treatment with TNF family ligands 
not only promote cell death, but also drive tumour development and progression due to 
inflammation which see TNF ligands as key mediators (398,399).  
Necrotic cells release intracellular materials such as SAP130, heat-shock proteins, 
histones, HMGB1, RNA and DNA that can trigger inflammatory reactions (279). Most 
necrotic deaths are inflammatory, although some might inhibit inflammation (400). These 
released proinflammatory signals initiates death or reparative responses that may 
maintain tissue integrity. Necrosis served to elicit rapid innate and adaptive immune 
responses in cells when faced with severe threats like viral infection (401) although 
inefficient clearance of necrotic cells may exacerbate the infection.  
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1.8.1 The switch: Apoptosis to necrosis 
Apoptotic and necrotic pathway complexes generally share common proteins. While cells 
induced by death receptors with intact apoptotic mechanism are rescued upon z-VAD-
fmk treatment, cell death in cells with compromised caspase activity is augmented. This 
exemplified the switch between apoptotic to necrotic cell death via the same stress 
stimulus which is dependent on the cellular context of the cells (283,389,402).  
Studies suggested the answer to this switch is the formation of varied death complexes 
downstream death receptor or cytotoxic stress activation (403). In the case of TNF 
signaling, complex I formed downstream receptor ligation includes TRADD,TRAF2/5, 
cIAP1/2, LUBAC and RIP1 kinase (404,405). In the absence or low level of cIAPs, 
complex I will detach from death receptor recruiting FADD and caspase 8. Termed as 
complex II(b) or death-inducing signalling complex (DISC), this formed the precursors to 
apoptotic cell death (406,407). Caspase 8 activation further cleaves RIP kinase proteins 
ensuring necroptosis inhibition (361). A subset of complex II, recruits FLIP proteins 
which resembles caspase 8 but lacks catalytically active residue, negatively affecting 
caspase 8 activity (408). RIP kinases are preserved and this complex is the precursors of 
necrotic cell death.  
The two pronecrotic complexes downstream cell death inductions are necrosome and 
ripoptosome. Necrosome formed from DISC upon caspase 8 abrogation or its activity 
inhibited coupled with the recruitment of RIP3 kinase to the complex (352). The 
phosphorylation of RIP3 via RIP1 kinase activates it and further interacts with its 
substrates downstream to elicit necrotic death (352). Notably, the ratio of overexpressed 
of the intact RIP3 versus cleaved RIP3 could convert apoptosis to necrosis (279).  
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Ripoptosomes are formed independent of death receptor pathway (409). This intracellular 
complex which involves RIP1 kinase, caspase 8 and FADD (409) formed upon depletion 
of IAPs (XIAP, cIAP1s) via Smac mimetics (346) or etoposide (346,410). In the presence 
of IAPs, RIP1 is inactivated in a ubiquitin-dependent manner which marks it for 
proteasomal degradation. Tenev et al. observed that upon proteasome inhibitors treatment 
alone, ripoptosomes are spontaneously assembled (346).  
The formation of ripoptosome centred on RIP1 activity (272,346). Unlike necrosome, this 
complex is able to stimulate caspase-mediated apoptosis as well as caspase independent 
necrosis dependent on FLIP isoforms (272). Other proteins such as caspase 10, cFLIPL 
RIP3 and TRIF can also be found in ripoptosome complexes depending on the type of 
stress stimuli different cells are subjected to. 
The overexpression of RIP1 are able to cause spontaneous ripoptosome formation as seen 
in HaCat cells (272). However, Darding and Meier pointed out that the formation of 
ripoptosome alone is not sufficient to cause death unless an additional signal is 
introduced such as DNA damage or cytokine signaling (409). 
1.9 Objective of studies 
The evasion of cell death is a hallmark of cancer (411). And cell death as we know it 
comes in many facets and forms. Apoptosis, the bona fide death machinery had been 
extensively studied and the sequential steps to its final demise elucidated (412). Cells 
with impaired apoptotic machinery, utilizes another way to die. Necrosis, an unregulated 
form of cellular death has long been regarded as a rudimentary cell death pathway (240).  
A messy exit, cell death through necrosis seems to undergo a violent explosion of plasma 
membrane with its content spilling out. Necrotic death usually triggers the release of 
proinflammatory cues or cytokines which further signalled many cellular targets. This 
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may also initiate an auto immune reaction (413). Recently, a programmable form of 
necrotic death challenged the dogma of necrotic death with the identification of receptor 
interacting protein 1 (RIP1) as a central mediator of this process (414).  
A subset of acute myeloid leukemia cells bearing cytoplasmic mutant nucleophosmin 
(NPMc) is resistant to TRAIL induced apoptosis (415). NPM, a ubiquitous nucleolus 
residing chaperone protein, has numerous cellular functions (8). A frameshift mutation at 
the C-terminus renders the aberrant translocation of NPM to the cytoplasm (5). This 
changes the interaction paradigm of NPM and possibly potentiates cell survival.  
Previous study showed that NPMc interacts and inhibits caspase 6 and 8 deregulating 
apoptosis as well as myeloid differentiation (1).  
This study aims to investigate how AML cells with NPMc mutation utilize alternative 
forms of cell death when apoptosis is inhibited. With renewed interest and progress in 
necrotic cell death, it is anticipated that the uncovering of pathways and/or mechanisms 
involved in the demise of this subset of AML cells, are able to assist in the development 









2 Materials and Methods 
2.1 Cell Culture 
OCI-AML2 (AML2) and OCI AML3 (AML3) cells were obtained from DSMZ 
(http://www.dsmz.de/) and cultured in Alpha MEM (Invitrogen) supplemented with 20% 
fetal bovine serum (FBS, Hyclone) and 1% penicillin/streptomycin (100U/ml penicillin 
and 100μg/ml streptomycin, Invitrogen).  HEK293T cell (gift from Dr Low Boon Chuan, 
NUS) was cultured in RPMI 1640 (Sigma) supplemented with 10% FBS and 1% 
penicillin/streptomycin. Hela cell (a gift from Dr Ge Rou Wen, NUS) was cultured in 
DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin/ 
streptomycin. Jurkat and HT-29 cells (a gift from Ms Pei Yi, NUS) were cultured in 
RPMI 1640 (Sigma) supplemented with 10% FBS and 1% penicillin/streptomycin. HL60 
(a gift from Ms Fen Yee, NUS) and KG-1 cells (obtained from ATCC) were cultured in 
Iscove‘s MEM (Sigma) supplemented with 20% FBS and 1%penicillin/streptomycin. 
Cell lines were maintained in a humidified atmosphere of 5% CO2 at 37
o
C. 
2.2 Plasmid constructs 
The human wild type receptor interacting protein 1 (RIP1), RIP3 and kinase domain point 
mutation forms (RIP1 kinase dead (KD) K45A, RIP3 kinase defective (KD) D160N) 
plasmids cloned into pEGFP-N1 vector were a kind gift from Dr Francis Ka-Ming Chan 
(University of Massachusetts Medical School). The human wild type RIP1 plasmid 
cloned into pcDNA3_FLAG vector was a kind gift from Dr Alexei Degterev (Sackler 
School of Graduate Biomedical Sciences, Tufts University).  
The human wild type and cytoplasmic mutant NPM cDNAs were reversed transcribed 
and cloned into pGEM-T Easy vector (Promega, USA). The constructs were excised 
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using EcoRI and subcloned into pGEX 4T-3 (GE Healthcare) and pAcGFP1-C1 vector 
(Clontech) for recombinant protein expressions (N-terminal GST tag) and transfection 
experiments respectively.  
2.3 Gene expression knockdown 
2 μg of short hairpin RNA (sh RNA) for wild type NPM (Invitrogen) construct cloned 
into pGFP-V-RS vector (OriGene) were used for transfection experiments. 2μg of RIP 
shRNA plasmid (h2) (sc-44326-SH, Santa Cruz Biotechnology) and RIP3 shRNA 
plasmid (h) (sc-61482-SH, Santa Cruz Biotechnology) were used for transfection 
experiments. shRNA plasmid-A (sc-108060, Santa Cruz Biotechnology) was used as 
control. All transfected cells were cultured in normal conditions for 48hrs before further 
treatment.  
2.4 Cell transfection 
OCI-AML2 and OCI-AML3 cells were transfected using Amaxa Nucleofector Kit V 
(VCA-1003, Lonza, AG) with 2 μg plasmid DNA with 1 x 106 cells using programme X-
001. HeLa cells were transfected using Lipofectamine 2000 (Invitrogen) following 
manufacturer‘s recommendations with 2 μg plasmid DNA.  
2.5 Expression of recombinant proteins 
The pGEX 4T-3 wild type NPM and NPMc plasmids were transformed in Escherichia 
coli BL21 (DE3) pLysS bacteria (Novagen). Transformed clones were inoculated in LB 
media incubated in the orbital shaker at 37
o
C. Upon reaching the optimal density of 0.8 at 
600nm, bacteria culture was induced with 0.1μM isopropyl thiogalactopyranoside (IPTG, 
Biorad) for 6hr at room temperature to express recombinant proteins. Bacteria were 
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harvested by centrifugation, resuspended and lysed in 10ml lysis buffer (1x Phosphate 
buffered saline (PBS), 1.5% dithiothreitol, 1% protease inhibitor cocktail mixture (Roche 
Molecular Biochemicals), 1% Triton X-100) via sonication with 10s pulses at 40% 
amplitude for 4 min with 10s intervals. The lysate was centrifuged and a clear lysate 
obtained and subsequently purified by affinity chromatography using glutathione 
sepharose beads (GE Healthcare) according to the manufacturer‘s recommendations. The 
protein-bound beads were washed with 1 x PBS with 1% Triton X-100 for five times and 
a final 1 x PBS wash.  
2.6 In-vitro translation of recombinant protein  
Recombinant RIP1 protein was expressed using an in-vitro translational (IVT) TNT® T7 
Quick Coupled Transcription/Translation System (Promega #L1170) with 0.5μg of 
pcDNA3_RIP1 plasmid following manufacturer‘s protocol. 1μg of IVT reaction product 
was used for subsequent experiments. 
2.7 Drug treatments 
20 μM of rotenone (R8875, Sigma Aldrich) was used induce cell death via mitochondrial 
disruption. 300ng/ml of TNF related apoptosis inducing ligand (TRAIL recombinant, 
GF0921, Millipore) was used to induce cell death via cell death receptor activation. 
20μM of etoposide (E13383, Sigma Aldrich) was used to induce cell death via DNA 
damage. 100ng/ml TRAIL treatment was used for differentiation induction for 48hrs or 
more. Inhibition of Crm-1 dependent NPM translocation to cytoplasm was achieved 
using 5ng/ml Leptomycin B (L 2913, Sigma-Aldrich) treatment for 1 hour. The RIP1 
degradation via Hsp90 inhibitor was achieved using 30μM Geldanamycin (BML-E1280, 
Enzo Life Sciences).  
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2.8 Inhibition of apoptosis and necroptosis 
Cells were treated with 20μM of z-VAD -fmk (pan-caspase inhibitor) (ALX-260-020-
M001, Axxora) for 30 mins to inhibit apoptosis before subsequent manipulations. Cells 
were treated with 30μM Necrostatin-1 (Nec-1) (BML-AP309, Enzo Life Sciences) to 
inhibit necroptosis for 30mins before subsequent manipulations. 
2.9 Cell lysis and subcellular fractionation 
Cells were harvested, pelleted down and lysed using hot SDS lysis protocol. SDS lysis 
buffer containing 100mM Tris-CL pH8.0, 2% SDS, 50mM DTT and 20% glycerol were 
used to lyse the cell pellet. Supernatant were incubated at 85
o
C for 10min and then 
sonicated for an interval of 01 for 15s at amplitude 40%. Incubation at 85
o
C was repeated 
and protein lysates were quantified and stored in -20
o
C. 
Cells were harvested, pelleted down and lysed using total cell lysis  (total cytosolic - 
nucleoplasmic extract) protocol. Cell lysis buffer (100mM HEPES pH 7.5, 5mM MgCl2, 
150mM NaCl, 1mM EDTA, 1% Triton X-100 + 1% protease inhibitor cocktail [AEBSF-
Hydrochloride, Aprotinin, E-64-Protease Inhibitor, EDTA-Disodium, Leupeptin-
Hemisulfate] ) was added to lyse the cells. The cell lysate was further then sonicated for 
an interval of 01 for 15s at amplitude 40%. The cell lysate was finally centrifuged at 
13,000rpm for 20 minutes to pellet the DNA and the supernatant was stored in -20
o
C. 
Essentially, both total cell lysis and hot SDS lysis protocol aimed to yield the total prote in 
of the cell. Hot SDS cell lysis method is preferred in some experiments as it is effective 
in preventing the degradation of proteins with short half-lives which are mostly degraded 
via the proteasomal pathway as compared to the total cell lysis protocol.  
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Cells were harvested, pelleted down and lysed to obtained S100 cell lysate. Detergent 
free cell lysis buffer (20mM Hepes-KOH, pH 7.5, 10mM KCl, 1.5mM MgCl2, 1mM 
EDTA, 1mM EGTA, 3mM dithiothreitol, 1% protease inhibitor cocktail) was added to 
swell the cells. The lysate was further dounced 25 times on ice using Wheaton Douce 
Homogenizer (Millville, #357542). The cell lysate was finally centrifuged at 13,000rpm 
for 20 minutes to pellet the DNA and the supernatant was stored in -20
o
C. 
2.10 Cell death assays 
Cells were treated with 300ng/ml TRAIL for indicated time points. Cells were harvested, 
washed twice with ice-cold PBS and resuspended in 100μL of binding buffer (140mM 
NaCl, 2.5mM CaCl2 and 10mM HEPES pH7.4) and incubated with 5μL of Annexin V-
FITC (BD Bioscience, #556570 and 200ng of 7-AAD viability dye (Invitrogen, #A1310) 
in the dark for 15 min. Samples were processed using BD FACSAria II flow cytometer 
(BD Bioscience) and analyzed using Cyflogic software (CyFlo Ltd).  
Muse® Annexin V and Dead Cell Kit (Merck Millipore, # MCH100105) was used to 
analyze live, early and late apoptosis, and cell death using manufacturer‘s protocol. 
Samples were processed using Muse® Cell Analyzer (Merck Millipore, #0500-3115) and 
plots generated using Muse® Annexin V and Dead Cell software module. 
Mitochondria integrity was assessed via Mitotracker Deep Red (Invitrogen, #M22426) 
staining for 30mins at 37
o
C, Cells were then harvested and fixed in ice cold 100% 
methanol and rinsed with PBS. Stained cells are analyzed using flow cytometry (BD 
FACSAria II) at 644nm excitation and 665nm emission.  
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2.11 Caspase assays 
Treated cells were harvested, washed twice with PBS and lysed using S100 lysis buffer. 
Clear protein lysates were obtained after douncing on ice and centrifugation. Equal 
amount of protein (50μg) containing 1 x reaction buffer with 10mM DTT (Biovision) 
was pipetted into 96 well microplates and incubated with 200μM of pNA-tagged caspase 
colorimetric substrates (Biovision). The colored pNA product were measured at 405nM 
at 2 min interval for 16hours. DEVD-pNA for caspase 3, VEID-pNA for caspase 6 and 
IETD-pNA for caspase 8. 
2.12 Blue Native electrophoresis and 2-D gel analysis 
Treated cells were harvested and protein lysate obtained using native cell lysis buffer (1 x 
Native PAGE
TM
 Sample Buffer (Invitrogen), 10% n-Dodecyl β-D-maltoside (DDM), 5% 
Digitonin). 5% (w/v) Coomassie Blue G250 sample additive was added prior to sample 
run with NativePAGE™ Running Buffer (Invitrogen). The control cells set were also 
subjected to the same procedure. Equal amount of native protein lysate was separated 
using 3-12% NativePAGE™ Gels (Invitrogen). The protein complexes separated via 
mass and physical shape. To negate separation via net charge, Coomassie Brilliant Blue 
dye is used to transfer additional charge to the proteins. 
The individual strips of the protein sample separated (containing protein complexes) were 
excised and subjected to a second dimension electrophoresis with 12% SDS PAGE to 
separate out individual proteins in a complex. First immunoblotting was carried out using 
RIP1 antibody. The same membrane was reblotted using NPM antibody to compare the 
localization of the each protein.  
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2.13 Co-immunoprecipitation of RIP1 containing complexes 
Treated cells were lysed using S100 cell lysis protocol. Two milligrams of Dynabeads 
(Cat no 142.03 M280 Tosylactivated, Invitrogen) were used to bind 40μg of mouse RIP1 
(Cat #610458, BD Transduction Laboratories) antibody using manufacturer‘s protocol. 
Three milligrams of total cell lysate was added to the beads and incubated with rotation 
for 24hrs at 4
o
C. The supernatant was removed and the beads were washed 3 times with 
total cell lysate buffer. The desired antigen was eluted using 30ul of Elution Buffer 
(Pierce) according to manufacturer‘s protocol or us ing 0.1M sodium citrate pH 3.0. 
Eluates were subsequently used for immunodetection using desired antibodies. A 
negative control (IP using normal mouse/rabbit IgG) and an input lane of 20μg protein 
lysate were also included.  
Other co-immunoprecipitation experiments using various antibodies followed the 
protocol above. 
2.14 Western Blotting 
Protein lysates were quantified using Bradford protein assay (#500-0201, Bio-Rad). 
Equal amount of protein lysates or eluates from immunoprecipitation were loaded in 10-
15% SDS PAGE gel and separated using Bio-Rad system. Protein was then transferred 
onto nitrocellulose membrane using Trans-Blot
®
 SD Semi-Dry Electrophoretic Transfer 
Cell (#170-3940, Bio-Rad) and probed with desired primary antibodies for overnight 
incubation at 4
o
C or 2hr at room temperature. Blots were subsequently incubated with 
secondary antibodies conjugated to HRP, goat anti-rabbit IgG-HRP (sc-2004, Santa Cruz) 
or goat anti-mouse IgG-HRP (sc-2031, Santa Cruz) and detected using ECL SuperSignal 
West Pico Chemiluminescent Substrate Kit (#34080 Pierce, USA) and images obtained 
using GBox Chemiluminescence System (Syngene). 
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Primary antibodies used were:  mouse RIP1 (BD #610458, 1:1000), rabbit cleaved RIP1 
D94C12 (Cell Signaling #3493s, 1:1000), mouse NPMc (a kind gift from Sir David Lane, 
p53 Lab, A*STAR), rabbit NPM (Cell Signaling #3542, 1:1000), mouse Actin (Sigma 
Aldrich #A5441, 1:10000), rabbit PARP-1 (Santa Cruz #sc-7150, 1:1000), mouse Hsp 90 
4F10 (Santa Cruz #sc-69703, 1:1000), rabbit RIP3 (Thermo Scientific #PA5-13996, 
1:500), rabbit LC3B (Cell Signaling #2775, 1:1000), rabbit MLKL (Cell Signaling 
#M6697, 1:1000), mouse caspase-8 IC12 (Cell Signaling #9746, 1:1000), rabbit caspase-
6 (Cell Signaling #9762, 1:1000), rabbit caspase 3 (Cell Signaling #9662, 1:1000), rabbit 
FADD (Santa Cruz  #sc-5559, 1:1000), rabbit Ras (Cell Signaling #3965, 1:1000), rabbit 
total ERK (Cell Signaling #9102L, 1: 1000), rabbit phospho-ERK (Cell Signaling 
#9101S, 1:1000), rabbit HMGB1 (Cell Signaling #3935, 1:1000)  
2.15 May-Grünwald-Giemsa (MGG) staining for cell differentiation 
This method is commonly used to determine the histology of blood cells. The dye 
contains a mixture of eosin, methylene blue and azures that will stain nuclei purple-red 
and cytoplasm light blue-gray to red violet. It is used to differentiate cell types in the 
myeloid lineage. Cells were induced for terminal differentiation with TRAIL treatment 
(100ng/ml) for 48hrs or more. Cells were harvested, washed twice in ice-cold PBS, 
cytospun onto glass slides and fixed in 100% methanol for 10min. The cells were then 
stained with May-Grünwald stain (BDH, diluted 1:2 times) for 7 min followed by Giemsa 
stain (BDH, diluted 1:9 times) for 8 min. The stained slides were rinsed briefly in 
deionised water and mounted with DPX (BDH). Images were obtained via inverted 
fluorescence microscope at 100 x oil immersion magnifications (Axiovert 25, Carl Zeiss 
Meditech, Germany).   
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2.16 Immunofluorescence 
Treated AML cells were harvested, washed twice in PBS and cytospun onto glass slides. 
HT-29 cells were grown onto glass coverslip and treated. The cells were fixed with 3.7% 
paraformaldehyde in PBS and permeabilized with 0.2% Triton X-100. The cells were 
blocked with 5% goat serum in PBS for 1hr at room temperature followed by overnight 
incubation with primary antibodies at 4
o
C. The cells were washed thrice with PBS and 
incubated with AlexaFluor-labelled secondary antibodies (Invitrogen, 1:1000) for 1 hr at 
room temperature. Cells were mounted in DAPI-containing Vectashield mounting media 
(Vector Labs). Images were obtained via inverted fluorescence microscope at 40 x 
magnifications (Axiovert 25, Carl Zeiss Meditech, Germany). Primary antibodies were 
used:  mouse RIP1 (BD #610458, 1:200), mouse NPMc (a kind gift from Sir David Lane, 
p53 Lab, A*STAR), rabbit NPM (Cell Signaling #3542S, 1:200) and rabbit RIP3 
(Thermo Scientific #PA5-13996, 1:200). Secondary antibodies: AlexaFluor 488 and 
AlexaFluor 647 
2.17 Microscopy 
Apoptosis was assessed using nuclear morphology examination upon DNA staining. 
Cells were harvested, washed twice with ice-cold PBS and resuspended in 100μL of 1 x 
PBS and incubated with 4mM Hoechst 33342 (Sigma-Aldrich) for 10 mins. Apoptotic 
cells with condensed and fragmented highly fluorescent nuclei were captured via an 
inverted fluorescence microscope at 40 x magnifications (Axiovert 25, Carl Zeiss 
Meditech, Germany).   
Primary and secondary necrosis was assessed using DNA staining pattern upon 
propidium iodide (PI) staining. Cells were harvested and fixed with methanol for 5min 
and acetone for 2min. Cells were resuspended in PBS containing 10µg/ml propidium 
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iodide and 5µg/ml RNaseA for 15min incubation at room temperature. Cells were 
examined under the fluorescence microscope. Upon PI staining, necroptotic cells showed 
primary necrotic cells‘ characteristics such as cytoplasmic swelling and condensation of 
chromatin that gives rise to ―patchy‖ staining. On the other hand, the nuclei of secondary 
necrotic cells are condensed and fragmented. The DNA staining is more homogenous as 
the chromatin structure was disrupted earlier on during apoptosis.    
 
2.18 NF-κB transcription factor assays  
Cells were subjected to various treatments, harvested and S100 protein lysate obtained.  
50 μg of S100 protein lysate were used for p65 and p52 activation using TransAM NF-
κB Family Transcription Factor Assay Kit #43296 according to manufacturer‘s protocol.  
3 Characterization of NPM protein expression and cell death in 
AML cells 
3.1 Introduction 
Nucleophosmin (NPM) is an abundant chaperone protein which is involved in many 
cellular processes such as ribogenesis and centrosome duplication (8). Overexpressions 
of NPM in several cancers have been reported (84–87). A frameshift mutation in the 
NPM gene confers an additional nuclear export signal (NES) motif that caused the 
accumulation of nucleolus residing NPM protein to the cytoplasm (59). Termed as NPM-
cytoplasmic positive (NPMc) mutation, it was first discovered in AML cells (416).  
Characterized as multifunctional chaperone protein, NPM is expected to have multiple 
interacting partners (18,37,103,178,183,185). How NPM mis-localization affects its 
interaction with other proteins would be an interesting idea to expound on. Aside from 
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the level of expression, the post translational modification of NPM such as 
phosphorylation and sumoylation are said to play an important role in DNA damage 
response, RNA binding, centrosome duplication, cell cycle and apoptosis. NPM is 
cleaved by granzyme M (417) and susceptible to caspase 3 dependent proteolytic 
cleavage which subsequently caused a decrease in cell survival (418).  
The characterization of NPM expression, post translational modifications, isoforms, 
cleavage and localization should be determined in human cell lines before further studies 
are performed.  Since NPM-cytoplasmic positive (NPMc) frequently occurs in AML 
cells, OCI-AML2 and OCI-AML3 are used as models for this study. OCI-AML2 
expresses wild type NPM that are mostly nucleolus bound whereas OCI-AML3 expresses 
both mutant cytoplasmic NPM (NPMc) and wild type NPM. The expression and state of 
NPM protein is further examined upon exposure to cytotoxic drugs that target different 
cellular pathways. These experiments give insights on how NPM protein response to 
cellular disturbances. The mode of cell death upon cytotoxic treatment is examined 
between the two types of AML cell lines to ascertain if the localization of NPM plays a 
role in cell death.  
The mitochondrial integrity and caspase activation is examined in relation to the different 
mode of cell death. The characterization of a new death phenomenon known as 
necroptosis, a form of primary necrosis cell death response, is in its earlier stages of 
discovery. Coupled with its necrosis like appearance, determination of this form of death 
requires several key experiments to characterize it. Comparison to HT-29 colorectal 
adenocarcinoma cell lines known to undergo necroptotic cell death upon TRAIL 
treatment in the presence of pan caspase inhibitor (z-vad), is included as a control in this 
study. The overexpression and knockdown of NPM was performed to determine its role 
in cell death.  
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3.2 Results 
3.2.1 NPM expression is unperturbed upon exposure to cytotoxic drugs in 
myeloblast cells  
OCI-AML2 and OCI-AML3 are used as a model system expressing different NPM 
isoforms. The expression of NPM was examined upon exposure to several cytotoxic 
agents to determine its stability. Rotenone (inhibitor of mitochondrial electron transport), 
etoposide (topoisomerase inhibitor) and TRAIL (TNF related apoptosis inducing ligand 
that interacts with death receptors to invoke cell death cascade) were used to examine 
NPM expression upon exposure to agents. Results showed that, NPM expression is 
unperturbed in both AML cells upon exposure to drugs (Fig 3.1). The stable NPM 
expression suggests that NPM does not play a role in the upregulation of cell division or 
cell cycle arrest upon these cytotoxic insults in AML cells.  
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3.1 Expression of NPM is unperturbed upon exposure to cytotoxic 
drugs in myeloblast cells. 
OCI-AML2 and OCI-AML3 were subjected to rotenone (20 μM), 
etoposide (20 μM) and TRAIL (300ng/ml) treatment ranging from 0.5hr 
to 48 hr. The cells were harvested and total cell lysate obtained. 20 μg of 
lysate were separated using SDS PAGE and immunoblotted using NPM 





3.2.2 NPM translocates to the cytoplasm upon cytotoxic treatment 
NPM is a shuttling chaperone protein. It resides in the nucleolus and performed its 
functions shutting to the nucleus, cytoplasm and back (8). Upon TRAIL treatment, NPM 
translocated from nucleoli to the nucleus and then the cytoplasm of OCI-AML2 cells (Fig 
3.2). The migration of NPM to the cytoplasm allows it to interact with proteins involved 
in the death signaling activation in an attempt for cell survival. This illustrates that NPM 
plays a cytoprotective role in cell homeostasis.  In OCI-AML3 cells, mutant cytoplasmic 
NPM resides aberrantly in the cytoplasm and unperturbed by TRAIL treatment. This 
highlight that the mis-localization of mutant NPM to the cytoplasm in OCI-AML3 cells 
might retard the functions of proteins involved in cell death rendering its survival. 
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3.2 Wild type NPM translocates to the cytoplasm upon cytotoxic 
treatment.  
OCI-AML2 and OCI-AML3 cells were treated with TRAIL (300ng/ml) 
for 24 hours.  Cells were harvested and fixed with 4% paraformaldehyde 
for 10 mins at room temperature. Immunofluorescence staining using 
mouse NPM antibodies (Invitrogen) and corresponding Alexa-Fluor 647 
labelled secondary antibody were performed. Cells were counter stained 
with DAPI-containing mounting media (Vector Laboratories). Images 
obtained via inverted fluorescence microscope at 40 x magnifications 
(Axiovert 25, Carl Zeiss Meditech, Germany).  Composite images were 
overlapped using Image J Software. White arrow indicates NPM 
translocation to the cytoplasm in 38.2% of the cell population measured. 
Scale bar represents 20 μM. 
 
 
3.2.3 Apoptosis is inhibited while necrotic cells number is high in OCI-AML3  
The mode of cell death was assessed in AML cells upon TRAIL treatment. Both AML 
cells were treated with TRAIL (300ng/ml) for 24 and 48 hours and the percentage of 
apoptotic cells represented by positive Annexin V staining were measured using FACs. 
Level of apoptotic Annexin V positive cells increased after 24 and 48 hours treatment in 
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OCI-AML2 cells. In OCI-AML3 cells, the number of apoptotic cells did not increase 
after over 24 hour treatment. This suggest that apoptosis is inhibited in OCI-AML3 (Fig 
3.3a). However, staining with propidium iodide (PI) and subsequent FACs analysis 
showed necrotic cells number is high in untreated OCI-AML3 cells.  Upon treatment with 
TRAIL the level of necrotic cells increased steadily in OCI-AML2 cells, but not as 
significantly in OCI-AML3 cells. This gives an indication that OCI-AML3 might employ 
an alternative form of cell death as apoptosis is inhibited (Fig 3.3b,c).  To further confirm 
that high necrotic cell number detected in FACs analysis is not false positive, differential 
PARP-1 cleavage was examined (Fig 3.3d).   
The treatment with TRAIL and cycloheximide (TC) combination induced cell death 
through TRAIL induction coupled with de novo protein synthesis inhibition. The 
treatment with TRAIL, cycloheximide and z-VAD-fmk (TCZ) combination induced 
necroptosis upon caspase inhibition. The treatment with TRAIL, cycloheximide and 
necrostatin-1 (TCN) combination inhibits kinase activity of RIP1 which is crucial for 
necroptosis. Lastly, the treatment with TRAIL, cycloheximide, z-VAD-fmk and 
necrostatin-1 (TCZN) combination inhibits caspase cascade and subsequently apoptosis 
as well as necroptosis. Apoptotic cell death yields PARP cleavage at 89kDa and 25kDa. 


















3.3 Apoptosis is inhibited in OCI-AML3 cells and necrotic cells 
number is high. 
a) AML cells were treated with TRAIL (300ng/ml) for 24 and 48 hours. 
Cells were stained by Annexin V and the percentage of apoptotic cells 
represented by positive staining was measured using FACs.  ^ n=4 * b) 
AML cells were treated as above and stained with 7-Aminoactinomycin 
D (7AAD). FACs measurements of positive stained cells were obtained 
and the number of cell death was expressed as a percentage of total 
events recorded.  ^n=3 c) Dual AnnexinV and 7AAD, viability staining 
of above treated cells followed by FACs analysis showed necrotic cells 
are high in untreated OCI-AML3 cells.  ^ independent experiments.* 
p<0.1 d) AML cells treated with different combination of TRAIL (T) 
(300ng/ml), cycloheximide (C) (10 μg /ml), z-VAD fmk (Z) (20 μM), 
Necrostatin-1 (N) (30 μM) for 6 hours. Cells were harvested and total 
cell lysate obtained. 20 μg of protein lysate was separated using SDS 
PAGE and immunoblotted using PARP-1 antibody. Actin is used as a 
loading control.  
 
 
3.2.4 OCI-AML3 cells have a high level of secondary necrotic cells although 
necroptosis cannot be induced  
Necrosis is an alternative form of cell death. Necroptosis or programmable necrosis can 
be induced through inhibition of caspase cascade with simultaneous ligands treatment 
activating the death receptor. Propidium iodide (PI) stained AML cells were examined 
under the microscope to determine its staining pattern. These staining patterns 
differentiate primary and secondary necrosis. Primary necrosis is a characteristic of 
programmed necrosis or cells that chose necrosis as the initial death pathway. Secondary 
necrosis is a by-product of cells that have undergone the other form of cell death namely; 
apoptosis thus represent the end fate of all dead cells.  
Both AML cells were treated with pan-caspase inhibitor z-VAD fmk to inhibit caspase 
cascade activation. Cells were then exposed to TRAIL (300ng/ml) and cycloheximide, 
CHX (de novo protein synthesis inhibitor) for 24 hours to induce necroptosis. Cells were 
then harvested, fixed, stained using propidium iodide (PI) and images were captured 
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using ZEISS microscope at 40 x magnification. Composite of brightfield and RFP images 
were generated using Image J software. Green pseudo channel was used to better contrast 
of the two merged channels. The same images were represented in black and white to 
highlight the DNA staining pattern. 
Differential PI staining shows the mode of necrotic death in a cell. Primary necrosis also 
known as necroptosis was characterized by the intact chromatin structure and ―patchy‖ 
staining. Primary necrotic cells displayed increased cytoplasmic swelling, nuclear 
membrane dilation and condensation of chromatin into ―patches‖. On the other hand, the 
nuclei of secondary necrotic cells are condensed and fragmented. The DNA staining is 
more homogenous as the chromatin structure was disrupted earlier on during apoptosis.    
Results showed OCI-AML2 undergoes a secondary form of necrosis upon apoptosis 
induction via TRAIL and cycloheximide treatment (Fig 3.4a). Upon necroptosis 
induction via TRAIL, cycloheximide and caspase inhibition with z-VAD fmk, OCI-
AML2 demonstrated primary necrosis staining. Interestingly, primary necrosis is not 
initiated in OCI-AML3 cells upon necroptosis induction. Instead, cells showed 
substantial secondary necrosis staining in untreated OCI-AML3 cells as well as in 
apoptosis and necroptosis induced population. This suggests OCI-AML3 has a high level 
of secondary necrotic cells and necroptosis cannot be induced.  
Another set of AML cells were treated as mentioned above with an addition of 
Necrostatin-1 (Nec/ Nec-1) to inhibit kinase activity of RIP1 blunting necroptosis. Cells 
were harvested after 6 hours and viewed under the bright view microscope (Fig 3.4b). 
Necrotic cells have a swollen appearance due to organelle swelling and a translucent 
cytosol while apoptotic cells have a shriveled morphology and condensed nuclei. Cells 
were counter stained with DAPI to analyze for condensed nuclei staining, an indication of 
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apoptosis. Images were taken using inverted fluorescence microscope at 10 x 
magnification. DAPI staining was enhanced in OCI-AML2 cells upon apoptosis 
induction (TC) and RIP1 kinase inhibition (TCN) but not in OCI-AML3 cells. Inhibition 
of caspase cascade with simultaneous necroptosis induction (TCZ) together with double 
inhibition of apoptosis and necroptosis (TCZN) rescued OCI-AML2 cells from apoptotic 
cell death indicated by decreased DAPI staining. This rescue is not demonstrated in OCI-
AML3 cells. 
Activation of necroptosis caused mitochondrial dysfunction through permeabilization of 
mitochondrial membrane and release of cytotoxic proteins like apoptosis-inducing factor 
(AIF) to the cytosol (419). Mitotracker Deep Red (Invitrogen) are cell permeable probes 
used to label mitochondria. Cells with intact mitochondria will accumulate this stain 
which diffuses passively across the plasma membrane. OCI-AML2 and OCI-AML3 cells 
treated with TRAIL (300ng/ml) over a time course up to 24 hours were stained with 
Mitotracker dyes (Fig 3.4c). Results showed that the mitochondria in OCI-AML3 cells 
are more preserved as compared to OCI-AML2 cells upon TRAIL treatment. This 
highlight that necroptosis affecting mitochondrial dysfunction is unlikely to occur in 

















3.4 Further induction of primary necrosis is inhibited in OCI-AML3 
cells. 
a) AML cells were treated with TRAIL (300ng/ml), cycloheximide (10 
μg /ml) and zVAD fmk (20 μM) for 6 hours. Cells were harvested and 
stained with propidium iodide (PI) for 30 mins and viewed under the 
inverted fluorescence microscope at 40 x magnifications (Axiovert 25, 
Carl Zeiss Meditech, Germany).  PI staining images were taken using 
RFP filter. Composite of brightfield and RFP images were generated 
using Image J software. Green pseudo channel was used to better 
contrast of the two merged channels. Same images are represented in 
black and white to highlight DNA staining pattern. Scale bar represents 
20 μM. b) AML cells were treated with TRAIL (300ng/ml with a 
combination of z-vad (20 μM) and nec-1 (30 μM). Z-vad was used to 
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inhibit apoptosis and induced necroptosis in the presence of cytotoxic 
stress. Necrostatin 1 (nec-1) was used to inhibit necroptosis. A set of 
enlarged images were added for comparison of the different morphology 
of cell death. Image of cells were taken using the light microscope at 40 
x magnification. Red arrow denotes necroptotic like morphology and 
black arrow denotes apoptotic like morphology. Images for DAPI stained 
cells were taken using the inverted fluorescence microscope at 10 x 
magnification. c) OCI-AML2 and OCI-AML3 cells were treated with 
TRAIL (300ng/ml) for duration of up to 24 hours. Cells were incubated 
with Mitotracker Deep Red (Invitrogen) for 30mins at 37
0
C and 
harvested. Cells were then fixed in ice cold 100% methanol and rinse 
with PBS. Stained cells are analyzed using flow cytometry (BD 
FACSAria II) at 644nm excitation and 665nm emission. Stained cells 
with intact mitochondria were expressed as a percentage of total cells 
analyzed. Results were tabulated from 3 independent experiments and a 
histogram of one representative analysis was shown.   
 
 
3.2.5 OCI-AML3 cells are inflammatory 
Necrosis is an inflammatory form of cell death compared to apoptosis. High mobility 
group 1 (HMGB1) chromatin proteins that are released into the extracellular matrix have 
been used to characterize the necrotic form of cell death (420). HMGB1 subsequently 
triggers inflammation in cells. Since the total level of HMGB1 is low in both AML cells 
(Fig 3.5a), identification of HMGB1 proteins that were released into the cell culture 
media is almost impossible as it would be masked by contaminating serum proteins. In its 
place, heat shock protein 90 (Hsp90) which is abundant in cells were used to assess 
inflammation. The secreted form of Hsp90 has important roles in angiogenesis and 
metastasis (421). 
HT-29 cells known to undergo necroptosis were used as a model system. To determine 
the inflammatory nature of necrosis, AML cells and HT-29 cells were treated with 
TRAIL (300ng/ml) and CHX (20 μM) for 6 hours to induce apoptosis. Necroptosis were 
induced using TRAIL (300ng/ml), CHX (20 μM) and z-VAD fmk (20 μM) for 6 hours. 
The culture media in which the cells were grown were harvested and separated using 
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SDS PAGE electrophoresis. Immunoblotting was performed on the samples and probed 
using Hsp90 antibodies. Extracellularly secreted Hsp90 is said to promote pro-
inflammatory signaling functions in cells.  
Results showed that necroptosis induced HT29 cells released a higher level of Hsp90 
proteins compared to when apoptosis was induced (Fig 3.5b). This further illustrate that 
necrosis is a more inflammatory form of death compared to apoptosis. The Hsp90 
proteins detected in apoptotic induced cells most probably contributed by secondary 
necrotic cells following apoptosis. OCI-AML2 releases Hsp90 proteins only when 
challenged with TRAIL. Surprisingly, untreated OCI-AML3 cells released Hsp90 
proteins and further treatment with TRAIL does not change the level of Hsp90 released. 
This showed that OCI-AML3 is highly inflammatory even before cytotoxic assaults 
which further confirmed its necrotic nature. The question is why are OCI-AML3 cells 
highly necrotic? One possible explanation is that inhibition of apoptosis in these cells 
caused a rudimentary backup form of cell death to emerge controlling cells‘ homeostasis. 
This alternative form of cell death is probably necrosis. However, our results showed that 
programmed necrosis or necroptosis could not be induced in OCI-AML3 cells. Thus, 
OCI-AML3 might have undergone other forms of alternative cell death, which eventually 












3.5 Release of pro-inflammatory proteins into the culture media. 
a) The level of total HMGB1 proteins from a cell panel was assessed. 
Total HMGB1 protein exists in a low level in AML cells. Hsp 90 with a 
more abundant expression is used as a marker for inflammation. b) Pro-
inflammatory proteins released to the culture media was harvested and 
separated via SDS PAGE and immunoblotted with Hsp90 antibodies 
upon cytotoxic treatment. HT29 cells were used as a control to illustrate 
the release of pro-inflammatory upon apoptosis (TRAIL/CHX) and 
necroptosis (TRAIL/CHX/zVAD) induction. 
 
 
3.2.6 Nucleophosmin degradation affects RIP1 cleavage and potentiates PARP-1 
cleavage 
Leong et al. demonstrated that apoptosis is inhibited in OCI-AML3 ―through direct 
interaction of cytoplasmic mutant NPM with cleaved caspase 6 and cleaved caspase 8‖ 
(1). Inhibition of apoptosis allows for a backup cell death mechanism to come forth. Tan 
et al. demonstrated that OCI-AML3 bearing NPMc upregulates autophagy upon 
cytotoxic stress with Arabinofuranosyl Cytidine (Ara-C) treatment (unpublished results). 
However, it was demonstrated that NPMc did not directly upregulate PI3K III – Beclin 1 
autophagy initiating complex although it is suggested that there may be an increased in 
cytoprotective autophagy with NPMc overexpression (unpublished results).  
It had been reported that necrosis occurs downstream of autophagic death and both 
processes shared common molecular pathway that may involve Receptor Interacting 
Protein Kinases (RIPKs). Since necroptosis is inhibited in OCI-AML3 cells (Fig 3.4a-c), 
we proceed to examine this pathway focusing on RIP1 kinase as its precursor. 
OCI-AML2 and OCI-AML3 cells were treated with TRAIL (300ng/ml) at varying time 
points up to duration of 24 hours. Cells were harvested and total cell lysate obtained. 20 
μg of cell lysate were separated using SDS PAGE and immunoblotted using RIP1 kinase 
antibody to assess the expression of RIP1 kinase.  Interestingly, RIP1 cleavage is 
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observed in untreated OCI-AML3 cells while it is cleaved in OCI-AML2 only after 
TRAIL treatment (Fig 3.6a). RIP1 is cleaved at D324 by activated caspase 8 (367) and 
promotes apoptosis directly by enhancing TRADD and FADD interaction (361). The 
presence of NPMc in the cytoplasm possibly stabilizes the interaction of RIP1 with 
caspase 8 thus promoting cleavage. Cleavage of RIP1 also prevents RIP1-mediated pro-
survival gene activation and inactivates its kinase activity needed for necroptosis 
OCI-AML2 and OCI-AML3 were subjected to NPM knockdown. 2 μg of sh NPM 
(Invitrogen) cloned in pGFP-V-RS vector was transfected into the cells and incubated in 
CO2 incubator at 37
o
C for 48hrs. Cells were treated with TRAIL (300ng/ml) for 6 hours 
and harvested. Total cell lysate were obtained and samples were separated using SDS 
PAGE and immunoblotted using NPM antibody to assess NPM protein knockdown. RIP1 
cleavage is detected in OCI-AML2 cells when treated with TRAIL (Fig 3.6b). Full length 
RIP1 kinase has a role in anti-apoptotic functions and its cleavage potentiates apoptosis. 
This cleavage decreases when NPM was knockdown following TRAIL treatment in OCI-
AML2 cells. Cleaved RIP1 enhanced apoptosis while inhibiting necroptosis and NF-κB 
pro-survival pathway activation (368). Notably, RIP1 cleavage detected in non treated 
OCI-AML3 cells decreased upon NPM knockdown.  This suggests that NPM expression 
correlates with RIP1 kinase cleavage in OCI-AML3 cells. PARP-1 cleavage was 
potentiated more readily in OCI-AML2 compared to OCI-AML3 cells with TRAIL 
treatment. NPM knockdown reversed this trend in AML cells possibly due to differences 
in cell death mechanism. NPM downregulation redirects OCI-AML2 cells from apoptotic 
to non apoptotic cell death while it releases apoptosis and necroptosis ‗inhibition‘ on 







3.6 Knockdown of NPM affects RIP1 cleavage and potentiates 
PARP-1 cleavage in OCI-AML3 cells.  
a) OCI-AML2 and OCI-AML3 cells were treated with TRAIL 
(300ng/ml) over a time course of up to 24hrs. Cells were harvested and 
total protein obtained. 20 μg of protein lysate were separated using SDS 
PAGE and immunoblotted using RIP1 kinase antibody. b) OCI-AML2 
and OCI-AML3 cells were transfected with 2 μg of pGFP-V-RS sh NPM 
(Invitrogen). 48 hours post transfection cells were treated with TRAIL 
(300ng/ml) for 6 hours and then harvested. Total cell lysate obtained and 
separated with SDS PAGE. Immunoblotting was performed using 




Aberrantly localized nucleophosmin enhanced cell survival in AML cells 
Nucleophosmin is a ubiquitous chaperone phosphoprotein that carries out many 
housekeeping functions. Overexpression of NPM in many cancerous cells is well 
documented as enhanced ribosome biogenesis promotes survival (65,88–90). OCI-AML3 
cells harbouring mutant cytoplasmic NPM was used to study the effects of aberrantly 
localized NPM and cell death. OCI-AML2 cells were used as control cells as they bear 
wild type NPM proteins.  
NPM‘s abundant expression and its role as a multifunctional protein suggest that it may 
interact with numerous proteins. We showed that NPM expression in both AML cells was 
unperturbed upon various cytotoxic drugs targeting different pathways (Fig 3.1). Upon 
cytotoxic stress, wild type NPM translocates from the nucleolus region to the nucleus and 
cytoplasm. This suggests that NPM may exert its cytoprotective functions through 
translocation to other organelles in order to interact or intercept cell death inducing 
proteins (Fig 3.2).  
This study then focuses on NPM localization rather than its expression influencing the 
stoichiometry with its interacting proteins. We showed that apoptosis is inhibited in OCI-
AML3 cells bearing mutant cytoplasmic NPM (Fig 3.3a). Mechanistically, Leong et al. 
(1) demonstrated that the direct interaction of cleaved caspase 6 and caspase 8 with 
NPMc inhibits caspase cascade progression and subsequent apoptosis. 
Cells with dysfunctional apoptotic machinery would unmask an alternative non apoptotic 
cell death pathway to maintain cell homeostasis. One of such alternatives is known as 
necrosis which is an unregulated form of non apoptotic cell death (422). However, new 
studies recently reported that necrosis can also be regulated (necroptosis) with RIP1 
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kinase as its precursor (4). Interestingly, we found that untreated OCI-AML3 showed a 
high level of necrotic cells and upon TRAIL treatment seems to favour necrotic than 
apoptotic death albeit not significantly (Fig 3.3b-c). Furthermore, PARP-1 cleavage 
patterns have been implicated to differentiate the type of cell death. PARP-1 cleavages at 
64 to 40 kDaltons indicate a necrotic form of cell death (Fig 3.3d). 
Further induction of necroptosis in OCI-AML3 seems to be inhibited but not in OCI-
AML2 cells (Fig 3.4b). Upon differential Propidium Iodide (PI) staining, OCI-AML3 
demonstrated high level of secondary necrotic cells rather than primary necrotic cells 
which is characteristic of necroptosis (Fig 3.4a). The integrity of mitochondria in both 
AML cells was also assessed. As necroptosis occurs via mitochondria dysfunction, more 
preserved intact mitochondria as in the case of OCI-AML3 cells indicates that 
necroptosis is not likely to occur (Fig 3.4c). With both cell death pathway inhibited, cell 
survival is clearly elevated in OCI-AML3 cells. 
However, why is the level of necrotic cells high in untreated OCI-AML3 cells? What 
causes it and what effect does it has on cell survival? It is suggested that necrotic cells 
could be an end product of other forms of cell death aside from necroptosis and apoptosis 
which could explain the phenomenon observed in OCI-AML3 cells. This occurrence will 
be further discussed in the following chapter.  
Mutant cytoplasmic NPM affects RIP1 cleavage and cell death 
The level of necrotic cells is substantial enough to create an inflammatory environment to 
enhance cell survival. It has been reported that inflammatory response has a vital role in 
carcinogenesis and tumour progression (279). High mobility group 1 (HMGB1) 
chromatin proteins that are released into the extracellular matrix have been used to detect 
necrotic form cell death. Due to its low abundance in OCI-AML3 cells, heat shock 
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protein 90 (Hsp90) was used instead as a pro-inflammatory marker (Fig 3.5a). 
Incidentally, the level of Hsp90 proteins released in the cell media was detected in OCI-
AML3 even before cytotoxic treatment (Fig 3.5b). This suggests that OCI-AML3 cells 
are pro-inflammatory and subsequent TRAIL treatment does not contribute to further 
inflammation.  
Since necroptosis is probably inhibited in OCI-AML3 cells, we examined the role of 
NPM with respect to RIP1 kinase, a precursor to this form of cell death. RIP1 is cleaved 
in OCI-AML3 cells prior to cytotoxic treatment (Fig 3.6a). We found that RIP1 cleavage 
increased in OCI-AML2 cells followed by increased PARP-1 cleavage upon TRAIL 
treatment (Fig 3.6b). NPM knockdown rescued RIP1 and PARP-1 cleavage in OCI-
AML2 cells possibly redirecting cell death from apoptosis to non apoptotic forms. In 
OCI-AML3 cells bearing NPMc, RIP1 cleavage was already detected and NPM 
knockdown actually decreased RIP1 cleavage. RIP1 is cleaved by active caspase 8 which 
enhances apoptosis and also prevents its role in pro-survival functions. However, a 
cleaved RIP1 also prevents the formation of necrosome and cell death via necroptosis.  
We previously reported that NPM prevents apoptosis through direct inhibition with 
cleaved caspase 8 (1). This inhibition does not seem to inhibit caspase 8‘s function to 
cleave RIP1 kinase. In fact, RIP1 cleavage is enhanced in the presence of NPMc. It is 
hereby hypothesized that mutant cytoplasmic NPM in the cytoplasm enhanced caspase 8 
mediated RIP1 cleavage through an unknown mechanism thus far possibly rendering 
RIP1 susceptible to caspase 8 mediated cleavage (Fig 3.7).  
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3.7 NPMc enhances caspase 8 mediated RIP1 cleavage. 
We hypothesized that NPMc in the cytoplasm enhanced caspase 8 
mediated RIP1 cleavage as in the case of OCI-AML3 cells. It is still not 
known how NPMc does this however the interaction of NPMc to RIP1 
might render it susceptible to caspase 8 mediated RIP1 cleavage. This 
then blunts necroptosis simultaneously apoptosis is already inhibited. In 
wild type NPM bearing OCI-AML2 cells, RIP1 cleavage enhances 
apoptosis but the minimal RIP1 cleavage still allow for necroptosis 
activation upon cytotoxic assault. (Red arrow represents cytotoxic stress. 









4 Cytoprotective function of mutant cytoplasmic nucleophosmin 
(NPMc) in alternative cell death 
4.1 Introduction 
Evading cell death is the mechanism of cancer progression. Understanding the mode of 
cell death in these cancer cells would facilitate in its eradication. Traditionally, cell death 
occurs via a programmed process called apoptosis. Apoptosis is a caspase dependent 
process and is identified by morphology changes such as cell shrinkage, nuclear 
fragmentation and formation of apoptotic bodies (423). Cell death can also occur via an 
alternative form of cell death termed necrosis. Unlike apoptosis, necrosis is known to be 
unregulated and is characterized by rapid loss of plasma membrane integrity (240). 
Compared to apoptosis, the necrotic death cell is a ―messy‖ affair as the content of the 
cells spilled out when the integrity of the plasma membrane is compromised. Necrotic 
cells are said to release factors that may induce inflammatory effects which may then 
activate an immune response or promote cancer growth (243,424).  
Galluzzi et al. reviewed that inhibition of apoptosis via caspase inactivation shifts cell 
death from apoptosis to necrosis (288). This switch in event depends on the 
serine/threonine kinase activity of receptor interacting protein 1 (RIP1) and its post 
translational modifications (425). This form of cell death exhibits necrotic death 
morphology, but are programmable via recruitment of RIP3 to a complex involving RIP1. 
FADD and caspase 8 (426). The discovery of this new programmed cell death 
(necroptosis) blurred the boundaries between the two forms of traditional mode of cell 
death and highlights that much is still not known in this area.  
Our previous study reported that mutant cytoplasmic nucleophosmin (NPMc) inhibits 
apoptosis via interaction with cleaved caspases 6 and 8 (1). Since inhibition of apoptosis 
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via caspase inactivation shifts cells towards necrotic death, the mode of cell death in 
OCI-AML3 cells bearing NPMc was examined. 
Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is a cytokine that is 
being used to induce apoptosis in several human cancer cell lines with an ability to keep 
normal cell unaffected. TRAIL is used to induce death via the extrinsic death receptor 
pathway in AML cell lines. It is reported that cancer cells treated with TRAIL in 
combination with caspase inhibitors induced necroptosis (427). TRAIL is also known to 
stimulate proinflammatory signaling NF-kB and MAP kinase cascade in apoptosis 
resistant cells (428). TRAIL is also known to promote progressive myeloid maturation in 
human HL-60 cell line and its eventual cytotoxicity (429).  
The formation of programmed necrotic complexes via extrinsic death pathway (TRAIL + 
zVAD fmk treatment) could also occur intrinsically independent of death receptor 
activation. This complex termed ripoptosome (346,348) formed spontaneously upon IAPs 
as well as FLIP depletion. Etoposide induced ripoptosome as it causes auto-ubiquitination 
and degradation of cIAPs (430–432).  
HT-29 colorectal adenocarcinoma and HeLa cervical cancer cell lines were used as 
model systems for the study of necroptosis induction.  
4.2 Results 
4.2.1 Mutant cytoplasmic NPM (NPMc) rescue cells from apoptosis and 
necroptosis 
OCI-AMl2 cells were transfected with 2 μg of pAcGFP NPMc, pAcGFP NPMwt and 
pAcGFP (control) plasmids respectively. Forty-eight hours post transfections, cells were 
divided into 3 portions and treated with TRAIL (300ng/ml), etoposide (20 μM) and 
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vehicle (DMSO) for 6 hours. Cells were then harvested and total cell lysate were 
obtained. 20 μg of total protein lysate were separated using SDS PAGE and 
immunoblotted using desired antibodies. PARP-1 cleavage was detected in OCI-AML2 
cells transfected with control plasmid upon cytotoxic treatment (Fig 4.1). OCI-AML2 
transfected with pAcGFP NPMwt plasmids showed significant PARP-1 cleavage 
compared to cells transfected with pAcGFP NPMc plasmids. Upon cytotoxic treatment, 
RIP1 cleavage is significantly higher in cells with overexpressed NPMc. OCI-AML2 
cells transfected with control and pAcGFP NPMwt plasmids only showed RIP1 cleavage 
upon cytotoxic treatment. RIP3 kinase is also elevated in pAcGFP NPMc transfected 
cells.  
PARP-1 cleavage via caspase 3 that yields a 89kDa fragment is indicative of apoptosis. 
Results showed that OCI-AML2 cells with overexpressed control and NPMwt 
demonstrated significant cleavage upon cytotoxic treatment. Meanwhile, cells 
overexpressing NPMc does not show significant PARP-1 cleavage upon cytotoxic 
treatment. This suggests that apoptosis is suppressed in NPMc expressing cells. 
The formation of RIP1-RIP3 complex is mandatory for cell death to proceed via 
necroptosis. These pro- necrotic interactions are stabilized by the kinase activities of both 
kinases. Caspase 8 inactivates RIP1 by cleaving it and suppressed its ability to induce 
necroptosis. Cells with overexpressed NPMc showed elevated RIP1 cleavage even before 
treatment. This suggests that necroptosis is inhibited significantly in NPMc 
overexpressed cells upon cytotoxic stress. Interestingly, the level of RIP3 is also elevated 
in NPMc expressing cells upon cytotoxic insults. Cleaved RIP1 is unable to 
phosphorylate RIP3 kinase and in turn could not induce necroptosis. It is not known why 




4.1 Overexpression of NPMc rescue OCI-AML2 cells from apoptosis 
and necroptosis  
OCI-AML2 cells were transfected with 2μg of pAcGFP NPMc, pAcGFP 
NPMwt and pAcGFP (control) plasmids respectively. 48hours 
posttransfection, cells were divided into 3 portions and treated with 
TRAIL (300ng/ml), etoposide (20μM) and vehicle (DMSO) for 6 hours. 
Cells were harvested and total cell lysate obtained. Equal amount of 
protein lysates were separated using SDS PAGE and immunoblotted 
using various antibodies.  
 
 
4.2.2 Cells bearing NPMc favours non apoptotic cell death 
OCI-AML2 and OCI AML3 cells were subjected to TRAIL (300ng/ml) treatment with 
varying duration between 1-24 hours (Fig 4.2). Cells were then harvested and stained 
with Annexin V and 7ADD separately and assessed using flow cytometry. Binding of 
fluorescently labelled annexins (phospholipid-binding proteins) to phosphatidylserines 
(PS) that are translocated to the extracellular membrane is a hallmark of apoptotic cells. 
The loss of cell membrane integrity allows for the uptake of viability dye 7-AAD into the 
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cell. An intact plasma membrane of a healthy or early apoptotic cells would exclude this 
dye. Necrotic cells or late apoptotic cells would be susceptible to 7-AAD staining.  
Annexin V staining of OCI-AML2 and OCI-AML3 cells were detected at a very low 
numbers. Annexin V staining of OCI-AML2 cells are higher compared to OCI-AML3 
and peaked at 24 hours treatment. TRAIL induced apoptosis more efficiently in OCI-
AML2 cells compared to OCI-AML3 cells. The number of apoptotic OCI-AML3 cells 
plateaued after 8 hour treatment whereas the percentage of apoptotic OCI-AML2 cells 
peaked at 24 hours.  
7-AAD staining increased steadily for OCI-AML2 cells and peaked after 4 hours 
treatment before exhibiting a descending trend at 24hours. The 7-AAD staining of OCI-
AML3 showed a slight elevated percentage before treatment. This level decreased 
slightly upon TRAIL treatment and the subsequent uptake of 7-AAD stain by OCI-AML3 
only peaked after 8 hours before a descending trend was observed at 24 hours. This result 
showed that necrosis was initiated after 4 hours of TRAIL treatment in OCI-AML2 cells. 
Necrotic cells were detected only after 8 hours of TRAIL treatment in OCI-AML3. The 
assessment of 7-AAD stained cells using flow cytometry allows for detection of necrotic 
cells but could not differentiate if it is a primary or secondary occurrence. Later detection 
of necrotic OCI-AML3 cells (after 8 hours), compared to OCI-AML2 cells, points to the 
possibility that necrosis is a secondary occurrence.  Results clearly illustrate that OCI-
AML3 maintains cell homeostasis via non apoptotic cell death. 
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4.2 Cells bearing NPMc favours non apoptotic cell death  
OCI-AML2 and OCI-AML3 cells were subjected to TRAIL (300ng/ml) 
treatment with varying duration up to 24hours. Cells were harvested and 
stained with Annexin V and 7-AAD separately and assessed using flow 
cytometry. Results were tabulated from 3 independent experiments. p-
value is indicated. 
 
 
4.2.3 Autophagy is enhanced in OCI-AML3 cells upon cytotoxic stress 
OCI-AML2 and OCI-AML3 cells were treated with TRAIL (300ng/ml) for varying 
duration. Total cell lysate were obtained after 6 hours treatment. 20 μg of protein lysate 
was separated using SDS PAGE and immunoblotted with autophagy marker Light chain 
3 (LC3)B antibody. Conversion of LC3B via cleavage of LC3B-I to LC3B-II form was 
expressed more in control OCI-AML3 compared to OCI-AML2 cells and this increased 
upon TRAIL treatment in OCI-AML3 cells (Fig 4.3b).  
Autophagy and necrosis are non apoptotic cell death pathways often observed when 
caspase activation is blocked upon stimulation by death stress (2). Interestingly, cells can 
maintain themselves transiently via a cell death process known as pro-survival autophagy 
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(433). This pro-survival characteristic occurs when cells are able to maintain cellular 
energy production by consuming their own intracellular molecules (434). However, once 
its bioenergetics is depleted, cells usually die by necrosis (435). The cleavage of LC3B 
isoform at the carboxy terminus yields the cytosolic LC3B-I form. Upon autophagic 
vesicles formation, LC3B-I form is converted to LC3B-II form for associations with 
autophagosomes (436). The conversion of LC3B from 18kDa type I to 16kDa type II 
occurs through lipidation by a ubiquitin-like system involving ATG3 and ATG7 (Fig 
4.3a) (437). Detection of this converted isoform is used as a definitive marker for 
autophagy occurrence (438). 
Results showed that conversion of LC3B-I to LC3B-II increased in OCI-AML3 steadily 
upon etoposide treatment up until the 6
th
 hour of treatment. This suggests that autophagy 
is enhanced upon cytotoxic stress in OCI-AML3 cells until a threshold is reached. OCI-
AML3 cells engaged autophagy as a primary mode of non-apoptotic cell death upon 
















4.3 Autophagy is potentiated in OCI-AML3 cells upon cytotoxic 
treatment  
a) Schematic diagram of autophagy (Adapted from Fleming et. al 
(Nature Chemical Biology 2011 Vol: 7, 9-17. (437) Chemical 
modulators of autophagy as biological probes and potential therapeutics) 
b) OCI_AML2 and OCI-AML3 cells were treated with TRAIL 
(300ng/ml) for varying duration up to 24 hours. Cells were harvested and 
total cell lysate obtained. Equal amount of protein lysate were separated 
using SDS PAGE and immunoblotted using LC3 antibody. Intensity of 
the blots were measured using ImageJ software and expressed as a 
relative intensity normalized against OCI-AML2 (No treatment) sample. 
The LC3B-II conversion was normalized against LC3B-I (blue bar) and 
Actin (red bar). 
 
 
4.2.4 RIP3 is overexpressed in OCI-AML3 cells and its functional kinase activity 
rescue cells from apoptotic death 
Total cell lysate were obtained from various cancer cell lines. 20 μg of protein lysate was 
separated using SDS PAGE and immunoblotted with desired antibodies. OCI-AML3 
showed elevated RIP3 expression compared to other cancer cell lines in the panel (Fig 
4.4a). It has been reported that upregulation of RIP3 is a characteristic of wound healing 
(390) which shares similar traits to inflammation process. RIP3 autophosphorylates itself 
and has been reported to be able to initiate RIP3-mediated necrosis when caspase 8 
expression is compromised (386,387). 
HeLa cells were transfected with pcDNA3_FLAG_RIP1, pEGFP_N1_RIP1 kinase dead 
(K45A), pEGFP_N1_RIP3, pEGFP_N1_RIP3 kinase defective mutant (D160N). Forty 
eight hours post transfection, cells are harvested and total cell lysate are obtained. 20 μg 
of protein lysate was separated using SDS PAGE and immunoblotted using desired 
antibodies. Results showed that overexpression of RIP1 and its kinase dead mutant 
promote apoptosis shown by caspase 3 cleavage (Fig 4.4b). Overexpression of RIP3 
inhibits caspase 3 cleavage. Meanwhile, overexpression of RIP3 kinase defective mutant 
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seems to degrade caspase 3 expression. This suggests that the functional kinase activity  
of overexpressed RIP3 is able to rescue cells from apoptosis. RIP3 overexpression might 




















4.4 RIP3 is overexpressed in OCI-AML3 cells and its functional 
kinase activity rescue cells from apoptotic death  
a) Total cell lysate were obtained from various cancer cell lines. Equal 
amount of protein lysate was separated using SDS PAGE and 
immunoblotted using various antibodies. b) HeLa cells were transfected 
with pcDNA3_FLAG_RIP1, pEGFP_N1_RIP1 kinase dead (K45A), 
pEGFP_N1_RIP3, pEGFP_N1_RIP3 kinase defective mutant (D160N). 
48 hours post transfection, cells were harvested and total cell lysate 
obtained. Equal amount of protein lysate were separated using SDS 




4.2.5 Abrogation of RIP1 kinase did not affect NPM stability and induced RIP3 
mediated necrosis 
OCI-AML3 cells were treated with various cytotoxic drugs combinations. 
TRAIL/cycloheximide (TC) treatment was used to induce apoptosis. 
TRAIL/cycloheximide/z-VAD fmk (TCZ) was used to induce necroptosis. 
Cycloheximide inhibits de novo protein synthesis while z-VAD fmk is a pan caspase 
inhibitor. TRAIL/cycloheximide/ z-VAD fmk/geldanamycin (TCZG) treatment was used 
to induce necroptosis with RIP1 abrogation. Geldanamycin degrades RIP1 via Hsp90 
inactivation. TRAIL/cycloheximide/ z-VAD fmk /necrostatin-1 (TCZN) treatment was 
used to induce necroptosis with RIP1 kinase activity inhibition. Cells were also subjected 
to TRAIL (T) treatment alone. After 6 hours treatment, cells were harvested and total cell 
lysate obtained. 20 μg of protein lysate was separated using SDS PAGE and 
immunoblotted using various antibodies. 
Abrogation of RIP1 kinase using Geldanamycin (20 μM) and the inhibition of its kinase 
activity using necrostatin -1 do not affect NPM expression in OCI-AML3 cells (Fig 
4.5a). Geldanamycin, an inhibitor of Hsp90, inhibits its function and association with 
RIP1. This further caused RIP1 inactivation, destabilization and degradation. This 
suggests that RIP1 expression and its kinase activities do not affect NPM stability.  
Although RIP3 kinase expression is known to be suppressed by geldanamycin (439), the 
expression is enhanced in OCI-AML3 upon caspase inhibition and geldanamycin 
treatment. O‘Donnell et al (276) reported that knockdown of RIP1 enhances necrosis in 
caspase 8 – deficient T cells when apoptosis and RIP1 ubiquitylation is abrogated. This 
suggests that RIP1 abrogation induced RIP3-mediated necrosis in OCI-AML3 cells with 
subsequent MLKL upregulation. However, this form of cellular demise is very 
inflammatory and may exacerbate cell damage.  
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Interestingly, RIP3 expression is downregulated upon necrostatin-1 treatment with 
simultaneous caspase cascade inhibition. Cho et al (352) reported that Nec-1 does not 
have any effects on RIP3 directly but the inactivation of RIP1 kinase by Nec-1 prevents 
its phosphorylation, interaction with RIP1 and necroptosis initiation. This is in agreement 
with reports stating that abolishing RIP3 expression effectively reduces the degree of 
tissue damage. However, it is not known how the state of RIP3 phosphorylation by RIP1 
at Ser 199 affects its stability.  
A subset of the treated OCI-AML3 cells was stained with the Muse® Annexin V and 
Dead Cell Kit (Merck Millipore). Stained cells are then processed using the Muse® Cell 
Analyzer and analyzed with Muse® Annexin V and Dead Cell software module. Results 
are presented in a quadrant showing Annexin V and 7-AAD staining. Treatment with TC 
showed OCI-AML3 was susceptible to early and late apoptosis (Fig 4.5b). Treatment 
with TCZ rescued cells from early and late apoptosis suggesting that necrosis is not 
enhanced upon caspase inhibition. RIP1 abrogation with geldanamycin (TCZG) does not 
significantly promote or abrogate cell death compared to TCZ treatment. However, seems 
to direct cell death towards the late apoptotic from early apoptotic state. Intriguingly, 
inhibition of RIP1 kinase activity using Nec-1 (TCZN) rescued it from cell death. These 
results are coherent with the hypothesis that abrogation of RIP1 increased RIP3-mediated 
necrosis but inhibition of its kinase activity alone prevents cell death.  
RIP3 is highly expressed in OCI-AML3 cells with distinct puncta staining (Fig 4.5c). 
However, necroptosis is not induced in OCI-AML3 cells exemplified by the absence of 
amyloid formation seen in HT-29 control cells upon 6 hours of TRAIL/cycloheximide 
and z-VAD-fmk treatment. Treatment with TRAIL/cycloheximide caused apoptotic death 




















4.5 Abrogation of RIP1 kinase did not affect NPM stability and 
induced RIP3-mediated necrosis in OCI-AML3 cells  
a) OCI-AML3 cells were treated with various cytotoxic drugs 
combination (see text). After 6 hours treatment, cells were harvested and 
total cell lysate obtained. Equal amount of protein lysate were separated 
using SDS PAGE and immunoblotted using various antibodies. b) A 
subset of cells from the above treatment was stained using Muse® 
Annexin V and Dead Cell Kit (Merck Millipore). Stained cells were 
processed using the Muse® Cell Analyzer and analyzed with Muse® 
Annexin V and Dead Cell software module. Results were presented in a 
quadrant showing Annexin V and 7-AAD staining. c) HT-29 and OCI-
AML3 cells were subjected to TRAIL/cycloheximide and 
TRAIL/cycloheximide/z-VAD-fmk treatments. Cells were harvested and 
cytospun onto glass slides. Immunofluorescence staining using RIP3 
antibody was performed with corresponding Alexa-Fluor 488 labelled 
secondary antibody. Images were obtained via inverted fluorescence 
microscope at 40 x magnifications (Axiovert 25, Carl Zeiss Meditech, 
Germany).  Composite images were overlapped using Image J Software. 
Green fluorescence indicates RIP3 staining and blue counterstaining 
with DAPI-containing mounting media.  
 
 
4.2.6 Knockdown of RIP1 promotes PARP degradation in OCI-AML3 upon 
cytotoxic stress 
OCI-AML2 and OCI-AML3 were transfected with 2 μg of shRIP1 and shvector (control). 
Forty-eight hours post transfections, half of the cell population was subjected to 
etoposide (20 μM) treatment for 6 hours while the other half treated with vehicle 
(DMSO). Cells were then harvested and total cell lysate obtained. 20 μg of protein lysate 
was separated using SDS PAGE and immunoblotted with desired antibodies.  
Knockdown of RIP1 using shRIP1 showed unperturbed NPM expression in both AML 
cells (Fig 4.6). Treatment of OCI-AML2 cells with etoposide caused caspases mediated 
PARP-1 cleavage confirmed by the presence of 89kDa fragment. In RIP1 knockdown 
cells, PARP-1 expression slightly decreased in OCI-AML2 and upon etoposide treatment 
PARP cleavage barely increases. This suggests that RIP1 plays a part in OCI-AML2 cells 
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apoptotic death. Whilst in OCI-AML3 cells with RIP1 knockdown, PARP-1 is almost 
degraded upon etoposide treatment. These results showed that cell death is most probably 
necrotic in OCI-AML3 with RIP1 abrogation. We can only speculate that PARP-1 
degradation is caused by RIP3 mediated necrosis as necroptosis is inhibited in the 
absence of RIP1 kinase. Moreover, PARP-1 degradation further inhibits cells from 
initiating PARP-1 mediated necrosis highlighting the importance of RIP3 mediated 
necrosis in AML cells homeostasis.   
 
4.6 Knockdown of RIP1 promotes PARP degradation in OCI-AML3 
upon cytotoxic stress 
OCI-AML2 and OCI-AML3 were transfected with 2 μg of shRIP1 and 
shvector (control). Forty eight hours post transfections, half of the cells 
population were subjected to etoposide (20 μM) treatment for 6 hours 
while the other half treated with vehicle (DMSO). Cells were then 
harvested and total cell lysate obtained. Equal amount of protein lysate 






Mutant cytoplasmic NPM (NPMc) maintain homeostasis via non apoptotic cell 
death 
Apoptosis is the main cell death pathway in which cell dies. When apoptotic machinery is 
defective or inhibited, cells die through non apoptotic pathway such as necrosis, 
autophagy and paraptosis amongst others. Recently, much interest in cell death studies 
has been on a programmable form of necrosis termed necroptosis. Mediated by RIP 
kinases, necroptosis is induced via death receptor stimuli upon caspase inhibition. Results 
obtained using OCI-AML3 expressing NPMc showed that apoptosis is inhibited upon 
TRAIL treatment and cells are necrotic after 8 hours of treatment (Fig 4.2). This suggests 
that OCI-AML3 undergoes non apoptotic form of cell death.  
To determine necroptosis is the cell death mechanism of choice, PI staining was 
employed to discriminate the type of necrotic cells found in OCI-AML3. Differential 
staining showed that OCI-AML3 are made up of secondary necrotic cells and these can 
also be found in untreated population. Secondary necrotic cells are by products of cells 
that have undergone other mode of cell death including apoptosis. Necroptotic cells 
showed primary necrotic cells characteristics such as cytoplasmic swelling and 
condensation of chromatin that gives rise to ―patchy‖ staining. This phenomenon is only 
observed in OCI-AML2 cells upon necroptosis induction but not in OCI-AML3 cells. 
Furthermore, cells with overexpressed NPMc showed higher RIP1 cleavage which 
inhibits necrosome formation and necroptosis (Fig 4.1). This clearly states that 
necroptosis is inhibited in NPMc expressing cells and the necrotic cells population is not 
from necroptosis.  
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Autophagy is another form of non apoptotic cells in which cells maintained its 
homeostasis. Tan et al. demonstrated that pro-survival autophagy occurs in OCI-AML3 
cells (unpublished data, personal communication). Autophagy is pro-survival once 
cellular energy production is maintained when cells consumed their own intracellular 
molecules. However, prolonged autophagy would eventually caused autophagic cell 
death and necrosis. It is reported that autophagic cell death requires RIP1 and JNK 
pathway activation and shown to arrest TRAIL induced apoptosis (440). OCI-AML3 
cells showed a higher expression of LC3B autophagic proteins than in OCI-AML2 cells 
(Fig 4.3b). And upon TRAIL treatment, OCI-AML3 cells showed an increasing 
conversion of LC3B-1 to LC3B-11 isoform with increased duration of drug exposure 
(Fig 4.3b). Therefore, it is suggested that OCI-AML3 may undergo autophagy upon 
cytotoxic stress and high necrotic cells might be a result from a prolonged autophagic 
state contributing to necrotic cell death.  
Another possible non apoptotic cell death is RIP3- mediated necrosis. RIP3 is 
overexpressed in OCI-AML3 cells compared to other cancer cell lines in the study (Fig 
4.4a). Overexpression of RIP3 potentiates the induction of this pathway, triggered when 
caspase 8 is defective as in the case of OCI-AML3 cells. It is shown that RIP3 
overexpression also inhibits caspase 3 cleavage exemplifying its ability to inhibit 
apoptosis (Fig 4.4b). Abrogation of RIP1 expression and functions potentiates RIP3-
mediated cell death (Fig 4.5a-b). Thus there is a possibility that high necrotic cells in 
NPMc expressing cells might also be contributed by this phenomenon.  
RIP Kinases is implicated in NPMc mediated cell survival 
RIP1 kinase is involved in several cell death pathways particularly apoptosis, necroptosis 
and autophagy. Upon examining the mode of cell death in OCI-AML3 cells, it is 
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imperative to assess the role of this group of kinases with respect to NPMc protein. It is 
demonstrated that RIP1 kinase is cleaved in NPMc expressing cells (Fig 4.5a). Cleaved 
RIP1 with defective kinase activity inhibits necrosome complex formation and 
subsequent necroptosis (Fig 4.5c). However, cleaved RIP1 enhanced apoptosis by 
promoting interaction between TNF receptor 1-associated death domain (TRADD) and 
FADD (366,367) while its kinase activity is dispensable. However, this apoptotic 
enhancement is probably silenced via NPMc interaction with cleaved caspase 8 inhibiting 
apoptosis in NPMc expressing cells (1). 
Abrogation of RIP1 kinase using geldanamycin and the inhibition of its kinase activity 
using necrostatin -1 did not affect NPM expression. These highlight the possibilities that 
RIP1 protein do not have an influence on NPM stability (Fig 4.5a). Simultaneously, RIP3 
mediated necrosis is enhanced in OCI-AML3 cells upon geldanamycin-abolished RIP1 
expression coupled with caspase cascade inhibition. However, RIP3 expression is 
abolished upon Nec-1 treatment in caspase cascade compromised environment. How the 
kinase activity of RIP1 affects stability and expression of RIP3 is not known. It is 
suggested that the post modification status of RIP3 may influence its fate. PARP-1 
degradation is also observed upon RIP1 kinase downregulation probably due to PARP-1 
over activation in line with necrosis induction.  
Geldanamycin is not a direct inhibitor of RIP1 kinase and have been reported to affect 
other signaling pathways as it targets molecular chaperone heat shock protein 90 (Hsp90) 
(441). As such, further RIP1 knockdown studies were done using shRNA. Results 
showed that NPM expression is not affected upon RIP1 kinase knockdown (Fig 4.6). 
Upon cytotoxic stress, cell death shifted from apoptotic to non apoptotic in OCI-AML2 
cells. PARP-1 degradation was also observed in OCI-AML3 cell lines possibly due to the 
upregulation of RIP3 mediated necrosis when RIP1 kinase is compromised (Fig 4.7). 
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PARP-1 degradation seems more apparent in OCI-AML3 cells compared to OCI-AML2. 
This strengthened the notion that RIP1 kinases may play a major role in NPMc mediated 
cell survival.  
 
4.7 Mode of cell death in NPMc expressing cells.  
In OCI-AML2 cells, death receptor mediated cytotoxic stress caused 
apoptotic cell death and upon caspase inhibition, death shifted to 
necroptosis. In OCI-AML3 cells, caspase inhibition via NPMc prevents 
death receptor mediated apoptosis and enhanced cleavage of RIP1 
blunting necroptosis. NPMc expression enhanced autophagy and 
abrogation of RIP1 potentiates RIP3-mediated necrosis. PARP-1 
degradation prevents PARP-1 mediated necrosis. It is hypothesized that 
the elevated number of necrotic cells in OCI-AML3 could be a 
secondary necrosis product of autophagic death or RIP3-mediated death. 
(Red arrow represents cytotoxic stress. Blue circle represents NPM, 





5 Receptor Interacting Protein 1 (RIP1) kinase interacts with 
nucleophosmin 
5.1 Introduction 
RIP1 kinase is involved in many cell death pathways namely apoptosis (358,442), 
necroptosis (419,443–445) and autophagy (446,447). RIP family proteins are 
serine/threonine kinases and are all involved in mediating NF-kB or cell death pathways. 
Extensive studies showed that the post translation modifications of RIP1 are responsible 
in determining its involvement in RIP1 centred complexes dictating different cell fate 
(346,347,350,356). The caspase 8 mediated cleavage of RIP1 kinase inhibits necrosome 
complex formation (368) with RIP3 kinase and subsequent necroptosis induction. 
Cleaved RIP1 fragment attenuates the NF-ĸB pathway (358,368)  and enhanced apoptotic 
signaling via promotion of TRADD and FADD interaction (361,448).  
It was established that apoptosis and necroptosis are inhibited in cells expressing NPMc. 
We also showed that NPM degradation affects RIP1 cleavage but abrogation of RIP1 
kinase does not affect NPM stability. This illustrated that NPM acts upstream of RIP1 
and in an environment where NPM is mis-localized to the cytoplasm, the probability of 
interaction with cytoplasmic residing RIP1 is heightened. Since there is a possible 
correlation between NPM expression and RIP1 cleavage, we further hypothesize that they 
might interact at some point in the course of cell physiology.   
It was demonstrated by Leong et al. (1) that NPMc interacts with cleaved caspase 8. 
Since caspase 8 interacts with RIP1 and cleaved it, we speculate that there is a high 
likelihood that NPMc forms complex with RIP1 directly or indirectly through the 
intermediation of caspase 8 which may cause RIP1 modifications thus affecting its 
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functions in cell death. It is therefore imperative to investigate the expression and 
stability of RIP1 in cells expressing NPMc. 
5.2 Results 
5.2.1 RIP1 kinase cleavage is potentiated in NPMc expressing cells 
OCI-AMl2 cells were transfected with 2 μg of pAcGFP NPMc , pAcGFP NPMwt and 
pAcGFP (control) plasmids respectively. Forty-eight hours post transfections, cells were 
harvested and total cell lysate were obtained. 20 μg of total protein lysate were separated 
using SDS PAGE and immunoblotted using desired antibodies. OCI-AML2 and OCI-
AML3 cells were also harvested and subjected to the same treatment.  
Immunoblotting with RIP1 kinase antibody showed increased RIP1 cleavage in NPMc 
expressing cell lines even before cytotoxic assault (Fig 5.1a). Meanwhile, cleavage of 
RIP1 kinase inhibits necrosome complex formation with RIP3 kinase and subsequent 
necroptosis induction (449). Cleaved RIP1 fragment attenuates the NF-ĸB pathway (368) 
and enhances apoptotic signaling via promotion of TRADD and FADD interaction 
(366,367). Upregulation of RIP1 cleavage in these cells highlighted the fact that NPMc 












5.1 RIP1 kinase is cleaved in NPMc expressing cells and NPM 
degradation corresponds to decreased RIP1 cleavage  
a) OCI-AML2, OCI-AML-3 and OCI-AMl2 cells transfected with 2 μg 
of pAcGFP NPMc , pAcGFP NPMwt  and pAcGFP (control) plasmids 
respectively were used. Forty-eight hours post transfections, cells were 
harvested and total cell lysate obtained. Equal amount of total protein 
lysate were separated using SDS PAGE and immunoblotted using 
desired antibodies. b) OCI-AML2 and OCI-AML3 was subjected to 
CHX (100 μg /ml) treatment for varying time points up to 24 hours. Cells 
were harvested and total cell lysate obtained. Equal amount of total 
protein lysate were separated using SDS PAGE and immunoblotted 
using desired antibodies.  
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5.2.2 Nucleophosmin degradation rescue cells from caspase 8 mediated RIP1 
cleavage 
The stability of RIP1 kinase in NPMwt and NPMc expressing cells respectively were 
measured upon treatment with protein synthesis inhibitor, cycloheximide (CHX). OCI-
AML2 and OCI-AML3 was subjected to CHX (100 μg /ml) treatment for varying time 
points up to 24 hours. NPM expression was found upwardly enhanced in OCI-AML2 
cells while OCI-AML3 cells showed an opposite trend (Fig 5.1b).  
In OCI-AML2 cells, elevated NPM expressions correspond to RIP1 cleavage. 
Interestingly, RIP1 cleavage decreased upon NPM degradation in OCI-AML3 cells. This 
supports the hypothesis that cytoplasmic residing NPM which encompasses the majority 
of NPM expressed in OCI-AML3 cells possibly inhibits necroptosis by promoting RIP1 
cleavage. Notably, NPM degradation is more apparent in OCI-AML3 cells compared to 
OCI-AML2 cells. It is not known why this is so. However, the localization of NPM 
protein might shed some light into its stability as hypothesized in (Fig 5.6). 
5.2.3 RIP1 kinase co-localizes with NPM at the cytoplasm 
To determine if NPM and RIP1 reside in close proximity, co- immunofluorescence was 
carried out. OCI-AML2 and OCI-AML3 cells were treated with TRAIL (300ng/ml) for 
24 and 48 hours respectively (Fig 5.2). Cells were harvested and fixed on glass slides. 
Co-immunofluorescence staining procedure was carried out using two primary antibodies 
against NPM (green) and RIP1 (red) respectively. Corresponding Alexa-Fluor labelled 
secondary antibodies was used and counterstained with DAPI-containing mounting 
media (Vector Laboratories).  
In OCI-AML2, NPM staining was observed in the nuclear region (red arrow) and at 
lower intensity at the cytoplasm. Results showed that NPM and RIP1 co-localizes at the 
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cytoplasm of untreated OCI-AML2 cells (white arrow). NPM is a shuttling chaperone 
protein. Although it resides in the nucleolus, it performs its shutting functions to the 
nucleus and cytoplasm. Upon TRAIL treatment, NPM and RIP1 co-localization 
intensified to include the nuclear region of cells that were undergoing cell death as the 
nuclear membrane integrity got compromised (yellow arrow). Previous results indicated 
that NPM translocated from nucleoli to nucleus and cytoplasm upon cytotoxic stress (Fig 
3.2). With the breakdown of the nuclear membrane, proteins are no longer 
compartmentalized and this phenomenon further allows for the two proteins to associate 
freely within the cell. 
In OCI-AML3, NPM staining is barely detected in the nuclear region of the cells. Mutant 
cytoplasmic NPM is known to sequester shuttling wild type NPM to the cytoplasm (59). 
As a result, both NPM (wild type and mutant) forms are predominantly in the cytoplasm 
(white arrow). The availability of NPM in the cytoplasm allows for its co-localization 
with RIP1. Upon TRAIL treatment, this co-localization was not observed in the nuclear 
region as in OCI-AML2 cells. Since OCI-AML3 cells are resistant to apoptosis, the 
nuclear membrane integrity is still intact to localize both proteins at the cytoplasm.  
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5.2 RIP1 kinase co-localizes with NPM at the cytoplasm  
OCI-AML2 and OCI-AML3 cells were treated with TRAIL (300ng/ml) 
for 24 and 48 hours respectively. Cells were harvested and fixed on glass 
slides. Co-immunofluorescence staining procedure was carried out using 
two primary antibodies against NPM (green) and RIP1 (red). 
Corresponding Alexa-Fluor labelled secondary antibodies was used and 
counterstained with DAPI-containing mounting media (Vector 
Laboratories). NPM and RIP1 co-localizes at the cytoplasm of untreated 
OCI-AML2 cells (white arrow). NPM and RIP1 co-localized to include 
nuclear region upon TRAIL treatment (yellow arrow). In OCI-AML3 
cells, both NPM (wild type and mutant) forms are predominantly in the 







5.2.4 NPMc interacts with endogenous RIP1 
To determine if NPM and RIP1 do interact and not just co-localizes, pulldown 
experiment was performed. S100 lysate from OCI-AML3 cells was obtained and added 
in increasing amount to GST-tagged NPMc for the stated duration (Fig 5.3a). The beads 
were harvested and washed several times in PBS. The beads were then added to 20μl of 
SDS-PAGE buffer and separated using SDS-PAGE. Immunoblot was carried out using 
desired antibodies.  
Results showed that endogenous RIP1 was detected after 2 hours incubation with GST-
tagged NPMc. The amount increased steadily corresponding to the increased amount of 
OCI-AML3 lysate being used. This result suggests that exogenous NPMc interacts with 
its wild type isoform and RIP1 kinase.  
5.2.5 Direct interaction of RIP1 kinase with NPM and NPMc 
Next, we examined if there was a direct interaction between RIP1 and NPM in the 
cytoplasm. In-vitro translational (IVT) product generated from 0.5μg of pcDNA3_RIP1 
plasmid using Promega System  and GST-tagged recombinant NPMc proteins were 
incubated in an in-vitro set up as shown below (Fig 5.3b). Pulldown assay using GST 
beads were performed for the stated duration. The beads were harvested and washed 
several times in PBS. The beads were then added to 20μl of SDS-PAGE buffer and 
separated using SDS-PAGE. Immunoblotting was carried out using desired antibodies.  
The results showed that RIP1 product was pulldown using GST beads upon incubation 
with GST-tagged NPMc after 2 hours.  The GST beads pulldown of RIP1 IVT increased 







5.3 RIP1 kinase interacts with NPM and its mutants in vivo and in 
vitro 
a) S100 lysate from OCI-AML3 cells was obtained and added in 
increasing amount to GST-tagged NPMc for the stated duration (Fig 
5.3a). The beads were harvested and washed several times in PBS. The 
beads were then added to 20μl of SDS-PAGE buffer and separated using 
SDS-PAGE. Immunoblot was carried out using desired antibodies.  
b) Pulldown assay using GST beads were performed for the stated 
duration. The beads were harvested and washed several times in PBS. 
The beads were then added to 20μl of SDS-PAGE buffer and separated 
using SDS-PAGE. Immunoblot was carried out using desired antibodies. 
* denotes non specific bands 
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5.2.6 NPM and RIP1 kinase interaction is unperturbed upon TRAIL treatment 
Next, we investigate if this interaction was perturbed upon TRAIL treatment. OCI-AML2 
cells were subjected to TRAIL treatment (100ng/ml) for 6 hours. The cells were then 
harvested and their protein lysate obtained using native cell lysis buffer. The control cells 
set were also subjected to the same procedure. 20 μg of native protein lysate was 
separated using blue native electrophoresis system (Invitrogen) which separates via 
protein mass as well as the physical shape and size of native complexes. The desired strip 
of the protein sample separated (containing native protein complexes) was excised and 
subjected to another 2-D gel electrophoresis to separate out individual proteins in a 
complex. First immunoblotting was carried out using RIP1 antibody. The same 
membrane was reblotted using NPM antibody to compare the localization of each 
protein.  
Results from immunoblotting with RIP1 antibodies showed that there are possibly two 
types of RIP1 containing complexes. Both RIP1 proteins were detected around ~72kDa 
(Fig 5.4). One type (referred to as form A) associates with relatively smaller protein 
complexes as revealed by the migration of its associated proteins to the right most side of 
the blot. Another type (referred to as form B) migrates slightly to the right and has a 
slightly higher molecular weight as compared to form A. We can only speculate that this 
is due to some post translational modifications (450,451) such as phosphorylated state of 
protein. When the membrane was reblotted with NPM antibody the results showed that 
NPM (~37kDa) was detected directly below the form B. Notably, this interaction is 








5.4 Direct interaction of RIP1 kinase with NPM is unperturbed by 
TRAIL treatment  
a) Schematic representation of a Blue Native Electrophoresis and 2-D gel 
analysis. Adapted from Camacho-Carvajal et al. (452) b) OCI-AML2 
cells were subjected to TRAIL treatment (100ng/ml) for 6 hours. The 
cells were then harvested and protein lysate were obtained using native 
cell lysis buffer. The control cells set were also subjected to the same 
procedure. Equal amount of native protein lysate was separated using 
blue native electrophoresis system (Invitrogen). The desired strip of the 
protein sample separated (containing protein complexes) was excised and 
subjected to another 2-D gel electrophoresis to separate out individual 
proteins in a complex. First immunoblotting was carried out using RIP1 
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antibody. The same membrane was reblotted using NPM antibody to 
compare the localization of the each protein. Blue arrow indicates RIP1 
(form A, ~72kDa) and blue arrow indicates RIP1 (form B, >72kDa). 
White arrow indicates NPM (~37kDa).  
 
 
5.2.7 Nucleophosmin interacts with RIP1 and caspase 8 but is not a member of 
pre-death inducing signaling complex (DISC) 
It is well established that RIP1 is cleaved by caspase 8 therefore the two proteins do 
interact (348). Leong et al. (453) have already shown that NPMc interacts with cleaved 
caspase 8. The present results (Fig 5.5c) showed that RIP1 also interacts with NPM 
cytoplasmic mutant form. Caspase 8 and RIP1 kinase are established members of the 
death inducing signaling complex (DISC) (454,455) that formed downstream death 
receptor activation.  Thus, we would like to determine if NPM already exist in the pre- 
DISC complex.  
S100 lysate of OCI-AML2 and OCI-AML3 were obtained and used for co-
immunoprecipitation experiment with caspase 8 antibody. Results showed that caspase 8 
was co-immunoprecipitated with NPM in both AML cell lines (Fig 5.5b). Cleaved 
caspase 8 was not detected in OCI-AML3 cells possibly due to competitive binding to 
NPMc which are abundant in OCI-AML3 cells.  
S100 lysate of HL60 cells overexpressed with NPMc was obtained and subjected to co-
immunoprecipitation experiment using RIP1 antibody. Results showed that RIP1 was co-
immunoprecipitated with exogenous NPMc and cleaved caspase 8 (Fig 5.5c).  
S100 lysate of OCI-AML2 and OCI-AML3 cells were obtained and subjected to co-
immunoprecipitation experiment using FADD antibodies to determine if NPM is a part of 
pre-DISC originating downstream the death receptor. Results from the experiments 
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showed that FADD did not co-immunoprecipate NPM together with caspase 8 (Fig 5.5d). 
This suggests that NPM participates in complexes containing caspase 8, RIP1 and 














5.5 Nucleophosmin interacts with RIP1 and caspase 8 but is not a 
member of pre-death inducing signaling complex (DISC)  
S100 lysate of OCI-AML2 and OCI-AML3 were obtained and used for 
co-immunoprecipitation experiment with a) NPM antibody specific to 
the N-terminal (Cell Signaling). b) caspase 8 antibody d) FADD 
antibody. c) S100 lysate of HL60 cells overexpressed with NPMc was 
obtained and subjected to co-immunoprecipitation experiment using 
RIP1 antibody. Immunoprecipitated lysate was subjected to gel 
electrophoresis and immunoblotted with a) NPMc antibody specific for 




Nucleophosmin co-localizes with RIP1 and modulates its stability 
RIP1 kinase is involved in many cell death pathway namely apoptosis, necroptosis and 
autophagy. The expression and stability of RIP1 was assessed with respect to different 
NPM isoforms expressed in AML cells. AML cells expressing NPMc potentiates RIP1 
cleavage (Fig 5.1a). Cleaved RIP1 kinase generates an NF-ĸB inhibitory fragment and 
attenuates this pathway. Apoptosis is also enhanced as the interactions of TRADD and 
FADD at the DISC are promoted. Cleaved RIP1 kinase also inhibits RIP3 
phosphorylation and necrosome formation. Necroptosis is then abrogated in these cells.  
The protein half-life was measured using cycloheximide to understand the stability of 
RIP1 and NPM. NPM degradation is more significant in OCI-AML3 than OCI-AML2 
cells (Fig 5.1b). Interestingly, RIP1 cleavage which was detected in untreated OCI-
AML3 cells decreased corresponding to NPM degradation. On the other hand, RIP1 
cleavage increased in OCI-AML2 cells over time. Notably, the location of NPM might 
contribute to RIP1 stability. It is noted that nucleolus residing wild type NPM protein 
translocated to nucleus and cytoplasm upon cytotoxic stress. Exposure to cycloheximide 
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facilitates this translocation thus increased RIP1 kinase and NPM interaction in the 
cytoplasm as in the case of NPMc expressing cells. This interaction (possibly in the 
presence of caspase 8) increased caspase 8 mediated RIP1 cleavage. This further explain 
the increased in RIP1 cleavage in OCI-AML2 cells which is an opposite occurrence in 
OCI-AML3 cells. Therefore, NPM degradation rescue cells from caspase 8 mediated 
RIP1 cleavage in OCI-AML3 cells.  
How NPM degradation prevents RIP1 cleavage is not known. It is suggested that NPM in 
the cytoplasm interacts with caspase 8 and RIP1 forming a complex, possibly stabilizing 
it. The close proximity of caspase 8 and RIP1 brought together by NPM protein, 
promotes its cleavage. To further investigate the possible occurrence of the above 
mentioned complex, co-immunofluorescence was carried out. Indeed results showed that 
RIP1 and NPM co-localizes at the cytoplasm (Fig 5.2). 
Nucleophosmin and RIP1 kinase interacts directly 
Several experiments were carried out to determine that NPM and RIP1 kinase interacts 
and not just co-localizes. Protein pulldown assay with GST-tagged NPMc protein was 
carried out using S100 OCI-AML3 lysate. Results showed that endogenous RIP1 was 
pulled down proportionately to the amount of lysate used (Fig 5.3a). Similarly, 
endogenous NPM (cytoplasmic mutant form included) was also pulled down as NPM is 
known to form oligomers and detection using N-terminus specific antibodies does not 
discriminate the isoforms.  
Using S100 OCI-AML3 lysate does not negate the possibility of RIP1 and NPMc 
interaction is facilitated by an intermediary protein. GST pulldown assay of varying 
constituent of RIP1 IVT products and GST-tagged NPMc proteins in vitro, clearly 
illustrate a direct interaction between RIP1 and NPMc (Fig 5.3b). 
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The direct interaction was further confirmed with Blue Native gel electrophoresis 
followed by 2-D gel analysis using OCI-AML2 native cell lysate which bear wild type 
NPM. Notably, results obtained showed that this interaction is unperturbed by TRAIL 
treatment (Fig 5.4).  
Immunoprecipitation assay further confirmed that caspase 8 interacts directly with NPM 
and RIP1 in both AML cells (Fig 5.5a-c). RIP1 and caspase 8 are known players of the 
death inducing signaling complex (DISC). However, co-immunoprecipitation using 
FADD antibodies did not successfully co-immunoprecipitate NPM proteins (Fig 5.5d). 
This suggests that although NPM interacts with both RIP1 and caspase 8, it is not a 
member of the pre-DISC. Therefore, it is suggested that there could be a presence of 
another complex aside from the pre-DISC which may contain NPM that can decide the 
fate of RIP1 kinase. This complex may eventually modulate the cell death pathway. 
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5.6 NPM degradation rescue cells from caspase 8 mediated RIP1 
cleavage  
The differential effects of caspase 8 mediated RIP1 cleavage in OCI-
AML2 and OCI-AML3 is modulated by NPM degradation. Upon 
cytotoxic stress, NPM translocated from nucleoli to nucleus and then the 
cytoplasm of OCI-AML2 cells. It interacts with RIP1 potentiating its 
cleavage and possibly interacts with caspase 8 which further enhanced 
this cleavage. In OCI-AML3 cells, cytotoxic stress caused a rapid 
degradation of NPMc which ‗eases‘ its exertion on caspase 8 and RIP1 
interaction and caused a decreased RIP1 cleavage. (Red arrow represents 
cytotoxic stress. Blue represents NPM, green represents RIP1 and yellow 







6 Perturbation in RIP1 expression and NPMc translocation 
leads to cell death and inhibition of pro-inflammatory 
signaling response 
6.1 Introduction 
There are many different survival and proliferation pathways triggered by TRAIL ligands 
(456,457). These pathways include NF-ĸB (458), Akt/NOS and MAPK/ ERK (459). 
RIP1 kinases for example, are involved in many cellular functions (341) and acts as a 
precursor to the NF-ĸB signaling pathway (460). NF-ĸB signaling pathway is known to 
promote cell survival and proliferation (461,462).  
Aside for NF-κB pathway activation, the MAPK/ERK pathway is often upregulated in 
cancer cells with TRAIL insensitivity (463). RIP kinases have also been implicated in 
ERK activation with studies suggesting that RIP1 kinase activity correlates with ERK 
pathway activation, albeit conflicting (340,464). The overexpression of RIP2 with intact 
kinase activity was shown to activate ERK2 (465,466). 
Notably, the activation of these pro-survival or proliferative pathways seems to be cell 
dependent. Therefore, it is crucial to ascertain if OCI-AML3 cells utilize these pro-
survival pathways to evade cell death. It has been established in our current study that 
RIP1 interacts with NPM/NPMc and potentiates RIP1 cleavage. In our experiments, we 
showed how this RIP1 cleavage blunts necroptosis and potentiates RIP3 mediated 
necrosis contributing to an inflammatory environment. 
Since RIP1 have been implicated in these pro-survival pathways, it is hypothesized that 
its interaction with NPM might influence the outcome of these downstream pathways. If 
proven right, the disruption of RIP1 and NPM interaction is a promising therapeutic 
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intervention in NPMc bearing cells as it promotes cell death and inhibits pro-
inflammatory survival pathway.  
6.2 Results 
6.2.1 Inhibition of nucleophosmin translocation to the cytoplasm potentiated cell 
death 
OCI-AML3 cells were subjected to Leptomycin B (5ng/ml) treatment for 1 hour. A 
control set without Leptomycin B treatment was also included. A portion of the treated 
cells was fixed onto glass slides and subjected to immunofluorescence using NPM 
antibodies. Stained cells were viewed under the microscope to assess the inhibition of 
NPM translocation to the cytoplasm (Fig 6.1a).  
Another portion was further treated with TRAIL (300ng/ml) for 6 hours. Cells were 
harvested and stained using Muse® Annexin V and Dead Cell Kit (The Muse™ System, 
Merck Millipore). Cell death was then measured using Muse® Cell Analyzer.  Data 
analysis of stained cells was generated as dot plots on Muse® Annexin V and Dead Cell 
software module. A dot plot of one experiment was shown as a representative (Fig 6.1b). 
Three independent experiments were performed and results were tabulated in the 
corresponding graph.  
Plots are categorized into quadrants indicating live, early apoptotic, late apoptotic and 
dead cells. Live cells are able to prevent the uptake of non-cell permeable 7AAD dye. 
Live cells do not expose its cell surface expressing phosphatidylserines as in apoptotic 
cells thus remained generally unstained by Annexin V. Early apoptotic cells are Annexin 
V positive cells which are normally 7AAD negative. These cells choose apoptosis as their 
main cell death pathway. These early apoptotic cells then progresses to late apoptotic 
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cells as the cells turned necrotic allowing for its DNA to be stained by 7AAD. This group 
of cells is positively stained by both dyes. Dead cells which are 7AAD positive does not 
necessarily equates to cells undergoing necrosis as it is the end stage of all form of cell 
death. A viable option for accurate discrimination would be to set up a time course 
experiment in which cell death can be tracked over a predetermined period. 
 Results showed that inhibition of cytoplasmic translocation of NPM in OCI-AML3 cells 
increased late apoptotic cells population in OCI-AML3 cells. Further treatment with 
TRAIL significantly potentiates both apoptotic and necrotic cell death in OCI-AML3 
cells. This result suggests that translocation of cytoplasmic NPM back to the nucleolar 
region potentiates cell death namely through necrosis when treated with TRAIL. This 
also suggests that abrogation of cytoplasmic NPM and RIP1 kinase interaction 
















6.1 Inhibition of NPM translocation to the cytoplasm potentiates cell 
death  
a) OCI-AML3 cells were subjected to Leptomycin B (5ng/ml) treatment 
for 1 hour. The treated cells was fixed onto glass slides and subjected to 
immunofluorescence using NPM antibodies. Stained cells were viewed 
under the microscope to assess the inhibition of NPM translocation to the 
cytoplasm (white arrow) b) A portion of cells from a) was further treated 
with TRAIL (300ng/ml) for 6 hours. Cells were harvested and stained 
using Muse® Annexin V and Dead Cell Kit (The Muse™ System, 
Merck Millipore).  Cell death was then measured using Muse® Cell 
Analyzer. Data analysis of stained cells was generated as dot plots on 
Muse® Annexin V and Dead Cell software module. A dot plot of one 
experiment was shown as representative. Three independent experiments 





6.2.2 Inhibition of RIP1 kinase activity did not enhanced apoptosis  in OCI-AML3 
cells 
OCI-AML2 and OCI-AML3 cells were subjected various cytotoxic drugs combination. 
TRAIL/cycloheximide (TC) treatment was used to induce apoptosis. 
TRAIL/cycloheximide/z-VAD fmk (TCZ) was used to induce necroptosis. 
Cycloheximide inhibits de novo protein synthesis (467)  while z-VAD fmk is a pan 
caspase inhibitor. TRAIL/cycloheximide/ necrostatin-1 (TCN) treatment was used to 
inhibit RIP1 kinase activity. After 6 hours treatment, cells were harvested and total cell 
lysate was obtained. 20 μg of protein lysate was separated using SDS PAGE. 
Immunoblotting was performed using various antibodies. Results showed that caspase 8 
and caspase 3 activities in OCI-AML2 cells were enhanced (Fig 6.2a) upon TC and TCN 
treatment. Caspase cascade is activated, a hallmark of apoptosis (468) when treated with 
TRAIL with simultaneous protein synthesis inhibition. RIP1 kinase inhibition failed to 
rescue apoptosis but enhanced it. On the other hand, enhancement of apoptosis was not 
observed in OCI-AML3 when RIP1 kinase activity is abrogated. Necroptosis cannot be 
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induced in OCI-AML3 cells thus inhibition of kinase activity of RIP1 does not perturb 
apoptosis. Notably, apoptosis was observed significantly in OCI-AML3 when treated 
simultaneously with cycloheximide (467). This further suggests that new pro-survival or 
anti-apoptotic proteins need to be synthesized to maintain OCI-AML3 cells‘ survival 
upon cytotoxic assault.   
A portion of cells subjected to the same treatment as above was stained using Annexin 
V_PE and 7AAD_PerCp dye. Cell death was measured using FACs analysis with PE and 
PerCp channels detection (Fig 6.2b). Levels of stained cells were represented in a stacked 
bar graph. Annexin V stained cells represent apoptotic cells while 7AAD stained cells 
represent necrotic cells. Upon apoptosis induction (TC), there is a significant increased in 
apoptotic cells in OCI-AML2 and this is significantly decreased upon pan-caspase 
inhibition (TCZ). Notably, TRAIL/cycloheximide/z-VAD fmk (TCZ) can also induced 
necroptosis. However, level of necrotic cells did not increase significantly in OCI-AML2 
cells. The 6 hours duration used for cytotoxic drugs treatment was possibly not long 
enough to detected significant necrotic cells caused by necroptosis. Level of necrotic 
cells does not change significantly upon various cytotoxic treatments in OCI-AML2 cells.  
In OCI-AML3 cells, treatment with TRAIL/cycloheximide (TC) significantly increased 
apoptotic cells. However, upon pan-caspase inhibition no significant decreased in 
apoptotic cells was observed as in the case of OCI-AML2 cells. This suggests that 
significant increased in Annexin V staining of OCI-AML3 cells after TC treatment is not 
caspase dependent. Treatment with cycloheximide prevents de novo protein synthesis. 
This then prevents production of pro- survival or anti-apoptotic proteins required to 
maintain cells‘ survival of OCI-AML3 upon cytotoxic assault. The positive Annexin V 
staining could also be contributed by late/secondary necrotic cells by which cell 
membrane loses its integrity and allows for the staining of phosphatidylserine (PS) in the 
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interior of the cell. Taken together, Annexin V positive cells detected in OCI-AML3 cells 
are probably product of secondary necrosis. Interestingly, the level of 7AAD positive 
cells does not change significantly upon cytotoxic treatments in OCI-AML3 cells.  
Inhibition of apoptosis, usually tipped the balance of cell death towards necroptotic death 
upon death receptor stimuli. The reverse is also observed. In view of the hypothesis that 
the necroptosis mechanism of NPMc expressing cells are defective, abrogation of the 
primary mediator of this pathway should not contribute to any perturbation to cell death 
pathway. Indeed, in OCI-AML2 cells where this necroptosis mechanism was shown to be 
functional, a shift in cell death pathway towards apoptosis was observed the moment 
necroptosis pathway is blunted by inhibition of RIP1 kinase activity. While in OCI-

















6.2 Inhibition of RIP1 kinase activity did not increased TRAIL 
induced apoptosis in OCI-AML3 cells  
a) OCI-AML2 and OCI-AML3 cells were subjected various cytotoxic 
drugs combination. TRAIL/cycloheximide (TC) treatment was used to 
induce apoptosis. TRAIL/cycloheximide/z-VAD fmk (TCZ) was used to 
induce necroptosis. Cycloheximide inhibits de novo protein synthesis 
while z-VAD fmk is a pan caspase inhibitor. TRAIL/cycloheximide/ 
necrostatin-1 (TCN) treatment was used to inhibit RIP1 kinase activity. 
After 6 hours treatment, cells were harvested and total cell lysate was 
obtained. Equal amount of protein lysate was separated using SDS 
PAGE. Immunoblotting was performed using various antibodies. b) A 
portion of treated cells in a) was stained using Annexin V_PE and 
7AAD_PerCp dye. Cell death was measured using FACs analysis with 
PE and PerCp channels detection. Levels of stained cells were 
represented in a stacked bar graph. Annexin V stained cells represent 
apoptotic cells while 7AAD stained cells represent necrotic cells.  
 
 
6.2.3 RIP1 kinase knockdown potentiated TRAIL induced cell death in OCI-
AML3 cells 
RIP1 kinase knockdown was performed using sh RIP1 and sh vector as a control in OCI-
AML2 and OCI-AML3 cells. After 48 hours, transfected cells were subjected to TRAIL 
(300ng/ml) treatment for 6 hours. Cells were harvested and total cell lysate obtained. 20 
μg of lysate was separated using SDS PAGE. Immunoblotting was further performed 
using various antibodies. RIP1 protein expression was assessed to determine successful 
protein knockdown (Fig 6.3). Knockdown of RIP1 kinase alone did not potentiates cell 
death in OCI-AML3 cells measured by PARP cleavage. Similarly, the level of NPM was 
unperturbed by RIP1 abrogation but RIP3 expression was slightly upregulated. However 
upon TRAIL treatment, PARP-1 was degraded suggesting occurrence of necrotic cell 
death (469). RIP1 downregulation possibly allows for RIP3 mediated necrosis form of 




6.3 TRAIL potentiated cell death upon RIP1 kinase knockdown in 
OCI-AML3 cells  
RIP1 kinase knockdown was performed using sh RIP1 and sh vector as a 
control in OCI-AML2 and OCI-AML3 cells. After 48 hours, transfected 
cells were subjected to TRAIL (300ng/ml) treatment for 6 hours. Cells 
were harvested and total cell lysate obtained. Equal amount of lysate was 
separated using SDS PAGE. Immunoblotting was further performed 
using various antibodies. 
 
 
6.2.4 RIP1 and RIP3 kinases knockdown did not potentiate myeloid 
differentiation in OCI-AML3 cells 
OCI-AML2 and OCI-AML3 cells were subjected to TRAIL (100ng/ml) treatment for 
48hours, subsequently harvested and fixed onto glass slides. Myeloid cells differentiation 
was assessed using May-Grünwald-Giemsa (MGG) staining. Cells were viewed under the 
microscope at 100x oil immersion magnification. Results showed that OCI-AML2 cells 
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were differentiated (white arrow) after 48 hours TRAIL treatment while OCI-AML3 
showed no occurrence of differentiation (Fig 6.4a).  
It was examined if the knockdown of RIP1 and RIP3 potentiates myeloid differentiation. 
Knockdown of RIP1 and RIP3 kinase was performed using sh RIP1 and sh RIP3 in OCI-
AML3 cells.  After 48hours, transfected cells were subjected to TRAIL (100ng/ml) 
treatment for another 48 hours and processed for MGG staining. Results showed that 
RIP1 and RIP3 knockdown did not potentiates myeloid differentiation of OCI-AML3 
cells after TRAIL treatment (Fig 6.4b). Notably though knockdown of sh RIP3 seemed to 

















6.4 RIP1 and RIP3 kinases knockdown in OCI-AML3 cells did not 
potentiate myeloid differentiation   
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a) OCI-AML2 and OCI-AML3 cells were subjected to TRAIL 
(100ng/ml) treatment for 48hours, subsequently harvested and fixed onto 
glass slides. Myeloid cells differentiation was assessed using May-
Grünwald-Giemsa (MGG) staining. Cells were viewed under the 
microscope at 100x oil immersion magnification. The outlines of the 
nucleus are demarcated for comparison. Differentiated myeloid cells are 
marked with white arrow. Schematic diagram showing myeloid line 
differentiation. Adapted from ―Physiology of Adult Homosapiens- Blood 
(Haematology: P lasma, blood cells, and coagulation) and Lymph‖. 
(http://www.ufrgs.br/imunovet/molecular_immunology/blood.html).  
b) Knockdown of RIP1 and RIP3 kinase was performed using sh RIP1 
and sh RIP3 in OCI-AML3 cells.  After 48hours, transfected cells were 
subjected to TRAIL (100ng/ml) treatment for another 48 hours and 




6.2.5 RIP1 and RIP3 kinases knockdown showed no significant differences in NF-
ĸB p52 and p65 activation of OCI-AML3 cells 
OCI-AML2 and OCI-AML3 cells were used to assay basal NF-ĸB p52 and p65 activity 
with respect to differential NPM isoforms expression. A subset of each cells were 
subjected to TRAIL (100ng/ml) for 24 and 48 hours respectively. Cells were harvested 
and nuclear extract obtained. NF-ĸB p52, and p65 assay was performed using TransAM 
® NF-ĸB Transcription Factor ELISA Kit (Active Motif). Activated transcription factors 
were measured using microplate reader at 650nM wavelength. NF-ĸB p65 is activated in 
OCI-AML2 cells but does not increase significantly in OCI-AML3 cells even after 48 
hours of TRAIL treatment (Fig 6.5a). While the increase in NF-ĸB p52 activation is 
significant in OCI-AML2 cells, it is barely activated in OCI-AML3 cells. This suggests 
that NF-ĸB activation via p65 (canonical pathway) and p52 (non-canonical pathway) 
does not play a role in maintaining homeostasis in OCI-AML3 cells.    
RIP1 and RIP3 kinase expression was knocked down using sh RIP1, sh RIP3 and sh 
vector as a control in OCI-AML2 and OCI-AML3 cells. After 48 hours post transfection, 
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a portion of the cells were subjected to TRAIL (300ng/ml) for 6 hours. Cells were 
harvested and nuclear extract obtained. NF-ĸB p52 and p65 activity assay was performed 
as mentioned above. Results showed that RIP1 and RIP3 knockdown decreased NF-ĸB 
p65 in OCI-AML2 but not OCI-AML3 cells (Fig 6.5b). This is in line with studies 
showing that NF-ĸB activation is impaired in the absence of RIP1 kinase (470,471).  
However, this decrease is not significant.  
Subsequent TRAIL (300ng/ml) treatment for 6 hours showed a further decrease in NF-ĸB 
p65 activation (although not significantly) in OCI-AML2 control cells but the activation 
remained unperturbed in RIP kinases knockdown cells. In OCI-AML3 cells, no 
significant changes were seen in both NF-ĸB transcription factors with or without TRAIL 
treatment. Similarly, NF-ĸB p52 activation was not significantly affected in both treated 
and untreated OCI-AML2 cells. This may suggest that OCI-AML2 activates canonical 
(472,473) rather than non-canonical NF-ĸB signaling pathway (474) although more 
evidence is needed to strengthen this assumption. Results above also clearly illustrate that 
NF-ĸB signaling pathway does not partake in maintaining homeostasis in OCI-AML3 
cells. One possibility is that RIP1 is highly cleaved in OCI-AML3 cells thus blunting NF-
ĸB signaling pathway altogether. Therefore OCI-AML3 cells might utilize another pro 


















6.5 RIP1 and RIP3 kinases knockdown showed no significant 
difference in NF-ĸB p52 and p65 activation of OCI-AML3 cells    
a) OCI-AML2 and OCI-AML3 cells were used to assay basal NF-ĸB 
p52 and p65 activity with respect to differential NPM isoforms 
expression. A subset of each cells were subjected to TRAIL (100ng/ml) 
for 24 and 48 hours respectively. Cells were harvested and nuclear 
extract obtained. NF-ĸB p52, and p65 assay was performed using 
TransAM ® NF-ĸB Transcription Factor ELISA Kit (Active Motif). 
Activated transcription factors were measured using microplate reader at 
650nM wavelength. b) RIP1 and RIP3 kinase expression was knocked 
down using sh RIP1, sh RIP3 and sh vector as a control in OCI-AML2 
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and OCI-AML3 cells. After 48 hours post transfection, a portion of the 
cells were subjected to TRAIL (300ng/ml) for 6 hours. Cells were 
harvested and nuclear extract obtained. NF-ĸB p52 and p65 activity 
assay was performed as mentioned above. 
 
 
6.2.6 RIP3 but not RIP1 kinase knockdown decreased ERK activation in OCI-
AML3 cells 
OCI-AML2 and OCI-AML3 were subjected to TRAIL (100ng/ml) treatment for 24 
hours. Cells were harvested and total cell lysate were obtained. 20 μg of total cell lysate 
was separated by SDS PAGE and immunoblotted using various antibodies. ERK 
activation was observed to be elevated in untreated OCI-AML3 cells. Upon TRAIL 
treatment, there was a slight upregulation of ERK activation suggesting that ERK 
pathway plays a role in cell survival of OCI-AML3 cells (Fig 6.6a).  
We then further examined if ERK activation is affected by RIP kinases knockdown. 
Knockdown of RIP1 and RIP3 kinases in OCI-AML2 and OCI-AML3 was performed 
using sh-RIP1, sh-RIP3 and sh vector as control. After 48 hours post-transfection, cells 
were subjected to TRAIL (100ng/ml) treatment for 24 hours. Cells were harvested and 
total cell lysate obtained. Immunoblotting was performed using various antibodies (Fig 
6.6b). Knockdown of RIP1 kinase does not decrease ERK activation denotes by the level 
of phosphorylated ERK in OCI-AML3 cells. On the other hand, knockdown of RIP3 









6.6 TRAIL decreased ERK activation upon RIP3 but not RIP1 
kinase knockdown in OCI-AML3 cells    
a) OCI-AML2 and OCI-AML3 were subjected to TRAIL (100ng/ml) 
treatment for 24 hours. Cells were harvested and total cell lysate were 
obtained. Equal amount of total cell lysate was separated by SDS PAGE 
and immunoblotted using various antibodies. b) Knockdown of RIP1 and 
RIP3 kinases in OCI-AML2 and OCI-AML3 was performed using sh-
RIP1, sh-RIP3 and sh vector as control. After 48 hours post-transfection, 
cells were subjected to TRAIL (100ng/ml) treatment for 24 hours. Cells 
were harvested and total cell lysate obtained. Immunoblotting was 




Inhibition of NPM translocation to the cytoplasm and the abrogation of RIP1 but 
not its kinase activity promote cell death 
Translocation of NPM to the cytoplasm affords its interaction with RIP1 kinase which 
potentially inhibits necroptosis. In our experiments, inhibition of NPM translocation to 
the cytoplasm using Leptomycin B (Fig 6.1a), an inhibitor of Crm-1-mediated nuclear 
export, decreased its chances of interaction with RIP1 kinase. In OCI-AML3 cells, 
mutant cytoplasmic NPM are in close proximity with RIP1 kinase protein at the 
cytoplasm. Inhibition of cytoplasmic NPM translocation to the cytoplasm decreased RIP1 
cleavage (unpublished results). Thus, the disruption of cytoplasmic NPM and RIP1 
kinase interaction potentiates cell death upon TRAIL treatment (Fig 6.1b).  
It has been established that necroptosis induction is dependent on its RIP1 kinase activity 
(475). Inhibition of the kinase activity abrogates necroptosis (443) and tipped the cell 
death balance towards apoptosis (358).. The apoptotic pathway is enhanced in OCI-
AML2 but not in OCI-AML3 cells upon RIP1 kinase activity inhibition (Fig 6.2b), 
exemplified by caspase activation (Fig 6.2a). Necroptosis cannot be induced in OCI-
AML3 cells thus inhibition of the kinase activity of RIP1 does not enhance apoptosis. 
Notably, apoptosis was observed significantly in OCI-AML3 when treated 
simultaneously with TRAIL and cycloheximide (Fig 6.2a). This further suggests that 
newly synthesized pro-survival or anti-apoptotic proteins are needed to maintain OCI-
AML3 cells‘ survival upon cytotoxic assault.   
Knockdown of RIP1 kinase alone did not potentiates apoptosis in OCI-AML3 cells 
however upon TRAIL treatment, PARP was degraded (Fig 6.3). This indicates the 
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occurrence of necrotic cell death. Accompanied by RIP3 upregulation, it clearly suggests 
that RIP1 knockdown potentiates RIP3 mediated necrosis in OCI-AML3.  
Terminal differentiation of blast cells decreases the capacity of these cells to divide and 
abrogate the development of acute myeloid leukemia. Therefore myeloid differentiation 
is another form of therapy beside cell death in which the diseased state can be alleviated. 
TRAIL treatment is shown to induce myeloid differentiation in AML cells as 
demonstrated by OCI-AML2 cells (Fig 6.4a). In OCI-AML3, TRAIL treatment failed to 
promote myeloid differentiation. It is further established that abrogation of RIP1 and 
RIP3 kinases in OCI-AML3 cells with or without TRAIL treatment failed to promote 
myeloid differentiation (Fig 6.4b). 
Cell survival in NPMc expressing cells take the path of ERK but not NF-ĸB p65 or 
p52 pathways activation 
It has been reported that RIP1 plays a role in development and maintenance of B cells. It 
is suggested NF-ĸB activation is impaired in the absence of RIP1 (476). Pro-survival NF-
ĸB activation is needed for proper regulation and normal functions of the immune 
system.  
NF-ĸB pathways consist of both canonical and non-canonical pathway. NF-ĸB p65 
canonical pathway activation is potentiated by RIP1 polyubiquitination at Lys377 by E3 
ligase cIAP-1 and c-IAP2 (430). Upon phosphorylation and degradation of NF-ĸB 
inhibitory (IĸBs) proteins, NF-ĸB translocates to the nucleus and trigger transcription of 
anti-apoptotic target genes.  
Notably, basal NF-ĸB p65 activation in NPMc expressing cells is lower to those of OCI-
AML2 cells (Fig 6.5a). With RIP1 kinase knockdown NF-ĸB p65 activation in OCI-
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AML2 decreases while the level in OCI-AML3 is generally unperturbed. This further 
suggests RIP1 kinase in OCI-AML2 cells is functional (Fig 6.5b).  
While an increase of NF-ĸB p52 non canonical pathway activation is observed in OCI-
AML2 cells when treated with TRAIL, it is barely seen in OCI-AML3 cells (Fig 6.5a). 
Caspase mediated RIP1 processing inhibits NF-ĸB activation. Therefore, enhanced RIP1 
cleavage in NPMc expressing cells impedes NF-ĸB activation. This suggests that NF-ĸB 
p65 and p52 activation does not play a role in cell homeostasis in NPMc expressing cells. 
Similarly, NF-ĸB p65 and p52 activation does not show a significant reduction or 
upregulation with RIP1 kinase knockdown in NPMc expressing cells (Fig 6.5b). 
We found that ERK protein is highly activated in untreated NPMc expressing cells. Upon 
TRAIL treatment, ERK activation is upregulated in OCI-AML3 but not OCI-AML2 (Fig 
6.6a). This suggests that ERK pathway may play a role in pro survival regulation of 
NPMc expressing cells. Knockdown of RIP1 kinase does not decrease ERK activation 
denotes by the level of phosphorylated ERK in OCI-AML3 cells. On the other hand, 
knockdown of RIP3 kinase abrogate ERK activation in OCI-AML3 cells (Fig 6.6b). It is 
previously observed that there is an elevation of RIP3 expression following RIP1 
knockdown. It is also suggested that this may potentiates RIP3 mediated necrosis in OCI-
AML3 cells. Interestingly, elevated activation of pro-survival ERK pathway in OCI-
AML3 cells possibly contributes to its homeostasis and this activation can be abrogated 
with RIP3 knockdown. 
The function of RIP3 kinase possibly underlies the cell fate of OCI-AML3 cells. Both 
RIP3 and RIP1 have similar kinase domain at their N-termini. Both possess RIP 
homotypic interaction motifs (RHIMs) which mediates their interaction during 
necrosome formation. Thus, it is imperative for future studies to determine if NPM 
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interacts with RIP3. RIP3 lies downstream of RIP1 in the necrot ic pathway and utilizes 
mixed lineage kinase domain-like (MLKL) and phosphoglycerate mutase family member 
5 (Pgam5) as substrates. Pgam5 is a mitochondrial phosphatase and its interaction with 
RIP3 in the context NPMc expression might unveil a more direct pathway to non-
apoptotic cell death in OCI-AML3 cells.   
This study overall illustrates that the function of RIP kinases in OCI-AML3 cells‘ 
survival is centered on cell death mechanism not myeloid differentiation or the activation 
of pro-survival signaling pathways (Fig 6.7). Disruption of RIP kinases promotes cell 
death in OCI-AML3 cells. This might pave the way in developing therapeutic approaches 








6.7 Disruption of RIP proteins in NPMc expressing cells promotes 
cell death  
RIP1 and RIP3 knockdown failed to perturb NF-ĸB activation or 
promote myeloid differentiation. However, RIP1 knockdown potentiates 
RIP3 mediated necrosis and RIP3 knockdown abrogates this and inhibits 
constitutive ERK activation. This RIP3 centric hypotheses highlight its 
potentially larger involvement in the survival of OCI-AML3 cells and 








7 Conclusion  
7.1 Perspective 
Implication of mutant cytoplasmic NPM (NPMc) on cell survival 
Nucleophosmin facilitates many cellular housekeeping functions. Mostly confined to the 
nucleolus, its chaperoning functions dictate its multi-interactions capabilities as it 
translocates across membranes to nucleus, cytoplasm and back again. The focus of this 
study is to examine a subset of mutant cytoplasmic NPM (NPMc) expressing myeloid 
cells that manage to evade cell death.  Expression of NPMc proteins allow for prolonged 
interactions with its cytoplasmic partners whereas in normal cells these interactions 
would be transient. This potentially shifts the interaction paradigm of NPM in the cellular 
context.  
Previous work done in the lab demonstrated that cleaved caspase 8 interacts with mutant 
cytoplasmic NPM and eventually inhibits apoptosis and myeloid differentiation (1). In 
this current study we further showed that necroptosis is inhibited in NPMc expressing 
cells contributed via its interaction with RIP1 kinase which renders it susceptible to 
caspase 8 cleavage. The exact mechanism in RIP1 cleavage enhancements is yet to be 
ascertained. However, enhanced RIP1 cleavage blunts necrosome formation and 
subsequent necroptosis.  
With two defective cell death systems, NPMc expressing cells evades cell death 
efficiently. However, minimal cell death is necessary to maintain cell‘s homeostasis. 
Notably, necrotic cell number is high in untreated NPMc expressing cells. Upon 
discriminatory PI staining, it has been established that necrotic cells are a product of 
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secondary necrosis. It is suggested that NPMc expressing cells undergo another form of 
non-apoptotic cell death which leads to secondary necrosis.  
Another work done in the lab (Tan et al., personal communication), demonstrated that 
pro-survival autophagy occurs in OCI-AML3 cells. How NPMc contributes to this 
occurrence is largely unknown. However, prolonged autophagy would eventually trigger 
autophagic cell death and necrosis. It is noted that RIP3, another key kinase involved in 
necroptosis is overexpressed in NPMc expressing cells. RIP1 and RIP3 kinases interact 
and synergistically phosphorylate each other forming a necrosome complex, the 
precursor to necroptosis.  
Interestingly, we showed that RIP3 can mediate necrosis sans RIP1 kinase to further 
phosphorylate its downstream target MLKL. Knockdown of RIP1 kinase enhanced 
necrosis demonstrated by PARP-1 overactivation. Taken together, knockdown of RIP1 
kinase potentiates for RIP3 mediated necrosis in NPMc expressing cells. The mechanism 
of this phenomenon is still elusive.  
Necrotic cell death is an inflammatory event. A steady pool of basal necrotic cells 
ensures the existence of an inflammatory cellular microenvironment. It has been reported 
that pro-inflammatory signaling cascade functions to facilitate proliferation, 
carcinogenesis and cell survival. Taken together, NPMc expressing cells are engaged in 
non-apoptotic and inflammatory form of cell death to prolong its survival which 
contributes to the acute nature of its disease manifestations.  
Disruption of RIP1 kinase and NPM interaction as therapy  
Aberrant translocation of NPM and/or NPMc from the nucleolus allows for its close 
association with RIP1 kinase. We showed that RIP1 kinase interacts directly with NPM 
and its mutant form suggesting that interaction would probably not take place at the C-
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terminus. Furthermore, it is observed that RIP1 cleavage increased in NPMc expressing 
cells and abrogation of NPM rescue this. It is suggested that there is probably an 
existence of a complex consisting NPM, RIP1 and caspase 8. NPM possibly increased the 
susceptibility of RIP1 to caspase 8 mediated cleavage. We also showed that this ―three 
proteins complex‖ is separate from the known pre-DISC although there is a possibility of 
other yet to be discovered interacting partners are involved.   
Since cell survival is centered on RIP1 kinase and NPM interaction in the cytoplasm, the 
disruption of this complex may promote normal cell function. Several strategies could be 
employed to prevent the two proteins from prolonged interactions.  
First, nucleophosmin translocation is a Crm-1 mediated nuclear export event. Therefore, 
treatment with Leptomycin B, an inhibitor of this nuclear export system prevents NPM 
translocation to the cytoplasm and eventually its interaction with RIP1.  
Second, knockdown of NPM prevents the formation of cytoplasmic NPM centered 
complex involving RIP1 kinase and caspase 8. The unavailability of NPM in the 
cytoplasm probably increased the stability of RIP1 kinase and protects against caspase 8 
mediated RIP1 cleavage. An intact RIP1 with functional kinase activity potentiates 
necrosome formation and subsequent necroptosis.  
Third, knockdown of RIP1 is shown to decrease the level of NPM expression. RIP1 plays 
a vital role development and maintenance of cells controlling the immune system. 
Although RIP1 kinase knockdown may promote cell death, it does so possibly by 
triggering RIP3 mediated necrosis. Thus, NPM downregulation could be a result of 
general cellular protein degradation upon excessive necrosis. Cell death via necrosis 
further promotes inflammatory microenvironment which may then promote 
tumorigenesis. Thus this form of therapy is a double edged sword.  
154 
Fourth, an overexpression of caspase-8 resistant RIP1 kinase mutant in NPMc expressing 
cells may further allow for normal necroptosis induction. However, the effects of 
overexpression of cleavage resistant RIP1 kinase have not been extensively studied. RIP1 
kinases are involved in other processes such as NF-ĸB pathway, apoptosis and 
autophagy. How the enhanced stability of RIP1 kinase affects cellular functions need to 
be further examined.  
Understanding the NPMc mediated survival pathway 
Aside from evading cell death, NPMc expressing cells promote pro-survival signaling to 
ensure enhanced cellular viability. Examining the downstream survival pathways that are 
activated in NPMc expressing cells may provide an insight to proteins that are involved 
upstream the cascade in the deregulation of cell death and/or survival. Many studies 
reported that the upregulation of both NF-ĸB and MAPK/ERK pro-survival pathway may 
results from TRAIL treatment (477). This is apparent in cells which is apoptosis resistant 
where pro-inflammatory signaling is activated (478). 
Notably, NF-ĸB (p65/p50) pathway is not elevated in NPMc expressing cells and it is not 
significantly upregulated upon TRAIL treatment.  Excessive RIP1 cleavage in OCI-
AML3 cells may prevent NF-ĸB pathway from functioning. Knockdown of RIP kinases 
OCI-AML2 decreased NF-ĸB activation while no change was observed in OCI-AML3 
cells which further highlight a defective RIP1 kinase.    
In this study, it was demonstrated that ERK is constitutively activated in NPMc 
expressing cells and further TRAIL treatment upregulates this. The mechanism in which 
NPMc affects ERK activation remains elusive although it was demonstrated that NPMc, 
total ERK and RAS proteins co localizes at the lipid raft of OCI-AML3 cells 
(unpublished results). However, knockdown of NPM did not downregulate ERK 
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activation with/without cytotoxic assault in NPMc expressing cells. This suggests that 
NPMc does not directly influence ERK pathway. Knockdown of RIP1 also did not inhibit 
constitutive ERK activation. Intriguingly, RIP3 knockdown in OCI-AML3 cells with 
simultaneous TRAIL treatment decreased ERK phosphorylation. This implicates RIP3 in 
the mediation of NPMc expressing cells survival.  
 
7.1 Working model summing up the interaction of RIP1 and NPM in 
the regulation of cell death 
Summary of the possible involvement of RIP proteins in NPMc 





7.2 Key observations elucidated in this study 
In OCI-AML3 cells, NPM is aberrantly translocated to the cytoplasm, 
allowing for its interaction with RIP1. This potentiates an increase in 
caspase 8 mediated RIP1 cleavage blunting necroptosis. RIP1 cleavage 
can be downregulated upon NPM knockdown. Paradoxically, the level of 
necrotic cells is high in OCI-AML3 cells. This secondary necrotic 
occurrence may be contributed via RIP3 mediated necrosis characterized 
by PARP1 degradation and RIP3 overexpression. OCI-AML3 cells 
release pro-inflammatory proteins even in an unchallenged state. On the 
other hand, RIP1 knockdown potentiates RIP3 mediated necrosis 
possibly demonstrating an overlapping / redundant role of RIP proteins. 
MAPK/ERK pathway is constitutively activated in OCI-AML3 cells and 






This thesis involves the integration of several cellular events and concepts in determining 
cell death or survival, with the objective of understanding AML etiology. Distinguishing 
cell death pathway is still an intriguing phenomenon and hardly distinct. With the 
emergence of various form of caspase independent cell death, loosely termed non-
apoptotic cell death, the categorization of the mechanisms in which cell die is far from 
over. The discovery of a programmable form of necrosis challenged the dogma of 
necrotic death as we know it. With the Pandora‘s Box wide open, many more players, 
overlapping cell death pathways and exceptions are coming out of the woodwork to join 
the death march.   
With this in mind, this thesis hoped to contribute to the understanding of the mechanism 
by which NPMc expressing cells evade TRAIL mediated cell death. While the results in 
this study highlights the involvement of RIP1 and NPMc and its interaction to be the 
possible driver of cell survival in NPMc expressing cells, there are a few additional 
experiments and criticisms that can be employed to strengthen the claims made in this 
study. 
Cell lines 
Both OCI-AML2 and OCI-AML3 cells used in this study are non-isogenic. It is assumed 
that the only difference between them is the Type A NPM mutation (NPMc) in OCI-
AML3 cells. A comparison table (Table 4) of both AML cell lines showed mutation of 
DNMT3A gene at different position. Although both cell lines are mutated at different 
positions on the DNMT3A gene, the mutations are within methyltransferase domain 
(479). These mutations similarly compromise DNMT3A protein functions that may affect 
DNA methylation and the one carbon pathway.  
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Beside this, both cell lines are isolated from patients of about the same age and with the 
same FAB classification. Almost 60% of NPMc mutation occurs in AML patients with 
normal cytogenetics. However, both OCI-AML2 and OCI-AML3 cells are not 
cytogenetically normal. Therefore, it is crucial to reconfirm this study using human 
primary cell lines preferably of normal karyotype. 
ROS measurements 
Mitochondrial dysfunction leads to increased ROS production which leads to the 
induction of active necrosis and initiates downstream cell damage. ROS is generated as a 
result of oxidative phosphorylation and precedes necrotic cell death. This measurement 
should be incorporated to ascertain the occurrence of RIP3–mediated necrosis.  
Electron microscopy 
Although the analysis of necroptosis in cells could be achieved via various methods, 
electron microscopy remains the gold standard to observe morphological changes unique 
to necrotic cells.  
HMGB1 detection in cell lysate 
The contaminating serum proteins in the media render detection of HMGB1 proteins via 
immunoblotting almost impossible. However, HMGB1 can be detected with an amount 
as low as 0.2ng/ml using readily available ELISA kit.  
RIP1 cleavage 
RIP1 is cleaved at D324 by activated caspase 8 yielding 38kDa protein. It was reported 
that RIP1 is cleaved by mitochondrial serine protease HtrA2/Omi between L451 and 
N462 region in a caspase dependent and independent manner generating 30kDa and 
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25kDa fragments respectively (480). Overexpressing different RIP1 mutants that are 
resistant to cleavage in NPMc expressing cells will further confirm if the cleavage is 
caspase 8- or HtrA2/Omi- mediated.   
Leptomycin B 
While Leptomycin B is successful in inhibiting NPMc transport back to the cytoplasm, it 
targets all proteins that utilized crm-1 dependent nuclear export pathway, some of which 
could be crucial for normal cell functions. Therefore, Leptomycin B is still not a viable 
option to be used as a therapeutic agent as it lacks specificity to inhibit only NPM protein 
translocation.  
Colony forming assay 
In the differentiation study, further confirmation using colony forming assay should be 
employed to ascertain if myeloid progenitor cells undergo terminal differentiation.  
Basal NF-κB activity in non cancerous cells 
Most cancer cells have an elevated activation of pro-survival pathway. When comparing 
basal NF-κB activation a control of normal cells must also be included.  
7.3 Future Works 
For a long time, necrosis has been side-lined as a backup cell death route to apoptosis. 
Unregulated, messy and dismissed as cell‘s last resort to demise, the study of necrosis 
failed to excite. With the discovery of a programmable form of necrosis and identification 
of RIP1 as a precursor of this cell death pathway, a new fervor is catching on. This 
current study managed to establish that necroptosis is inhibited in NPMc bearing cells 
due to RIP1 cleavage possibly via its interaction with NPM at the cytoplasm. It was also 
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established that RIP3 overexpression and MAPK/ERK pathway constitutive activation 
occur in OCI-AML3 cells. Intriguingly, abrogation of RIP1 potentiated RIP3-mediated 
necrosis upon cytotoxic stress. MAPK/ERK constitutive activation was down regulated 
upon RIP3 knockdown further implicating RIP3 kinase in the deregulation of OCI-AML3 
cells. These findings served as pointers in the etiology of NPMc bearing cells. Further 
studies are required to elucidate the mechanism of RIP3 and its modulation of necrosis in 
the context of NPMc expressing cells. Scope of future works would include: 
Determining the interaction domain of RIP1 and NPM 
We established that RIP1 binds to NPM/NPMc. Various RIP1 deletion mutants tagged to 
GST can be generated and subjected to pulldown assay using OCI-AML3 lysate to map 
out the interaction domain of NPM/NPMc. Once the domains are established, defective 
mutants can be generated and introduced back into the cell to reascertain that RIP1 and 
NPM interaction modulates cell death. This will facilitate in the development of small 
peptide or drugs that may inhibit NPM/NPMc binding to RIP1. 
For a start, several protein computational software are available online such as Haddock 
and Zdock servers that are able to predict the interaction domain of proteins based on 
their 3D structures which can be obtained via RCSB Protein Data Bank (www. rcsb.org). 
This software uses an energy-based scoring function to evaluate possible binding modes 
of the two proteins. Below are the predictions generated using the 3D structures of C-
terminal domain of NPM and RIP1 protein obtained from RCSB Protein Data Bank and 








7.3 Protein binding predictions using Zdock 
a) 3D structure of the C-terminal domain of Nucleophosmin. Front view 
(2VXD) (left) and Crystal structure of the complex of RIP1 kinase in 
complex with necrostatin-1 analog. Front (4ITH)(right). Sources: RCSB 
Protein Data Bank (www.rcsb.org) b) Protein binding predictions of the 
two proteins mentioned above with NPM C-terminal (Hs): PDB 2VXD 
(grey) and RIP1 kinase domain (Hs): PDB 4ITH (colours). Showing just 
one prediction of interaction domain (left) and all five predictions of the 







Investigating increased RIP1 susceptibility to caspase 8 mediated cleavage upon 
NPM interaction 
The stability of RIP1 in the presence of caspase 8 and NPM in an in vitro setting needs to 
be assessed. An in vitro experiment showing the actual enhancement of RIP1 cleavage by 
caspase 8 in the presence of NPM at differing concentrations and time points can be 
performed.  
Isolating the ternary complex of NPM, caspase 8 and RIP1  
Initial co-immunoprecipitation experiments using RIP1 antibodies failed to successfully 
precipitate NPM, its mutant NPMc and caspase 8 in a complex using OCI-AML2 and 
OCI-AML3 cell lysate. Co-immunoprecipitation with RIP1 antibodies using lysate of 
HL60 cells with overexpressed NPMc managed to precipitate cleaved caspase 8 (Fig 
5.5c). However, RIP1 proteins could not be detected in most blots. There is a possibility 
that the complex formation is transient and could not be capture using co-
immunoprecipitation. RIP1 could also be degraded or cleaved by caspase 8 thus it is 
suggested that the utilization of caspase 8 with defective cleaving activity will be 
included in the next co-immunoprecipitation and pulldown experiments. Alternatively, 
the use of gel filtration experiment could be adopted however this technique needs time 
for optimization.  
Investigating the mutation status of RIP1 and RIP3 in AML cells 
The mutation status of RIP proteins in both AML cells need to be established. Mutation 
of RIP proteins might affect its post translational state and subsequent cell fate. Direct 
PCR product sequencing can be used to screen for point mutations and sequences are 
compared against known mutation databases. 
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Investigating the probable interaction between RIP3 and NPM /NPMc 
RIP1 and RIP3 share similar domain structure with exception of a missing death domain 
in RIP3. RIP3 function to modulate necrotic events downstream of RIP1 dependent 
necrosome. With recent works identifying several RIP3 partners which are mostly 
mitochondrial associated proteins, the interaction with NPM/NPMc (if any) would 
provide a direct link to mitochondria mediated cell death. Several methods can be 
employed for interaction study such as protein co-localization, co-immunoprecipitation, 
pull-down assays and in vitro interaction assay with cell free expressed proteins.  
Employing ROS inhibitors or RIP3 knockdown to reduce the inflammatory nature 
of OCI-AML3 
OCI-AML3 cells released pro-inflammatory cytokine. It was suggested that although 
programmed necrosis induces cell death it also promote cell growth and metastasis due to 
the pro-inflammatory nature. We intend to investigate if treatment with ROS inhibitors 
increases the susceptibility of OCI-AML3 cells to cell death upon TRAIL treatment. 
Alternatively, we intend to investigate if the RIP3 knockdown blunt RIP3 mediated 
necrosis and will it reduce the pro-inflammatory status of the cells. 
Isolating RIP3 containing complexes in NPMc expressing cells upon RIP1 
knockdown and TRAIL treatment  
Several RIP3 complexes exist upstream necrosis induction. It was established that 
abrogation of RIP1 potentiates RIP3 mediated necrosis in OCI-AML3 cells exemplified 
by PARP-1 over activation and degradation. We intend to identify the members of RIP3-
centred pronecrotic complexes formed upon RIP1 knockdown and TRAIL treatment by 
co-immunoprecipitation using RIP3 antibodies. This is followed by immunoblotting 
against known interactors such as RIP1, caspase 8, MLKL and NPM. Alternatively, 
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eluates could be subjected to proteomic studies such as MALDI-TOF to ‗fish‘ out new 
candidate proteins of RIP3 mediated necrosis. 
 
7.4 Future Works 
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